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ABSTRACT 
 
 
ELIZABETH BRANDON-WARNER. Effects of silibinin on ethanol-mediated 
hepatocellular carcinoma progression in male and female mice (Under the direction of 
DR. IAIN H. MCKILLOP) 
 
 
Ethanol is a significant risk for the development of hepatic cirrhosis and 
progression to hepatocellular carcinoma (HCC). While females are more susceptible to 
the deleterious effects of ethanol, the incidence of cirrhosis and HCC is significantly 
higher in males than females. Previous reports identify a role for oxidative stress and 
inflammation in mediating the effects of ethanol on hepatocarcinogenesis, suggesting 
antioxidants may protect the liver from the deleterious effects of ethanol. Plant-derived 
antioxidants have been used for millennia to treat liver disease, yet rigorous scientific 
validation of efficacy is rare. Silibinin, a flavinoligand derived from Milk thistle (Silybum 
marianum), is one such compound indicated to possess potent antioxidant properties and 
historically cited as a hepatoprotectant.  
In these studies we sought to determine the effects of ethanol on HCC promotion 
and progression using in vitro and in vivo rodent models. Using dedifferentiated rat 
hepatoma cells (H4IIE) that constitutively express alcohol-metabolizing enzymes, we 
demonstrated ethanol enhanced cellular oxidative stress, and proliferation. Pre-treatment 
of cells with silibinin significantly inhibited ethanol metabolism (via cytochrome 
P4502E1), oxidative stress, and proliferation. These data indicate silibinin may be an 
effective antioxidant with which to inhibit ethanol-dependent HCC progression.  
We next employed an in vivo diethylnitrosamine (DEN) model of 
hepatocarcinogenesis in male and female mice (21-25 day old). Using this model foci 
 
 
 
iv
develop within ~20 weeks and HCC within ~40 weeks. Mice were fed dietary silibinin 
(0.5%, (w/w), 9 weeks) with or without chronic alcohol feeding (10/20% (v/v) in drinking 
water, alternate days, 8 weeks) to coincide with foci or HCC development. Using this 
approach, ethanol preferentially promoted foci formation in males versus females, effects 
exacerbated during HCC progression. Ethanol-dependent increases in tumor incidence 
and volume in males occurred concomitant with increased CYP2E1 expression and 
activity, depleted glutathione/increased oxidative stress, and hepatic injury. Conversely, 
ethanol did not alter tumor incidence or volume in females, and changes in oxidative 
stress were not evidenced. Analysis of cellular apoptosis demonstrated increased cell 
death in female mice maintained on ethanol that developed DEN-induced hepatic foci.  
Inclusion of silibinin in the diet did not significantly reduce DEN-initiated foci 
formation or HCC progression in either males or females, with or without ethanol. Of 
note, measures of liver injury and oxidative stress were improved in animals fed silibinin 
during foci development, yet silibinin exacerbated the effects of ethanol during later-
stage HCC progression. Finally, analysis of immune system signaling cascades 
demonstrated a net increase in cytokine expression and Th1/Th2 effectors in female, 
ethanol fed mice, effects inhibited by silibinin.  
In conclusion these data demonstrate silibinin effectively inhibits ethanol-
dependent HCC cell growth in vitro. However, while chronic ethanol feeding promoted 
foci formation and HCC progression in male mice in vivo, dietary silibinin did not 
reverse these effects. Conversely, ethanol failed to significantly affect tumor incidence or 
burden in females. This lack of ethanol-dependent hepatocarcinogenesis enhancement in  
females is due, at least in part, to altered immune and apoptotic responses. 
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CHAPTER 1: GENERAL INTRODUCTION 
 
 
1.1.  Hepatocellular Carcinoma: 
 1.1.1. Epidemiology and Risk Factors:  The liver is a multi-cellular organ 
organized into several discrete, interactive cell types that can give rise to distinct types of 
hepatic tumors. Hepatocellular carcinoma (HCC) is a cancer arising from the 
transformation of hepatocytes, the parenchymal cells of the liver, and accounts for 85 to 
90% of all primary liver tumors (McKillop, 2005; Okuda, 2000). HCC is the fifth most 
common malignancy diagnosed worldwide with an incidence of approximately 1 million 
new cases diagnosed annually (El-Serag, 2007; Ferlay, 2008; Gomaa, 2008; McKillop, 
2006; Ogawa, 2009). Globally, ≈600,000 deaths are attributed to HCC, making it the 
third leading cause of cancer related mortality (El-Serag, 2007; McKillop, 2006; Ogawa, 
2009).  
 The highest frequency of HCC occurs in Southeast Asia and sub-Saharan Africa 
which account for >80% of cases. Documented risks for HCC are largely preventable,  
environmental factors that include Hepatitis C (HCV) and B (HBV) viral infection, 
aflatoxin B exposure, non-alcoholic fatty liver disease (NAFLD) and chronic alcohol 
abuse (Altekruse, 2009; El-Serag, 2007; McKillop, 2006). Unlike other commonly 
diagnosed malignancies, HCC lacks familial markers and develops primarily in the 
context of persistent inflammation, injury and cirrhosis associated with exposure to 
underlying risk factors. Geographical variations in prevalence of these risk factors 
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parallels disease distribution related morbidity and mortality (Altekruse, 2009; El-Serag, 
2007). Rates for HCC have been increasing in Western societies with men 3 to 5 times 
more likely to develop HCC than women (Davis, 2008; El-Serag, 2007; McKillop, 2005). 
In the United States age adjusted incidence of HCC has tripled in the three decades from 
1975 to 2005 (Altekruse, 2009).  The most common risk factor in the United States is 
HCV infection, followed by chronic alcohol abuse, metabolic syndrome and NAFLD 
associated with obesity and diabetes mellitus (El-Serag, 2007; McKillop, 2005).  
Eighteen million Americans are estimated to abuse alcohol which remains a major 
risk associated with HCC in the United States (Christof et al., 2008; El-Serag, 2002). 
Disease pathology follows a predictable course, 100% of chronic ethanol abusers will 
develop steatosis. Despite the high incidence of fatty liver, only 10-30% of those 
individuals will progress to hepatitis, and only 8-20% of those will progress to cirrhosis.  
Finally, of those that progress to cirrhosis, only 15% eventually develop HCC (Vidali, 
2007).  Incidence of HCC increases progressively with age, as it is rarely diagnosed 
before age 40 except where HBV viral infection is endemic (El-Serag, 2002). The mean 
age distribution at diagnosis is between 50-70 years of age with women presenting with 
disease an average of 5 years later than men (El-Serag, 2007). Recent studies indicate a 
trend towards a younger age of acquisition in both males and females (El-Serag, 2002). 
Differences in disease development between males and females may be related to sex-
specific differences in environmental exposure to carcinogens as males tend to drink 
more alcohol and have higher rates for cigarette smoking (Ferlay, 2008).  
1.1.2. Diagnosis, Staging and Treatment: Hepatocellular carcinoma is complex 
and presents with a high degree of heterogenicity that is influenced by underlying 
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etiology. Currently, prognosis remains poor, due in part to long disease latency and lack 
of early diagnostic markers (Bosch, 2005; Ogawa, 2009; Thorgeirsson, 2002). HCC is a 
slow-growing malignancy that, when detected early, can be treated by surgical resection. 
However, the interval between initial onset of disease to clinically detectable HCC is 
typically measured in decades (Gomaa, 2008; Ogawa, 2009). Confirmation is often 
delayed until advanced stage, and is usually accompanied by advanced fibrosis and 
cirrhosis with impaired hepatic function (El-Serag, 2007; McKillop, 2006; McKillop, 
2005). By the time patients present with symptoms of abdominal pain, weight loss and 
fatigue, the tumor is typically ≥10 cm in diameter and has usually metastasized 
(Domínguez-Malagón, 2001). This delay in diagnosis limits therapeutic options and 
contributes to an abysmal survival rate, which is estimated at only 7 to 8 months 
following diagnosis (El-Serag et al., 2008).  
In clinical practice, individuals at high risk for developing HCC are screened by 
ultrasoundography and serum markers for α-fetoprotein (AFP) (Zhang et al., 2004). Use 
of AFP is not an accurate predictor of disease as 40% of patients with HCC do not 
produce AFP, and patients of African descent have normal AFP levels at 500 ng/mL 
(Ferenci et al.). On detection of liver lesions in patients with cirrhosis further testing 
utilizing contrast-enhanced x-ray computed tomography (CT) or magnetic resonance 
imaging (MRI) is conducted followed by percutaneous liver biopsy of lesions greater 
than 1 cm (Bruix and Sherman, 2005). Multiple staging systems have been developed, 
including the Barcelona Clinic Liver Cancer (BCLC) scale, which is the currently 
endorsed system for evaluating clinical HCC (Bruix and Sherman, 2005; El-Serag et al., 
2008). Treatment options are commensurate with the grading scale. Surgical resection, 
 
 
4
liver transplantation or local ablation techniques are viable in early HCC (Grade A); 
disruption of  tumor arterial blood supply combined with delivery of either drugs or 
radioactive partials is recommended for patients at intermediate stage (Grade B); 
advanced stage (Grade C) is generally treated by chemotherapy agents, of which 
sorafenib is the only one currently recommended; terminal stage (Grade D) is restricted 
to palliative and supportive care (Bruix and Sherman, 2005).    
Surgical resection is potentially curative; however the 5 year risk for cancer 
recurrence exceeds 70% (Duffy et al., 2008; El-Serag et al., 2008). Liver transplantation 
is considered an optimal treatment because it removes both the malignancy and diseased 
liver which may contain small undetected focal lesions that contribute to recurrence 
(Thomas and Zhu, 2005). The severity of liver dysfunction and features of comorbidity 
complicate surgical intervention. In these cases, tumors are treated by ablation 
techniques. One alternative, percutaneous ethanol injection (PEI) is administered in 
tumors less than 2 cm in diameter (Lencioni et al., 2003). Radiofrequency ablation (RFA) 
is currently used more frequently and affords a higher rate of complete tumor necrosis 
and may have an efficacy similar to that of surgical resection (Forner et al., 2009; 
Goldberg et al., 2000).  
Hepatic tumors are highly vascular, receiving most of their blood supply from the 
hepatic artery, while in normal hepatic tissue, 80% of the blood flow is supplied by the 
hepatic portal vein (Llovet et al., 2008). One treatment option exploits this feature by 
disrupting the arterial blood supply to the tumor through transarterial chemoembolization 
(TACE). In this procedure a cocktail of chemotherapeutic agents and gel-foam particles 
is delivered into the hepatic artery supplying the tumor; it is recommended in patients 
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without metastasis (Forner et al., 2009; Nicolini et al., 2010). Alternately, transarterial 
radioembolization (TARE) is a similar method that utilizes radioactive resin or glass 
beads (Forner et al., 2009).  
Few pharmacological or chemotherapeutic agents are available to treat HCC, in 
part due to increased resistance to conventional treatments (Thomas and Zhu, 2005).  
Additionally, as the liver is the primary site of xenobiotic metabolism, severe hepatic 
dysfunction results in poor tolerance to systemically delivered therapies. It has also been 
demonstrated that HCC is characterized by a multi-drug resistant (MDR) phenotype that 
results from over-expression of an energy-dependent efflux pump, encoded by the MDR1 
gene (Lasagna et al., 2006).  Currently, Sorafenib, an oral multi-kinase inhibitor that 
targets Raf kinase, vascular endothelial growth factor receptor (VEGFR) and platelet-
derived growth factor receptor (PGDFR) signaling pathways is the only therapeutic 
offered for HCC (Zhu, 2008). However, treatment has been reported to provide only a 
marginal increase in survival from 7.9 months to 10.7 months (Llovet et al., 2008).  
1.2.  Hepatocarcinogenesis:  
 1.2.1. Etiology:  Eighty-five percent of HCC occurs within a background of 
chronic liver disease, advanced fibrosis, and cirrhosis. This pathobiology suggests a role 
for oxidative stress with a pattern of recurrent hepatocyte injury and regeneration that 
may facilitate the accumulation of tumorigenic mutations (Farazi et al., 2003; Karin and 
Greten, 2005; Sasaki, 2006). Tumorigenesis is a multistage process that occurs with the 
accumulation of genetic and epigenetic mutations that allow cells to overcome multiple 
barriers to cancer development (He et al., 2008; Karin and Greten, 2005; Sasaki, 2006; 
Thorgeirsson, 2002). Tumorigenesis in HCC is influenced by factors produced in 
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surrounding liver tissue and liver cell types, although specific mechanisms are poorly 
understood and vary according to underlying risk factors (Farazi et al., 2003; Sasaki, 
2006; Thorgeirsson, 2002).  
 Multiple carcinogenic pathways are altered in HCC; but, changes in hepatocyte 
growth factors, somatic mutations, protease and matrix metalloproteinase overexpression, 
and oncogene activation can all be identified early during hepatic inflammation and 
chronic hepatitis (McKillop, 2006; Thorgeirsson, 2002). These changes become more 
extensive during the progression of liver injury through fibrosis to cirrhosis and HCC 
(Thomas and Zhu, 2005). Cirrhosis is the single most common underlying risk for HCC 
and is associated with hepatic injury due to viral infection or chronic ethanol abuse. 
There is a common pattern of disease progression beginning with steatosis, necrosis and 
inflammation. Inflammation precipitates activation of hepatic stellate cells leading to 
increased collagen deposition, fibrosis and cirrhosis (McKillop, 2006; McKillop, 2005; 
Thorgeirsson, 2002). Hepatocarcinogenesis is considered a multi-hit model; beginning 
with initial exposure to a carcinogen which can initiate hepatocyte transformation 
followed by chronic hepatitis and inflammation that leads to fibrosis and cirrhosis 
(Thorgeirsson, 2002). Malignant cells pass through three stages, initiation, promotion and 
progression whereby transformed cells progress histologically from benign precursor 
lesions to malignant neoplasms (Domínguez-Malagón, 2001) (Figure 1.1: schematic 
illustration of initiation, promotion and progression). This multistage process has been 
described in a variety of organ systems (Dragan and Pitot, 1992).   
  1.2.2. Initiation of HCC: The first stage in hepatocarcinogenesis is marked by 
formation of abnormal individual cells with irreversible genetic changes. This occurs  
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Figure 1.1:  Multistage carcinogenesis can be divided into three distinct stages: In the 
first phase tumor initiation is characterized by mutational events affecting the DNA 
leading to activation of oncogenes and/or inactivation of tumor suppressor genes. Tumor 
promotion is characterized by the clonal expansion of selected initiated cells, and the 
final stage is malignant conversion which occurs through the accumulation of additional 
mutations that allow for increase in tumor growth and the acquisition of invasion and 
metastasis potential.  Modified from (Lin and Karin, 2007) 
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through activation or disabling of cellular circuits that control cell division, survival, and 
senescence (Hanahan and Weinberg, 2000; Thorgeirsson, 2002). These cells are 
generated through somatic mutations in normal hepatocytes or by genotoxic actions of 
hepatocarcinogens. Many xenobiotic compounds ingested and metabolized by the liver 
can become activated by cytochrome P450 enzymes to pro-carcinogens that induce 
structural and regulatory genetic changes that generate these early mutations, thereby 
increasing the potential for hepatocarcinogenesis (Czekaj, 2004; Dragan and Pitot, 1992). 
Additionally, these hepatocarcinogens are often both mutagenic and cytotoxic and 
contribute to increased generation of intrahepatic reactive oxygen species (ROS) (Ogawa, 
2009). DNA-damaging agents, such as ROS, increase the mutation rate within cells 
(Storz, 2005). ROS can induce direct effects on DNA, as well as modulate signaling 
cascades that contribute to tumor development (Storz, 2005). Early stages of initiation are 
associated with increased chromosomal instability (CIN) and genetic mutations, which 
can lead to a malignant phenotype (Barash et al., 2009; Domínguez-Malagón, 2001). 
Genetic mutations that activate genes capable of promoting cell proliferation or survival 
potential drive the initiation phase of carcinogenesis (Czekaj, 2004; He et al., 2008; 
Ogawa, 2009; Sasaki, 2006). However, initiation by itself is not sufficient for cancer to 
progress. Additional selective pressure on these cell populations can be derived from 
non-parenchymal cells within the lesion creating a favorable microenvironment for 
promotion and progression (Ogawa, 2009; Thorgeirsson, 2002). Selected initiated cells 
have the potential to expand clonally in the presence of promoting factors (Dragan and 
Pitot, 1992). 
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1.2.3. Promotion of HCC:  Promotion occurs when the pool of initiated cells 
expand to form pre-neoplastic lesions. Promotion requires the expression of growth 
factors or cytokines that initiate a proliferative phenotype (He et al., 2008).  This process 
occurs either through cellular, or extracellular, signals that lead to immortalized cells that 
are concomitantly resistant to growth inhibitory signals, apoptosis and anti-tumor 
immunity (He et al., 2008). During promotion selected initiated cells clonally expand into 
foci of altered hepatocytes (AHF) that are responsive to a promoting agent. This step is 
thought to be reversible and may require chronic exposure to the promoting agent for an 
extended period of time (Domínguez-Malagón, 2001). Key to the actions of the 
promoting agent during this stage is the potential reversibility of its actions on initiated 
cells on withdrawal (Dragan and Pitot, 1992). These cells are thought to be 
heterogeneous precursor cells that possess a variety of genetic alterations. One (or more) 
of these genetic changes likely conferring enhanced survival, and these cells have the 
potential for full malignant transformation (Dragan and Pitot, 1992).  
1.2.4. Progression of HCC:  During progression, subsets of AHF (1-5%) progress 
to a completely neoplastic phenotype (Domínguez-Malagón, 2001). This process is 
marked by accumulation of additional genetic mutations that permit these cells to 
overcome restrictions on proliferation, escape apoptosis, and obtain a motile phenotype. 
Unlike the stages of initiation and promotion, progression is an irreversible transition 
(Dragan and Pitot, 1992). Transformation into a malignant immortalized cell is  
associated with increases in expression of oncogenes and inhibition of tumor suppressors. 
Necessary changes in gene expression are not limited to transcriptional activation, but 
also translation and post-translational mechanisms (Domínguez-Malagón, 2001). Tumor 
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progression can be enhanced by the presence of superoxide anions (O2
-), and hydrogen 
peroxide (H2O2), both of which have been reported to activate pathways that induce cell 
proliferation and promote survival during tumor progression (Sasaki, 2006; Storz, 2005). 
Oxidative stress and hypoxia within the tumor environment can also activate signal 
pathways that promote neovascularization, a critical step in tumor progression (Storz, 
2005). 
1.3.  Role of ethanol/ethanol metabolism in hepatic injury: 
1.3.1. Ethanol Metabolism in Hepatocytes:  As with many xenobiotic compounds, 
the liver is the primary site of ethanol metabolism and absorption (Lieber, 2000; Nagy, 
2004). There are three metabolic pathways for catabolism of ethanol. Two successive 
oxidation reactions are required to metabolize ethanol and produce acetate and water 
(Lieber, 2000; Nagy, 2004). Each pathway contributes differently to the elimination of 
ethanol and each is localized to different sub-cellular compartments. These pathways 
generate the same primary metabolite, but exert different metabolic consequences on 
hepatic function (Lieber, 2000; Nagy, 2004). The liver removes approximately 90% of 
ethanol in circulating blood following oral ingestion (Lundquist, 1962). The first 
metabolite in the oxidation of ethanol is acetaldehyde, a toxic and highly reactive 
intermediate that is a known carcinogen (Cunningham, 2003; Lieber, 2000; Lundquist, 
1962; McKillop, 2005; Nagy, 2004; Poschl and Seitz, 2004; Seitz and Becker, 2007). 
Ethanol is first converted to acetaldehyde by removing two electrons which are 
transferred to nicotinamide adenine dinucleotide (NAD) to form reduced nicotinamide 
adenine dinucleotide (NADH) and acetaldehyde (Cunningham, 2003; Lieber, 2000). 
Acetaldehyde is, in turn, oxidized by aldehyde dehydrogenase (ALDH) to acetate and 
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water within the respiratory chain of the mitochondria (Cunningham, 2003; Lieber, 
2000). Polymorphisms in the enzymes associated with these pathways can influence rate 
of absorption, distribution and elimination of ingested ethanol (Cunningham, 2003; 
Lieber, 2000; Nagy, 2004). The contribution of each pathway to the elimination of 
ethanol are regulated, in part, by the rate and amount of ethanol consumed as well as 
duration of exposure (Figure 1.2, Major pathways of ethanol metabolism).  
Alcohol dehydrogenase (ADH), a zinc metalloenzyme is located in the cytosol 
and accounts for the majority of ethanol metabolism with moderate, short term exposure 
(Lieber, 2000; McKillop, 2005; Nagy, 2004). The microsomal ethanol oxidizing system 
(MEOS), located in the endoplasmic reticulum, utilizes an inducible mixed function 
oxidase; cytochrome P450 2E1 (CYP2E1), which is activated under conditions of 
excessive or chronic ethanol exposure (Lieber, 2000; McKillop, 2005). The third pathway 
mediated by catalase and located in the peroxisomes requires a mechanism for generating 
hydrogen peroxide (H2O2) (Lieber, 2000). It appears to act only in the presence of high 
concentrations of ethanol and has a limited role in ethanol metabolism (Alter, 2009; 
Lieber, 2000; Nagy, 2004).  
 1.3.1.1. Alcohol Dehydrogenase Pathway:  Alcohol dehydrogenase (ADH) genes 
encode a family of enzymes that metabolize several substrates that enter the liver for 
biotransformation and elimination. Five different classes are encoded in seven genes 
(ADH1-ADH7) (Edenberg, 2007; Jelski, 2008b; Lieber, 2000; Lieber, 1997b). These 
enzymes function to metabolize hydroxysteroids, lipid peroxidation products, ethanol and 
retinol (Jelski, 2008b; Lieber, 2000). They are zinc-dependent homo- or heterodimeric 
isoforms, class I, II and IV are important for ethanol metabolism. Class I and II being  
 
 
12
 
Figure 1.2:  ADH and CYP2E1 pathways of ethanol metabolism: Under moderate 
occasional consumption, most EtOH is metabolized by ADH/ALDH to acetate and water. 
Chronic, long term consumption induces the microsomal ethanol oxidizing system 
(MEOS) pathway and cytochrome P450 2E1 (CYP2E1). This pathway generates reactive 
oxygen speices (ROS), partially reduced EtOH product – hydroxyethyl radical (HER) and 
lipid peroxidation by-products MDA and 4-HNE (modified from McKillop and Schrum 
2006).  
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identified and characterized in the liver (Jelski, 2008b; Lieber, 2000). Several ADH 
isoenzymes are expressed in the gastric mucosa and account for first pass ethanol 
metabolism (Lieber, 2000). Chronic long term exposure reduces the expression of gastric 
ADH and impairs the efficacy of first pass metabolism (Lieber, 2000).   
Three different polymorphisms of ADH2 have been identified; ADH2*1, 
ADH2*2 and ADH2*3 produce enzymes with varying rates of ethanol metabolism and 
production of acetaldehyde (Jelski, 2008b; Monzoni, 2001). Numerous studies have 
attempted to link these variations to both ethanol dependence and the severity of hepatic 
disease (Jelski, 2008b; Lieber, 2000; Nagy, 2004). Isoform ADH2*2, which may be more 
prevalent in individuals of Asian descent, is the most active isoenzyme. It produces 
acetaldehyde at a rapid rate that leads to untoward side effects, such as facial flushing, 
and tachycardia. This isoform has been linked to formation of hepatic lesions (Jelski, 
2008b; Monzoni, 2001). Early hepatic effects initiated by ADH mediated metabolism 
relate to changes in REDOX status through alterations in hepatocyte NAD/NADH ratios.  
 1.3.1.2. Cytochrome P450 2E1 Pathway:  Chronic long-term exposure to ethanol 
induces the microsomal CYP2E1 enzyme. It has been reported to increase 4-10 fold in 
livers of chronic ethanol users (Lieber, 2000; Lieber and Decarli, 1989). CYP2E1 is an 
enzyme from the cytochrome P450 superfamily of hemeproteins that serve as terminal 
oxidases during biotransformation of ingested and endogenous compounds. Oxygen is 
required for its catalytic function, as such small amounts of O2
.- can be produced during 
decay of oxygenated p450 complexes. This enzyme is not limited to metabolic 
conversion of ethanol to acetate and water, but participates in the metabolism of many 
xenobiotics that produce reactive, often toxic metabolites and activate pro-carcinogens 
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(Cederbaum, 2006; Lieber, 2000; Lu, 2008). This activity is enhanced in alcoholics and 
has been reported to persist for weeks after cessation of ethanol consumption  (Lieber, 
2000). The induction of this enzyme is thought to contribute to enhanced ethanol 
tolerance that has been identified in alcoholics (Lieber, 2000; Lu, 2008). Metabolism 
mediated by CYP2E1 represents a major source of ROS during its catalytic cycle 
(Cederbaum, 2006; Lieber, 2000; Lu, 2008). In addition to acetaldehyde, this enzyme is 
poorly coupled and produces several species of oxy-radicals that can contribute to 
ethanol-mediated injury. This pathway is a source of partially reduced O2 to O2
- with 
generation of H2O2 following dismutation of the superoxide anion. It also allows for 
incomplete oxidation of ethanol, resulting in the formation of 1-hydroxyethyl radical 
(HER) (Cederbaum, 2006; Koop, 1992; Lu, 2008). CYP2E1 mediated metabolism is a 
major source of oxidative stress resulting from the imbalance between ROS formation 
and clearance, combined with the repair of ROS mediated cell damage. Reactive oxygen 
species react with cell constituents, inactivating enzymes, denaturing proteins and 
damaging DNA. These processes promote depletion of cellular antioxidant GSH which 
can exacerbate free-radical toxicity and lipid peroxidation (Albano, 2006; Lieber, 2000).  
A genetic polymorphism  has been identified in the promoter region of the 
CYP2E1 gene (Cederbaum, 2006; Monzoni, 2001; Nagy, 2004). This polymorphism, 
identified as C2, is characterized by increased CYP2E1 gene expression. The 
contribution of the C2 variant on ethanol-induced liver injury and oxidative stress has not 
been determined (Cederbaum, 2006; Monzoni, 2001; Nagy, 2004). Most ethanol is 
metabolized by ADH, but chronic long-term or excessive consumption induces CYP2E1, 
amplifying its function during clearance of ethanol from the body (Caro, 2004; 
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Cederbaum, 2006).  A major source of ROS in hepatocytes is from ethanol-inducible 
CYP2E1, and ethanol exposure increases CYP2E1 activity by 4-10 fold (Albano, 2008; 
Cederbaum, 2006; Lieber, 2000; Ronis, 1996). This increase in levels of CYP2E1 is 
primarily by a post-translational mechanism involving substrate binding and stabilization 
of the enzyme (Cederbaum, 2006). (Figure 2: Major pathways of ethanol metabolism). 
1.3.1.3. Acetaldehyde Metabolism:  Acetaldehyde dehydrogenase catalyzes the 
oxidation of 90% of all acetaldehyde produced from ethanol, converting it into acetate 
and water (Jelski, 2008a; Lieber, 2000). Hepatic clearance of acetaldehyde is primarily 
dependent on the action of ALDH I, a cytosolic enzyme, and ALDH II located in the 
mitochondrial matrix (Jelski, 2008a). Liver mitochondrial ALDH II accounts for the 
catabolism of more than 65% of acetaldehyde, while ALDH I removes approximately 
20% of acetaldehyde generated during ethanol metabolism (Jelski, 2008a). As with ADH, 
there are polymorphisms in ALDH that influence the rate of acetaldehyde elimination 
(Jelski, 2008a). Two alleles have been identified for ALDH II; ALDH2*1 and ALDH2*2 
(Vasiliou, 1999). It has been reported that individuals possessing the ALDH2*2 variant 
are deficient in ALDH activity (Jelski, 2008a; Vasiliou, 1999). This leads to rapid 
accumulation of acetaldehyde on consumption of ethanol that is accompanied by adverse 
side effects, facial flushing, increased heart rate, and headache (Jelski, 2008a).  
 1.3.1.4. Sex-mediated differences in ethanol metabolism:  Individual variations 
are known to exist in the metabolic clearance of ethanol. In some cases these variations 
can be attributed to polymorphisms in the genes encoding transforming enzymes ADH, 
ALDH and CYP2E1 (Edenberg, 2007; Monzoni, 2001; Simon, 2002). Additionally, sex 
related differences have been reported to contribute to variations in the absorption, 
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distribution and elimination of ethanol (Chen, 1999; Crabb, 1995; Lieber, 2000; 
McKillop, 2005; Qulali and Crabb, 1992). On consumption, ethanol is rapidly absorbed 
into the bloodstream from the stomach and small intestine (Mumenthaler, 1999). This 
rate of absorption is influenced by the amount and concentration of ethanol ingested, the 
presence or absence of food in the digestive tract, and the rate of hepatic metabolism of 
ethanol entering the liver from the portal vein. Women demonstrate higher blood alcohol 
content (BAC) following ingestion of equal amounts of ethanol compared to men 
(Mumenthaler, 1999).These differences relate in part to body composition, women have a 
lower total water content and higher fat content compared to men which can influence the 
volume of distribution of ethanol (Mumenthaler, 1999). Women also demonstrate a lower 
rate of first pass metabolism. Although this remains controversial, some studies reporting 
that women have lower gastric ADH activity that accounts for a small fraction of first 
pass metabolism (Frezza et al., 1990; Lieber, 2000; Mumenthaler, 1999). Other factors 
including genetics, age, chronic ethanol ingestion, and gastric morphology, also influence 
expression and efficacy of gastric ADH during first pass metabolism (Julkunen, 1985; 
Yin, 1997). Additional evidence suggests that estrogen influences the expression of both 
ADH and CYP2E1 (Chen, 1999; Simon, 2002). 
Women are reported to have an increased susceptibility to the toxic effects of 
ethanol and ethanol induced liver injury in response to chronic ethanol ingestion  
(Becker, 1996 ; Donato et al., 2002; Frezza et al., 1990; Lieber, 2000). This is likely due 
to a combination of factors that relate to metabolism, pharmacokinetics and estrogen- 
dependent immune response. Livers of females exposed to ethanol tend to have increased 
fat accumulation, high levels of plasma endotoxin, more infiltrating neutrophils and 
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increased oxidative stress and free-radical adducts (Thurman, 1998). Estrogens are 
reported to increase gut permeability and portal endotoxin levels which in turn amplifies 
Kupffer cell activity and increases expression of pro-inflammatory cytokines (Kono et 
al., 2000; Thurman, 1998).  
 Female rats exposed to ethanol demonstrated a two-fold increase in nuclear 
factor-κB (NFκB), a transcriptional factor that mediates immune response, and a 3-fold 
increase in inflammatory cytokine TNFα mRNA (Kono et al., 2000). Despite an 
increased susceptibility to ethanol induced liver injury identified in females, the long 
term sequela with progression to fibrosis, cirrhosis and HCC are more common in males 
(Becker, 1996 ; El-Serag, 2007; McKillop, 2005; Yu and Chen, 1993) 
1.3.2. Ethanol and Hepatocarcinogenesis:  Chronic ethanol abuse in humans is 
defined as ingestion of more than 50-70 grams per day for a prolonged period of time, 
and there is a strong correlation with heavy alcohol intake and hepatic disease 
(Cunningham, 2003; Lieber, 2000). Initial injury following chronic, prolonged exposure 
consists of steatosis (fatty liver).  As consumption persists, injury advances to alcoholic 
hepatitis, fibrosis, cirrhosis, and can ultimately lead to HCC (Bosch, 2005; McKillop, 
2006; Thorgeirsson, 2002). The mechanisms involved remain unclear, in part due to the 
impact of other complicating factors such as nutritional deficits, and variations in the 
types and frequency of beverages consumed, as well as exposure to other toxins (Lieber, 
2001; McKillop, 2005).  There is no consensus on the relationship between dose-effect 
and risk of HCC (Donato et al., 2002). HCC develops in people with cirrhosis caused by 
chronic excessive ethanol abuse. Ethanol by itself has not been identified as a carcinogen 
in animal studies, and a direct link between alcohol liver injury and HCC has not been 
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established, (Seitz et al., 1998; Seitz and Becker, 2007). Rather, it is the metabolism of 
alcohol and metabolites produced in the liver are thought to contribute to injury and 
hepatocarcinogenesis (Poschl and Seitz, 2004; Seitz and Becker, 2007). Many of the 
deleterious consequences of ethanol and ethanol metabolism on hepatic function relate to 
the specific metabolic and toxic disturbances that are inherent to each metabolic pathway. 
Actions of ethanol can be direct or indirect and can differ for men and women in part due 
to differences in metabolic clearance (Donato et al., 2002). In addition, there is synergy 
between ethanol consumption and other risk factors in the progression of liver disease to 
fibrosis, cirrhosis and HCC (Donato et al., 2002).  
1.3.2.1. Altered REDOX Status and ROS:  Effects of ethanol in the liver can be 
direct and indirect in nature, and their severity is dependent on many factors. Major 
metabolic changes resulting from ethanol metabolism produce a shift in hepatic REDOX 
status (Lieber, 2000; Nagy, 2004). Oxidation of ethanol produces acetaldehyde and H+  
which reduces NAD to NADH. Oxidations of acetaldehyde by ALDH in the second step 
of this process generate additional H+ and lead to the accumulation of excess reducing 
equivalents which overwhelm the ability of hepatocytes to maintain REDOX homeostasis 
(Lieber, 2000; McKillop, 2006). This shift in cell REDOX status impairs carbohydrate 
and lipid metabolism and contributes to overall metabolic stress and morphological 
changes within hepatocytes (Lieber, 2001).  
There are multiple mechanisms for production of free-radicals during ethanol 
metabolism (Albano, 2006; Bailey and Cunningham, 2002; Lieber, 2001; McKillop, 
2006). Major sources of ethanol-induced ROS and reactive nitrogen species (RNS) occur 
at different sub-cellular levels during enzymatic reactions (Albano, 2006; Lieber, 2001). 
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The formation of ROS, such as O2
- and H2O2 represent important mediators of oxidative 
injury in many diseases (Albano, 2006). Superoxide is produced in several reactions, 
while it is not a potent oxidant per se, many other oxy-radicals are derived from it 
(Albano, 2006). Reduction of O2
- by superoxide dismutase (SOD) generates H2O2. When 
this reaction occurs in the presence of transition metals such as iron (Fe2+/Fe3+), which is 
often released from hepatocytes, hydroxyl radicals (OH) can be generated in a Fenton 
reaction (Albano, 2006; Cunningham, 2003; Knect, 1993; Lieber, 2001). Superoxide can 
also react with nitric oxide NO to form peroxynitrite (ONOO-). Either of these (hydroxyl 
or peroxynitrite) radicals can interact directly with ethanol to produce an α-hydroxy-ethyl 
radical (Knect, 1993). Most RNS are derived from NO, but the extent to which this 
molecule is protective or damaging remains unclear. Hepatic nitric oxide signaling 
promotes cell survival and is anti-apoptotic in hepatocytes. It is also required for hepatic 
regeneration following liver injury (Fausto, 2000). Additionally, hepatic vasoconstriction 
associated with acute ethanol exposure and cirrhosis is associated with decreased 
synthesis of NO (Albano, 2008). Nitric oxide also inhibits lipid peroxidation by 
attacking lipid peroxyl radicals and terminating lipid peroxidation reactions (Rubbo, 
2000).  
1.3.2.2. Pathobiology of Aldehydes:  The first metabolite produced in all 
metabolic pathways during hepatic ethanol metabolism is acetaldehyde (Jelski, 2008a; 
Lieber, 2000). Numerous in vitro and in vivo experiments have demonstrated that 
acetaldehyde has direct mutagenic and carcinogenic effects (Homann, 2001; Lieber, 
2000; Muller and Sies, 1987; Seitz et al., 1998; Tuma and Casey, 2003). Induction of 
CYP2E1 is directly associated with the stimulation of lipid peroxidation and subsequent 
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production of 4-HNE and MDA. These are key components of oxidative stress in ethanol 
related hepatic injury (Albano, 2006; Cederbaum, 2006; Lieber, 2001).  
Formation of malondialdehyde (MDA) and 4-hydroxynonanol (4-HNE) occurs 
through the activity of ROS produced during oxidation of ethanol and by acetaldehyde. 
Induction of CYP2E1 with ADH, and in conjunction with impairment of mitochondrial 
function, can overwhelm the capacity for ALDH mediated oxidation of acetaldehyde 
(Albano, 2006; Lieber, 2000). This can generate an imbalance in the level of 
acetaldehyde that favors lipid peroxidation, and the formation of acetaldehyde adducts 
with cell constituents (Albano, 2006; Tuma, 1996). Acetaldehyde readily interacts with 
cell membranes and is a potent inducer of lipid peroxidation forming additional toxic 
aldehydes, MDA and 4-HNE (Tuma and Casey, 2003) Acetaldehyde and other aldehydes 
produced in hepatocytes during metabolic processes are chemically reactive, capable of 
interaction with proteins and other biological molecules including DNA to form adducts 
(Lieber, 2000; Muller and Sies, 1987; Seitz et al., 1998; Tuma and Casey, 2003). The 
presence of ROS, and DNA-ethanol or aldehyde adducts are likely key events in DNA 
mutagenesis that lead to malignancies, and are associated with DNA damage in organs 
prone to inflammation induced carcinogenesis (Barash et al., 2009; Bartsch and Nair, 
2004). Additionally, impaired DNA repair during acute inflammation and oxidative stress 
contribute to tumorigenesis. Acetaldehyde, MDA and 4-HNE also bind rapidly to cellular 
proteins inducing conformational changes and impairing function (Seitz et al., 1998). 
Unstable adducts formed in hepatocytes can be rapidly converted to other products, or to 
stable adducts which can remain in the cell for extended periods of time. Acetaldehyde 
preferentially reacts with the lysine residues in protein sequences, while 4-HNE interacts 
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primarily with lysine, cysteine and histadine (Tuma and Casey, 2003). In addition, there 
are multiple cross reactions between aldehydes and other byproducts of ethanol 
metabolism, including HER that can exacerbate adduct related damage. Acetaldehyde 
and MDA react with proteins in a synergistic manner generating hybrid adducts 
consisting of two molecules of MDA and one of acetaldehyde that also target lysine 
(Tuma and Casey, 2003). The formation of aldehyde adducts are considered key events in 
the development and progression of ethanol induced liver injury.  
Ethanol exerts additional effects on lipids and fatty acids in hepatocytes. Excess 
ethanol in hepatocytes can condense with free fatty acids in a reaction catalyzed by fatty 
acid ethyl ester synthase to form fatty acid ethyl ester (FAEE) (Alter, 2009; Nagy, 2004). 
Concentrations of these FAEEs are highest in the heart, pancreas and liver; organs that 
are also sensitive to the toxic effects of ethanol (Alter, 2009; Nagy, 2004). They 
accumulate in the plasma, mitochondrial, and lysosomal membranes and can impair the 
function of cell membranes and organelles (Alter, 2009).  
1.3.2.3. Altered Energy Metabolism: Chronic ethanol consumption alters hepatic 
mitochondrial structure, impairs function, and disrupts hepatic energy homeostasis by 
depletion of cellular ATP (Bailey et al., 1999). Concomitantly, oxidation of ethanol in 
hepatocytes increases the metabolic demand for oxygen (Cunningham, 2003). This can 
produce oxygen deficits (hypoxia) in liver tissue, primarily the centrilobular area and 
central vein (Cunningham, 2003; Lieber, 2001). This localized hypoxia impairs cellular 
energy production during nutrient catabolism thereby inhibiting synthesis of sufficient 
adenosine triphosphate (ATP) to carry out biochemical reactions (Cunningham, 2003). 
Oxidation reactions produce excess reducing equivalents (NADH) during the transfer of 
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electrons. These electrons are released from NADH and transferred to a series of 
molecules during oxidative phosphorylation in the respiratory chain of the mitochondria 
(Bailey and Cunningham, 2002). Physical changes in the mitochondrial membrane 
produce increased membrane permeability and inhibit efficient transfer of electrons. This 
results in the production of superoxide anion, a source of hepatic ROS and oxidative 
stress (Cunningham, 2003; Lieber, 2001). Chronic ethanol consumption alters the 
function and activity of all complexes, except complex II of the respiratory chain (Bailey 
and Cunningham, 2002). These changes are associated with decreased concentrations of 
two sub-units of the membrane-spanning portion of the ATP synthase complex and 
impedes ATP synthesis in mitochondria of ethanol-exposed hepatocytes.  This results in a 
deficit of usable energy and may impair cell stress responses (Bailey and Cunningham, 
2002). Additionally,  presence of ROS in the hepatocytes directly damages mitochondrial 
proteins and DNA which accelerates mitochondrial aging and promotes cellular apoptotic 
pathways (Bailey and Cunningham, 2002).  
1.3.2.4. Ethanol, Oxidative Stress and Inflammation:  The major source of anti-
oxidant defense in hepatocytes is Glutathione (GSH), a thiol compound synthesized 
primarily in the cytosol, then transported into the mitochondria and nucleus, where it 
functions as an antioxidant and the only source for mitochondrial metabolism of H2O2 
(Alter, 2009). There is a 50-85% decrease in mitochondrial GSH associated with chronic 
ethanol exposure, but this deficit is due to impaired transport not reduced cytosolic 
synthesis (Albano, 2006; Fernandez-Checa, 1997). The potential for ROS production, 
combined with impaired transport of GSH, and associated with chronic ethanol 
consumption, results in a depletion of antioxidant defenses and precedes morphological 
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changes and impaired mitochondrial function (Albano, 2006; Bailey et al., 1999). 
Mitochondrial DNA (mtDNA) located in the mitochondrial matrix near the inner 
membrane is vulnerable to damage from ROS. It lacks protective histones and has 
incomplete repair mechanisms (Sasaki, 2006). This vulnerability to oxidative injury 
likely accounts for increases in mtDNA mutations which are found in tumor cells at a rate 
that is 2 to 3 times higher than those found in nuclear DNA (Sasaki, 2006). These 
mutations adversely affect the genes encoding proteins in the oxidative phosphorylation 
pathway. Mutations to mtDNA produce an increase in ROS and decrease in ATP 
production that may contribute to carcinogenesis.  
Oxidative stress is thought to be a key mediator in the priming effect of ethanol 
on inflammatory responses (Lieber, 2001; Nagy, 2004). Hepatocytes, Kupffer and stellate 
cells all appear to be sensitized to inflammatory stimuli by chronic ethanol exposure 
(Lieber, 2001; Nagy, 2004). Development of steatohepatitis is due in part to the increased 
levels of LPS that enters the liver from the portal vein. LPS is a potent activator of 
inflammatory responses (Albano, 2006). Generation of ROS/RNS occurs partially 
through NADPH-oxidase activity in activated hepatic macrophages (Kupffer cells). This 
is a major contributor of pro-oxidants that promote inflammatory changes (Albano, 2006; 
Lieber, 2000; Lieber, 2001). Chronic ethanol exposure increases gut permeability 
allowing bacterial cell components to enter the liver (Albano, 2006; Lieber, 2001; 
Thurman, 1998). Kupffer cells are activated when increased LPS from gram-negative 
bacteria enters the portal vein from the gastrointestinal tract and interacts with the 
endotoxin receptor; CD14 (Enomoto, 2001; Thurman, 1998). These activated 
macrophages produce ROS and the inflammatory cytokine TNFα (Enomoto, 2001; 
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Thurman, 1998). Of note, females have been reported to have higher levels of gut-derived 
LPS in their blood following ethanol exposure than males; however, the expression of 
androgen receptor increases risk of infection (Ikejima et al., 1998; Kono et al., 2000). The 
response to gut-derived LPS in Kupffer cells is amplified with chronic ethanol exposure 
and makes hepatocytes more vulnerable to TNFα (Hoek, 2002), although other factors 
must also influence this process since tolerance develops with long term exposure 
(Jarvelainen, 1999). Hepatic accumulation of oxidants and acetaldehyde can stimulate 
stellate cells to produce type I collagen (Nieto, 2006). This response is initially mediated 
by acetaldehyde directly, but after long term ethanol/acetaldehyde exposure activation of 
cytokines TGFβ and TNFα contribute to the fibrogenic process (Nieto, 2006). This 
establishes a complex process of liver damage and repair associated with inflammation 
mediated by ROS, growth factors and cytokines produced by multiple cell types in the 
milieu of the liver (Albano, 2006; Nieto, 2006) 
One of the earliest manifestations of alcohol induced liver injury  is accumulation 
of fatty acids, micro- and macro-vesicular steatosis (Albano, 2006; Lieber, 2000; Nagy, 
2004). In many patients this is followed by cell ballooning and necrotic cell death. 
Steatosis is thought to  result from changes in the cell REDOX state and accumulation of 
NADH that shifts the balance from fatty acid oxidation to activity of fatty acid synthesis 
and fatty acid accumulation (Lieber, 2000; Nagy, 2004). Other metabolic disturbances 
may also contribute to the accumulation of triglycerides (fatty acids) in the liver, 
including increased mobilization of peripheral fat, enhanced hepatic uptake of circulating 
lipids, and enhanced lipid synthesis (Lieber, 2001). It is an important link between 
inflammation and inflammatory immune responses, and may increase hepatic sensitivity 
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to oxidative stress. Additionally, it may shift hepatic metabolic responses that contribute 
to ethanol induced liver injury and progression to HCC.  
Reactive oxygen species in cells and tissues under pro-oxidant conditions are 
important triggers and modulators of cell signaling. ROS are also a source for chemical 
modifications of biological molecules that can interfere with normal function (Arteel, 
2003). The cumulative effects of these changes result in a characteristic pattern of injury 
that begins with hepatic steatosis, apoptosis and necrosis of hepatocytes. This is 
accompanied by inflammation, formation of regenerative nodules, and activation of 
Kupffer cells and hepatic stellate cells that can contribute to HCC progression (Alter, 
2009; Lieber, 2000). Prolonged exposure to ROS initiates nuclear DNA damage, alters 
epigenetic programs and modifies gene expression patterns (Sasaki, 2006). Oxidative 
stress causes specific DNA mutations that result in base mispairing through formation of 
8-hydroxy deoxyquanosine (8-OHdG) (Sasaki, 2006). This can occur by direct ROS 
interaction with guanine at the C8 position on DNA, or guanine oxidation in the 
nucleotide pool during DNA replication (Sasaki, 2006). Formation of 8-OHdG in DNA 
produces G to T transversions. The primary pathway for repair of this transversion is 
through single-nucleotide repair (Sasaki, 2006). When 8-OHdG is incorporated into DNA 
from the nucleotide pool A:T to C:G transversions can occur. Both errors are widely 
associated with mutations in oncogenes and tumor suppressors (Sasaki, 2006). In 
addition, this DNA damage can affect DNA methylation. DNA methylation is important 
in regulating gene expression and protecting from DNA strand breaks under conditions of 
oxidative stress (James et al., 2003).  
1.4.  HCC promotion and progression:  
 
 
26
1.4.1. Ethanol in HCC Promotion and Progression:  The risk for developing HCC 
increases when daily ethanol consumption exceeds 80g/day for more than 10 years 
(Morgan, 2004). While cessation of ethanol consumption would seem an obvious 
intervention to prevent the progression of liver injury and cirrhosis to HCC, this has been 
demonstrated not to be the case. In fact, the odds ratio of developing HCC when 
compared to active drinkers was demonstrated to increase 5 fold if ethanol consumption 
stopped within 5 years, and 4 fold if it stopped in the past 6-10 years (Donato et al., 2002; 
Morgan, 2004). The odds ratio did not return to that of current drinkers until after a10 
year abstinence from ethanol consumption. This raises intriguing questions as to the 
effects of ethanol and its inherent consequences on hepatic pathology and related 
oxidative stress on promotion and progression in initiated cells.  
Oxidative stress is a critical factor in the pathogenesis of ethanol induced liver 
disease progressing to cirrhosis and the formation of early pre-neoplastic lesions (Sasaki, 
2006). Additionally, oxidative stress has the potential to have dual, yet opposing roles 
that influence all three stages of carcinogenesis (Reuter et al., 2010). Production of ROS 
can have anti-tumor effects through induction of cellular senescence, genomic instability 
and subsequent induction of apoptosis. Alternately, continuous exposure to ROS can 
produce clones that have high tolerance for oxidative stress that allows them to acquire 
malignant qualities inducing a proliferative phenotype with high genomic instability and 
cellular motility that is resistant to apoptosis (Balkwill et al., 2005; Storz, 2005). Hepatic 
tumor progression is a multistage process that occurs in the setting of hepatic cirrhosis 
with scar formation and fibrous septae that encompass regenerative nodules of 
hepatocytes and dysplastic foci (McKillop, 2006; Okuda, 2002).  Inflammation and 
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oxidative stress within this tumor environment places selective pressure on cells favored 
for growth and survival.  
 1.4.2. Oxidative Stress and Innate Immune Response: Oxidative stress occurs 
when there is an imbalance between the production of reactive metabolites, free radicals 
and ROS and the cellular mechanisms for eliminating them. This imbalance produces 
damage to cell structures and biomolecules as well as somatic mutations that can 
contribute to cancer (Reuter et al., 2010). On initiation of oxidative injury immune cells 
are recruited to the site through an acute phase response that activates the innate immune 
system; sustained activation leads to activation of adaptive immune(Albano, 2002). The 
immune system serves both as a major tumor suppressor during immune surveillance, as 
well as an initiator and tumor promoter. Recruitment of inflammatory cells with 
stimulation to produce ROS is an important aspect of tumor promotion (Albano, 2002; 
Reuter et al., 2010). Immune surveillance is a key defense mechanism against the 
development of cancer. Escape from immune surveillance by transformed cells increases 
the probability that it will become cancerous. The immune system has a key role in 
mediating hepatic inflammation, but ethanol exposure can impair immune function 
(Albano, 2002; Hoek, 2002; Osna, 2007). In addition, oxidative stress and ROS produced 
during ethanol metabolism contribute to abnormal gene expression, block cell-to-cell 
communication and modify signal cascades leading to unrestricted proliferation, 
inhibition or promotion of apoptosis (Reuter et al., 2010; Vidali, 2007). The 
consequences of this during cancer progression can vary depending on the cell type 
targeted. Ethanol mediated ROS can induce apoptosis in T-regulatory cells and 
hepatocytes, or alternately inhibit apoptosis in populations of hepatocytes (Ishihara et al., 
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2010; Vidali, 2007). Additionally, H2O2 and superoxide anion have been reported to 
induce mitogenesis, which may selectively act on initiated cells and drive promotion 
(Devadas et al., 2002). Decreases in the population and function of multiple immune cell 
types are associated with poor prognosis in HCC and are influenced by chronic ethanol 
exposure (Jinushi et al., 2005; Mandrekar et al., 2004; Mantovani, 2008). For example, 
the lytic activity of natural killer (NK) cells is decreased by ethanol exposure (Morgan, 
2004). In human ethanol-induced cirrhosis there is evidence of decreased numbers as 
well as impaired function of NK cells, impairment of dendritic cell maturation, and 
decreased expression of major histocompatability complex (MHC) (Bowen et al., 2004; 
Jinushi et al., 2005; Mandrekar et al., 2004; Morgan, 2004). These alterations impair 
immune cell response and function,  as well as cytokine and chemokine responses within 
the tumor milieu and may abrogate immunosurveillance creating a permissive 
environment for HCC progression (Lin and Karin, 2007; Mantovani, 2008).  
Multiple cell types are activated during ethanol-induced injury, and participate in 
the progression of hepatic disease to cirrhosis and HCC. Stellate cells become activated, 
following chronic ethanol exposure from a quiescent vitamin A (retinol) storing cell to a 
myo-fibroblastic-like collagen secreting cell phenotype that drives fibrotic changes in the 
liver (Lieber, 2001). Kupffer cells and lymphocytes enhance this response by secreting 
pro-fibrogenic mediators such as ROS, TNFα, IL-6, and TFG-β (Albano, 2006; Hoek, 
2002; Thurman, 1998). Initial steps in ethanol induced inflammation occur when Kupffer 
cells increase production of TNFα, an important pro-inflammatory mediator (Nagy, 2004; 
Thurman, 1998). This cytokine can transduce signals that regulate cell activation and 
proliferation, cytotoxicity and apoptosis (Nagy, 2004; Vidali, 2007). In addition, pro-
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inflammatory cytokines induce hepatocytes to express class II MHC, making them 
capable of directly presenting intracellular oxidized proteins to CD4+ lymphocytes 
(Osna, 2007; Vidali, 2007). Collagen deposition, fibrosis, and cirrhosis which are an 
integral part of  alcoholic liver disease(ALD), as well as the major underlying risk for 
HCC are linked to cytokines secreted by CD4+T lymphocytes (Osna, 2007; Vidali, 
2007). Activation of pro-inflammatory cascades in Kupffer cells stimulates secretion of 
other pro-inflammatory cytokines, chemokines and receptors; IL-1β, IL-6, IL-8, 
macrophage chemotactic protein-1 (MCP-1, also RANTES), CD14 receptor, ROS and 
NO through activation of transcription factor nuclear factor-κB (NFκB) (Thurman, 1998; 
Vidali, 2007; Wheeler, 2003). In addition, CXC and CC chemokines and receptors have 
been characterized in steatohepatits, fibrogenesis and cirrhosis; CXCL 1, 5 and 8 and 
CCL 2, 3, 4, and 5 and receptor CXCR3 (Haukeland et al., 2006). Of these, CCL2 is 
upregulated by both Kupffer and stellate cells in the portal tracts and fibrous septa of 
liver tissue and CXCR3 is an important receptor in regulating chronic liver inflammation 
(Haukeland et al., 2006). These chemokines, among other functions, can induce ROS 
production, attract neutrophils and promote their extravastation. This correlates with 
recruitment of  CD8+ and CD4+ lymphocytes to areas of necrosis and intralobular 
inflammation that is associated with alcoholic hepatitis (Vidali, 2007). Under 
physiological conditions, Kupffer cells respond to low concentrations of endotoxin by 
producing TNFα, IL-10, and ROS that down regulate antigen presentation by dendritic 
and endothelial cells to suppress T-cell activation.  
 Cytokines and chemokines are crucial in initiating and sustaining the 
inflammatory response in steatohepatitis. Persistent inflammation results from the 
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accumulation of lymphocytes which become organized into a stable inflammatory 
infiltrate (Day, 2006). Lymphocytes and neutrophils can be recruited from the portal 
tract, sinusoids or hepatic veins by chemokines, such as intercellular adhesion molecule-1 
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and vascular adhesion protein-1 
(VAP-1) present in the endothelium (Chosay, 1997). Chronic ethanol exposure and 
alcoholic hepatitis are linked to an increase in the expression of these molecules in portal 
and hepatic endothelial tissue, due in part to TNFα (Adams, 1994; Hoek, 2002; Lieber, 
2001). Additionally, cytokine expression can positively or negatively influence CYP2E1 
expression (Wang et al., 2010; Z. Abdel-Razzak, 1993).  
 Increased titers of auto-reactive antibodies and antibodies that target 
acetaldehyde, MDA, 4-HNE adducts or HER have been identified in patients with 
ethanol-induced cirrhosis (Albano, 2002; Israel et al., 1988; Vidali, 2007).  Additionally, 
liver specific antibodies, anti-nuclear (AN), smooth muscle-α-actin (SMA),  as well as 
antibodies to ADH, and CYP2E1 have also been found in these patients (Stewart et al., 
2004). The presence of these antibodies increases the ability to trigger antibody mediated 
cytotoxicity and correlates with both lymphocyte infiltration and frequency of hepatocyte 
apoptosis (Albano, 2002; Stewart et al., 2004). Clinical studies report elevated titers of 
antibodies towards lipid-peroxidation adducts, and oxidized phospholipids are more 
prevalent in chronic ethanol drinkers with fibrosis and cirrhosis than in patients with no 
liver injury or those with fatty liver only (Vidali, 2007). Presence of these antigens is 
associated with B-cell activation and leads to increased periportal infiltration of T-
lymphocytes that express markers associated with activation, and memory phenotype that 
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also possess an increased capacity for secreting pro-inflammatory cytokines (Batey et al., 
2002; Osna, 2007).  
Metabolic and nutritional factors likely contribute to modulation of inflammatory 
and immune responses during ethanol induce injury. Obesity and diabetes have been 
identified as features of comorbidity in the development and progression of disease 
(Vidali, 2007). Adipose tissue secretes adipokines (leptin and adiponectin) that can 
modulate immune responses (Rogers et al., 2008; Tilg and Moschen, 2006). Adiponectin 
is reported to exert an anti-inflammatory action by depressing B-cell proliferation and T-
cell activation. Conversely, leptin has demonstrated pro-inflammatory activity by 
favoring a Th1 cytokine profile and stimulating T-cell survival and proliferation (Tilg and 
Moschen, 2006). Chronic ethanol ingestion suppresses adiponectin which may potentiate 
a pro-inflammatory Th1 response (Rogers et al., 2008; Vidali, 2007). Disruption or 
exploitation of these processes by tumor cells may create a permissive environment for 
promotion and progression in HCC. 
1.4.3. Cell and Molecular Signaling:  Ethanol and ROS can directly activate 
signaling pathways that promote proliferation and survival, notably members of MAPK 
and NFκB family (Aroor and Shukla, 2004; Storz, 2005). Pro-inflammatory mediators 
activate AP-1, NFκB, STAT1 and STAT3 in myloid derived immune cells. However, in 
malignant or premalignant cells these transcription factors can mediate proliferation, 
survival and angiogenesis contributing to cancer progression (Yoshimura, 2006). Ethanol 
and oxidative stress are inducers of NFκB which up-regulates ≈100 genes on its 
activation to coordinate inflammatory and innate immune responses (Reuter et al., 2010). 
In addition to pro-inflammatory genes, many of these target genes induce proteins that 
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promote angiogenesis and inhibit apoptosis (Yoshimura, 2006). Pro-inflammatory 
cytokines also activate the MAPK cascade which leads to activation of cJune NH2-
terminal kinase (JNK) and p38 or c-fos through IL-6 signaling. This induces AP-1 which 
has been demonstrated to have a role in cancer progression (Yoshimura, 2006). STAT1 
and STAT3 are important links between inflammation and cancer as well as anti-tumor 
immunity. STAT3 is persistently phosphorylated in HCC and up regulates genes 
important for tumor progression, while STAT1 which induces growth inhibition and 
apoptosis, has comparatively low phosphorylation levels in HCC (Yoshimura, 2006). 
Oxidative stress and ethanol associated changes in energy metabolism can institute a state 
of hypoxia in hepatic tumors that leads to activation of genes involved in angiogenesis 
through HIF1α and VEGF. Neovascularization through this pathway has been reported to 
be a critical step in cancer progression (Behrend et al., 2003; Storz, 2005; Torimura et al., 
1998). In addition to regulating growth and angiogenesis, ethanol and ROS can activate 
pathways that direct metastasis and motility. The cellular processes linked to this are 
associated with decreased cell adhesion and increased migratory potential that allows 
cancer cells to enter the vasculature and escape detachment-induced cell death (Storz, 
2005).  
1.4.4. Role of Sex Hormones in Promotion and Progression:  Risk of developing 
HCC is 2 to 8 fold higher in males compared to females, suggesting a role for sex-
hormones and sex-hormone signaling, in addition to variations in risk exposure (Eagon, 
1996; Eagon, 1991; El-Serag, 2007; Lui et al., 2000). Sex hormone mediated differences 
in hepatic tumorigenesis may be due to differential response to toxic insults that disrupt 
normal sexually dimorphic gene expression (Rogers et al., 2007). Natural and synthetic 
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sex-hormone and steroid hormone signaling have been reported to promote ethanol-
induced liver injury and HCC progression (Christopherson et al., 1975; Eagon, 2001; 
Guy and Auslander, 1973; Henderson et al., 1973). Several studies have reported that 
androgens and androgen receptor (AR) signaling directly influence HCC progression and 
may induce a proliferative state (Nakagama, 1991; Scoccia et al., 1991; Yu and Chen, 
1993). Conversely, lower incidence of HCC in females has been linked to estrogen 
signaling and sex differences in modulation of immune responses, liver metabolic 
pathways and sex dependent differences in growth hormone and receptor expression 
during ethanol-induced liver injury (Becker, 1996 ; Bird, 2008; Eagon, 2001; Kovacs, 
2002; Naugler, 2007). Over expression of epithelial growth factor receptor (EGFR) was 
identified in HCC, and is reportedly enhanced by AR signaling as levels were determined 
to be higher in males compared to females (Scoccia et al., 1991). Inflammatory immune 
responses appear to be reduced by estrogen receptor (ER) α and β activation, but steatosis 
and infection may be sustained by AR activity (Naugler, 2007). Nuclear receptors are 
implicated in signaling pathways that modulate all these cell responses and male 
sensitivity to disease progression may be based on imbalances in nuclear signaling or 
cross interaction between multiple receptors. Sexual dimorphisms in expression of NFκB, 
STAT3, STAT1 and AP-1 have been identified and are likely influenced by AR and ER 
signaling. With aging and menopause protective effects of estrogen are abated and risk 
for hepatocarcinogenesis increases (Shimizu et al., 2001).  
1.5. Antioxidants:  
 1.5.1. Antioxidants in Ethanol-Induced Liver Injury:  Ethanol and its metabolites 
influence multiple cell types within the liver parenchyma that contribute to the 
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progressive nature of liver injury (Hoek, 2002; Yoshimura, 2006). Reactive oxygen 
species are generated by several mechanisms during ethanol metabolism and drive many 
of the toxic and inflammatory processes. Ethanol and its metabolites initiate changes in 
energy metabolism, ROS, and inflammation (Albano, 2006; Cunningham, 2003; 
McKillop, 2006). These processes promote global disruptions in both innate and adaptive 
immune responses, cellular and molecular signaling, as well as modifications to 
epigenetic programming, expression that influences disease progression (Hoek, 2002; 
Osna, 2007). In addition, production of other toxic aldehydes interact with cell constitutes 
to impede cell function, alter gene transcription, and impair DNA replication and repair. 
Combined, this contributes to the pattern of disease progression mitigated by oxidative 
stress that leads to cirrhosis and produces genetic damage that may eventually result in 
HCC. The link between oxidative stress and cancer and many progressive diseases has 
been supported by epidemiological and experimental data. This connection is further 
supported by success of antioxidant therapies that prevent or inhibit cancer progression 
(Gonda et al., 2009).  
 Reactive oxygen species are generated under normal physiological conditions. 
They are formed by incomplete single-electron reduction of oxygen (Albano, 2006; 
Arteel, 2003; Medina and Moreno-Otero, 2005). They are generated during many 
enzymatic processes in numerous cell types. In excess they have a potentially deleterious 
effect especially when normal defense mechanisms, superoxide disumutase (SOD), 
catalase, glutathione peroxidase, GSH are overwhelmed leading to oxidative stress 
(Albano, 2006; Albano, 2008; Medina and Moreno-Otero, 2005). Chronic ethanol 
exposure contributes to a state of persistent oxidative stress that may facilitate all stages 
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of hepatocarcinogenesis (Medina and Moreno-Otero, 2005). Antioxidants may be an 
effective means of preventing these deleterious effects. Numerous in vivo and in vitro 
studies have demonstrated that antioxidants, iron chelators or GSH replenishing agents 
can be effective in preventing the damaging effects of ethanol, although these studies 
have not translated into an effective therapy (Arteel, 2003; Medina and Moreno-Otero, 
2005). Additionally, the administration of antioxidants had been demonstrated to inhibit 
growth and progression of many cancers (Storz, 2005).  
1.5.2. Silibinin:  Silymarin is the extract of Silybum marianum (Milk Thistle) 
seeds, and is a mixture comprised of 70 - 80% flavinolignads and 20 - 30% undefined 
chemical fraction (Gazak, 2007; Lee, 2003). The major, and most biologically active 
component, is silibinin, which occurs as a 1:1 ratio of two diastereomers silybin A, and 
silybin B (Saller, 2001). Other flavinolignans are present in the silymarin complex, 
isosilybin A and B, silychristin, silydianin, (Figure 1.3: Flower and molecular structures) 
and taxifolin. The pharmacokinetics of silymarin are generally standardized as silibinin 
(Lee, 2003). There is considerable variability in the proportions of the various 
flavinoligands. This is influenced by the environmental conditions and location in which 
it is grown as well as the methods under which the extractions are prepared (Gazak, 2007; 
Saller, 2001). Silibinin is readily available as an over-the-counter herbal supplement. Its 
only prescribed medical use is to prevent uptake of Amanita phalloides, death cap 
mushroom toxin in hepatocytes, thereby protecting hepatic tissue (Carducci et al., 1996). 
Bioavailability of silibinin is relatively low and is dependent on many factors 
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Figure 1.3:  Drawing of Silybum marianum (Milk Thistle) and molecular structures 
of 6 major flavinoligands. Silymarin is derived from the seeds of the Milk Thistle plant. 
The extract contains a mixuture of flavinoligands consisting of, silychristin, silydianin, 
isosilybin A, isosilybin B, silybin A and silybin B. Silibinin is the most abundant and 
biological active compound in the mixture, and is comprised of a 1:1 ratio of 
diastereoisomers silybin A and silybin B (Wen et al., 2008) 
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including other components in the extract (such as fat, cholesterol, proteins), the 
concentration of the extract itself and variations in the individual flavinoligands (Saller, 
2001). Peak concentrations in serum are reached between 2 and 9 hours after oral 
ingestion. A small fraction (3-8%) of silibinin is excreted in urine, 20-40% is stored in 
the bile as glucuronide and sulfate conjugates, and the remainder is excreted in feces 
unchanged (Saller, 2001). Silibinin has very few side effects, even at high dosages. This 
is due, inpart, to its low solubility which prevents development of toxic levels (Gazak, 
2007). Side effects recorded during trials were limited to those associated with allergic 
reaction or gastrointestinal disturbance (Gazak, 2007). 
 1.5.2.1. History of silibinin:  There is a long history for use of plants and plant 
derivitives as natural remedies by physicians, herbalists, and folk healers for treatment of 
diseases. Silymarin has been used for the treatment of liver and gallbladder pathologies, 
and as a hepatoprotectant against ingested poisons for thousands of years. It first appears 
in a written compendium as described by Theoprastus in the 4th century B.C (Gazak, 
2007). Although largely forgotten during the Dark ages it has been mentioned in medical 
pharmacopeias for over 2000 years (Gazak, 2007). It is thought to function as an anti-
oxidant, anti-lipid-peroxidant, anti-fibrotic, while producing anti-inflammatory, immuno-
modulatory effects that promote liver regeneration. It has been used for treatment of viral 
and toxic hepatitis, fatty liver, cirrhosis, and ischemic injury (Saller, 2001). Currently, 
preparations of silibinin are used for treatment of cirrhosis, chronic hepatitis, and liver 
diseases associated with alcohol consumption or exposure to environmental toxins 
despite the fact that its efficacy in treating these diseases has not been firmly established 
(Gazak, 2007). Various studies report improvements in liver function as measured by 
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decreases in alanine-aminotranferase (ALT) levels, but there has been limited evaluation 
of other parameters or clinical measures (Gazak, 2007). Reports have cited both positive 
and negative effects in limited numbers of patients (Gazak, 2007; Saller, 2001). 
Additional reasons for the controversy, and lack of direct confirmation of its efficacy or 
mechanism of action may relate to inconsistencies in the formulations used, as well in the 
quality of scientific inquiries (Gazak, 2007). Additionally, the activity of silibinin on 
disease pathologies may be specific to the organ or cell type and bioavailability of the 
drug relative to dosage and time course of treatment (Saller, 2001).  
 1.5.2.2. Silibinin in ethanol-induced hepatic injury:  Flavinoids possess 
antioxidant activity, which was thought to be the basis of their therapeutic effect. 
However, studies conducted on the free-radical scavenging properties of silibinin found 
that it was ineffective at scavenging superoxide anion and had no reaction with hydrogen 
peroxide, but reacted rapidly with hydoxy radicals (Mira et al., 1994; Saller, 2001). 
Silibinin is  associated with increased SOD activity in vitro and in vivo as well as 
decreased lipid peroxidation and increased cellular GSH (Feher, 1988; Saller, 2001). 
Early emphasis on medical use of silibinin focused on efficacy to ameliorate high degrees 
of oxidative injury associated with free-radical damage in acute and chronic ethanol 
toxicity with and without cirrhosis (Saller, 2001). Measures of liver function as 
determined by ALT, and histology were improved, oxidative stress and lipid peroxidation 
were decreased and GSH levels were preserved (Stickel and Schuppan, 2007). In 
addition, patients were found to have decreased fibrotic response associated with 
decreased leukotriene formation in Kupffer cells. This prevented activation of stellate 
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cells and corresponded to a decrease in collagen type I expression (Stickel and Schuppan, 
2007).  
 1.5.2.3. Silibinin in cancer:  The majority of studies using silibinin have focused 
its antioxidant properties, but recent studies have identified new mechanisms of action 
that may have therapeutic uses in cancer treatment (Gazak, 2007).  There are 
inconsistencies in the formulations used, which complicates assessment of efficacy. The 
scope of its potential application has spread beyond the liver to include the heart, brain, 
kidneys, skin and prostate (Gazak, 2007). These additional modes of activity, besides 
regulation of inflammation, include modulation of steroid hormone receptor activity and 
drug transporters, and chemoprotection (Cornelli, 2007; Gazak, 2007). Cellular 
mechanisms of its anticancer properties can be categorized as growth inhibitory, anti-
angiogenic, anti-invasive, and pro-apoptotic (Bhatia et al., 1999; Chen et al., 2005; Lee et 
al., 2007; Momeny et al., 2008; Singh, 2004b; Tyagi, 2004; Zi, 2008). Many of these 
properties are activated in a very cell specific manner and are not always replicated in 
different cancer cell types (Cheung et al., 2010). 
 Silibinin exerts multiple effects on growth stimuli and growth factors. Growth 
inhibition associated with silibinin was identified in both LNCaP and DU134 (human 
prostate cancer cell line) mediated by increased expression of cell cycle inhibitors 
(Kip1/p27, Cip1/p21 and p53) (Chen et al., 2005; Cornelli, 2007; Varghese, 2005) . 
Alternate mechanisms of inhibition occurred through decreased activity of pathways 
activated by specific growth factors (EGF, IGF) (Cornelli, 2007; Zi, 2008).  Mitogen 
activated protein kinase signaling (MAPK/ERK1/2) is a component of these pathways, 
and signaling was inhibited in prostate, cervical and bladder cancer. This occurred 
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through decreased phosphorylation, corresponding to decreases in cell proliferation 
(Cornelli, 2007; Momeny et al., 2008; Ramasamy and Agarwal, 2008; Singh, 2004a). 
Multiple intermediary steps are involved in growth-factor mediated pathways. 
Interruption of these intermediates has also been demonstrated to impede tumor growth 
(IRS-1, P13K/Akt) (Bhatia, 1999; Ramasamy and Agarwal, 2008; Singh, 2004a).  
 Silibinin has been reported to inhibit inflammatory responses and subsequently 
improve apoptotic responses within tumors, and decreases angiogenesis through 
suppression of NFκB (Saliou, 2001; Singh, 2004a). Inhibitory properties may in part be 
related to silibinin-mediated inhibition of mitogen activated protein kinase cascades, and 
JNK (Manna, 1999; Saliou, 2001). Transcription activation by NFκB is modulated by 
REDOX regulation and contributes to IL-6, IL-1, and TNF expression. These cytokines, 
can in turn activate NFκB, which creates a positive feedback loop. Dampening of NFκB 
activity induces anti-cancer properties by decreasing TNF inflammatory response, 
increasing apoptosis and impaired angiogenesis (Karin and Greten, 2005; Tyagi et al., 
2009). This activity was modulated by silibinin, through decreased phosphoryaltion and 
degradation of inhibitory protein IκB  (Hill et al., 1999; Saliou, 2001). Reported anti-
cancer benefits of silymarin relate in part to inhibitory effects on growth and promotional 
effects on apoptosis. This occurs through multiple possible pathways, including p53 and 
facilitated release of cytochrome C with downstream activation of caspase 3 and 9 
combined with a corresponding decrease in surviving protein (Manna, 1999; Singh and 
Agarwal, 2004).  
Nuclear hormone receptors also play an integral role in activating transcription 
programs that can stimulate cancer growth. Silibinin, diasteriomer silybin B has been 
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reported to initiate partial activation of estrogen-receptors. This has implications for 
estrogen responsive tumors and those in which estrogen is deemed protective (Mueller, 
2004). Both silymarin and silybin have demonstrated anti-androgenic activity in 
androgen-responsive prostate cancer cell line LNCaP (Singh, 2004a).   
There has been a dramatic increase in published studies regarding the efficacy of silibinin 
as either an adjuvant therapy or directly to treat HCC over the past decade. Growth 
inhibitory effects were identified in HepG2 and HepG3 cell lines (Momeny et al., 2008; 
Varghese, 2005). Several pathways reported to be disrupted by silibinin are integral in the 
pathogenesis of HCC. 
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1.6. Hypothesis:  Silibinin will inhibit ethanol-dependent hepatic tumor progression in 
vitro and in vivo by inhibiting hepatic oxidative stress associated with ethanol 
metabolism.   
1.6.1. Specific aims: 
1. Determine the effects of ethanol on cell proliferation and ethanol metabolism in 
the absence and presence of silibinin in a rat hepatoma cell line in vitro. 
2. Identify mechanisms by which chronic ethanol intake alters HCC progression in 
male and female mice using a DEN model of hepatocarcinogenesis.  
3. Define the effects and mechanisms whereby dietary silibinin alters ethanol-
dependent changes in HCC progression in male and female mice using a DEN 
model of hepatocarcinogenesis.  
 
 
 
 
 
 
 
 
CHAPTER 2: MATERIALS AND METHODS 
 
 
2.1. In vivo Models of Hepatocellular Carcinoma 
2.1.1 Animal Assurances:  Male and female B6C3 F1 mice, Jackson Laboratories 
(Bar Harbor, ME) were used for these studies. All animal Protocols were approved by 
Carolinas Medical Center Institutional Animal Care and Use Committee (IACUC). 
Animals were housed in the vivarium at Cannon Research Center, Carolinas Healthcare 
Systems, and approved by the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC).  
2.1.2 Materials: Neonatal (21-25 day old) male and female B6C3 mice were 
purchased from Jackson Laboratories (Bar Harbor, ME), Diethylnitrosamine, olive oil, 
Heparin, 99% ethanol CH3CH2OH (200 proof), and silibinin (Batch # 128K1503, 
certified as a 1:1 ratio of silybin A and silybin B) were purchased from Sigma-Aldrich 
Chemical (St. Louis, Mo). Syringes (1 ml) with 23 gauge needles were purchased from 
VWR Scientific. Isoflurane was purchased from Abbott Labs (Abbott Park, IL). AIN-
93M mouse chow and AIN-93M mouse chow with silibinin (0.5% w/w) was purchased 
from DYETS (Bethlehem, PA). Ear tags were purchased from National Band and Tag 
Co. (Newport, KY). Goldenrod animal lancet 5 mm purchased from MEDipoint, 
(Mineola, NY).  
2.1.3. DEN Initiation:  Mice were given access to food and water ad libitum and 
maintained on a 12-hour dark/light cycle in compliance with Research Animal Use and 
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Care Guide. Male and female B6C3 mice (21-25 days old) were received from Jackson 
Labs and allowed to acclimate to the vivarium at CMC for 48 hours. After 48 hours, mice 
were transported to a satellite treatment area where they were randomly divided into 24 
or 48 week treatment groups, and further divided into individual male or female treatment 
groups designated as control (C), ethanol-drinking water only (E), silibinin diet only (S), 
diethylnitrosamine (DEN) initiated only (D), DEN plus ethanol drinking water (D+E), 
DEN plus silibinin diet (D+S), and DEN plus ethanol drinking water and silibinin diet 
(D+ES). Animals were then individually anesthetized by isoflurane inhalation in a bell 
jar. Anesthesia was confirmed by gauging response to pain stimulus. Animals were 
weighed and DEN, dissolved in olive oil to a final concentration of 0.1 mg/ml was 
administered at 1 milligram per kilogram (1 mg/kg) body weight by intraperitoneal 
injection using a 1 ml syringe with a 1”, 23 gauge needle. Alternately, animals were 
given an ip injection of an equal volume of olive oil without DEN as determined by body 
weight. Following ip injection with DEN or vehicle animals were ear tagged and caged in 
individual groups and monitored for signs of distress for 4 hours prior to being 
transferred back to vivarium. Mice were monitored daily with weights measured and 
recorded once per week. Animals were allowed to recover for 15 or 39 weeks before any 
additional treatments were administered (Figure 2.1, Experimental timeline).   
2.1.4. Silibinin diet and ethanol-drinking water regimes: Silibinin diet formulated 
from AIN93M mouse chow with or without 0.5% (w/w) Silibinin, DYETS (Bethlehem, 
PA) was introduced to male and female animals in Sil, D+S and DES groups 
commencing at 15 or 39 weeks. Animals were weighed everyday for one week and 
dietary intake was estimated and compared to pair-matched animals not receiving 
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silibinin diet. At 16 or 40 weeks animals were weaned onto ethanol drinking water 
regime. Initially, animal groups designated to receive ethanol drinking water (E, D+E and 
DES) were introduced to 5% (v/v) ethanol in drinking water for 3 days, on day 4 ethanol 
concentration was increased to 10% (v/v) for 2 days followed by an increase to 20% (v/v) 
at which time ethanol drinking water was alternated daily 10/20% (v/v) for the remainder 
of the experiment, with animals sacrificed at 24 or 48 weeks. On beginning either 
silibinin diet or ethanol drinking-water regime, alone or in combination, animal weights 
were measured and recorded twice each week.  
2.1.5. Liver resection and tissue collection: At 24 or 48 weeks, animals were 
transported to satellite treatment area, and anesthetized by isoflurane inhalation. Once 
anesthetized, blood was collected following a sub-mandibular venipuncture into 
microcentrifuge tubes with Heparin (1000 Units/ml) followed by cervical dislocation. A 
midline incision was made with liver and spleen tissue excised. Livers were weighed, 
examined for visible lesions, and representative liver sections (4-6mm) taken from the 
left, right, median, and anterior lobes. Sections were either snap frozen in liquid nitrogen 
and stored prior to analysis (-800C), or fixed in 10% neutral buffered formalin (24 hours) 
prior to transfer to 70% (v/v) EtOH for histological processing/analysis.  
Multiple lobes of the liver were dissected, with whole spleen and liver dissections 
placed in cryovials, flash frozen in liquid nitrogen, with additional sections placed in 
tissue cassette with optimal cryostat tissue (OCT) compound and rapidly frozen by 
submerging in a slurry of dry ice in -70oC isopentane. Remaining liver tissue was placed 
in 10% neutral buffered formalin for histology.   
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Figure 2.1: Experimental timeline. Infant mice (21-25) were give i.p. injections of 
vehicle (olive oil) or DEN (1 mg/kg). Silibinin diet was begun at 15 or 39 weeks 
continuing for 9 weeks, ethanol drinking-water was introduced at 16 or 40 weeks 
continuing for 8 weeks. Animals were sacrificed at 24 or 48 weeks. 
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2.2. Isolation of RNA: 
2.2.1. Materials:  RNeasy and Qia-shredder kits were purchased from Qiagen 
(Valencia, CA). Isopropyl alcohol, 100% ethanol, glycerol, sodium acetate, 100x Tris 
(hydroxymethyl) aminomethane (Tris)-Ethylenediaminetetraacetic acid (EDTA) solution 
ethidium bromide solution and diethyl pyrocarbonate (DEPC) were purchased from 
Sigma Aldrich (St. Louis, MO). Model 5402 and 5415 centrifuges and a model 5331 
thermocycler were purchased from Eppendorf (Hauppauge, NY). CFX96 Touch Real-
time polymerase chain reaction (PCR) detection system and SYBR Green Supermix 
master mix, agarose powder, gel boxes and DNA loading dye were purchased from 
BioRad (Hercules, CA). RQ1 DNase treatment, ImpromII reverse transcriptase with 
random primers for cDNA synthesis, GoTaq Green PCR master mix kits and 100 b.p. 
DNA ladder were purchased from Promega (Madison, WI). Primer pairs were purchased 
from IDT (Coralville, IA) (Table 2.1). 10x Tris-Boric Acid-EDTA (TBE) buffer was 
purchased from USB (Cleveland, OH). A digital camera, camera box and 
transilluminator, and photo acquisition software were purchased from Eastman-Kodak 
(Rochester, NY).  
2.2.2. RNA Isolation from Animal Tissue: RNA was isolated from liver and 
spleen tissue from individual animals in each treatment group, as per the manufacturer’s 
instructions using RNeasy® kits. Briefly, flash frozen tissue was homogenized in RTL 
buffer. This solution was then loaded into Qia-shredder® spin columns and the columns 
centrifuged at 16,000 x g for 1 minute at RT.  One volume of 50% EtOH (v/v) in ultra-
pure water was added to the flow through, pipetted and transferred to an RNeasy® 
column. Columns were centrifuged at 16,000 x g for 15 seconds at RT. Washed three 
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times (16,000 x g: 15 seconds, 15 seconds, 2 minutes at RT) with proprietary buffers as 
supplied in the kit. A final spin at 16,000 x g, 1 minute at RT was performed with 35-50 
μl of DEPC water. Typical yields were between 250-500 ng/μl in 40 μl.  
2.2.3. Reverse transcription PCR: Reverse transcription was performed, as per the 
manufacturer’s instructions using the Promega ImProm II® RT system. Reaction 
mixtures were prepared in 0.5 mL PCR tube, and consisted of 0.5 μl of random hexamers 
(supplied as 0.5μg/ml in water), 1μg RNA template (equal amounts,1 μg from individual 
animals in each treatment group pooled), 1 μl RQ1 buffer and 1 μl RQ1 DNAse and 
nuclease-free water was added to adjust each reaction mixture to a final reaction 
volume/tube of 9 μl. Tubes were placed in an Eppendorf thermocycler and incubated at 
37oC for 30 minutes. After this incubation, the reaction was paused and 1μl RQ1 stop 
reagent was added, then reaction was incubated at 75oC for 10 minutes followed by 25 oC 
for 30 seconds. At this time the reaction was paused, and a master mix, consisting of the 
following components (per reaction) was added: 2 μl nuclease-free water, 4 μl ImPromII- 
5x reaction buffer, 2 μl MgCl2 (6 mM), 1 μl dNTP mix, 1 μl ImPromII Reverse 
Transcriptase. The total master mix volume per reaction was 10 μl, and this was aliquoted 
into PCR tubes and the following program completed in the thermocycler: 25 oC (5 
minutes), 42 oC (30 minutes), 95 oC (5 minutes), after which the reaction was cooled to 4 
oC. At this time, 300 μl 100% EtOH with 2 μl 3.0M sodium acetate (pH 5.2) was added 
to RT product and precipitated overnight at -70 oC, Following precipitation, cDNA was 
centrifuged at 4 oC, 14,000 x g for 10 minutes and 100% EtOH was aspirated, 300 μl 70% 
EtOH was added and sample vortexed followed by second centrifugation (4 oC, 14,000 x 
g, for 10 minutes). Following centrifugation 70% EtOH was aspirated and cDNA was 
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suspended in 35 μl nuclease-free water. cDNA was quantified yields,  were typically 
between 100-350 ng/μl.  
Measures of CYP2E1 mRNA expression performed using mouse or rat specific 
CYP2E1 primer pairs (Table 2.1). cDNA was diluted to 100 ng/μl and Promega GoTaq 
Green® master mix prepared with the following constituents  (12.5 μl master mix, 1 μl 
forward primer (1.0 μM), 1 μl reverse primer (1.0 μM), 8 μl nuclease-free water). The 
total volume of master-mix per reaction was 23 μl. This was aliquoted into 0.2 mL PCR 
tubes and 2 μl cDNA (100 ng/μl) template was added and amplified using an initial 
denaturing of 95oC for 2 minutes, followed by 30 cycles of 95 oC (45 seconds), 55 oC (45 
seconds), 72 oC (45 seconds) and a final extension of 72 oC for 2 minutes. Final product 
was eluted on a 2% agarose gel containing 10μl/100 mL of ethidium bromide (EtBr), 8 μl 
100 b.p DNA ladder was added to the first well and 10 μl of each reaction sample was 
added to subsequent wells. The gel was resolved at 90 mA until the dye front reached the 
end of gel, at which time, the gel was transferred to a transilluminator and digital images 
captured. Signal intensity was semi-quantified using NIH-ImageJ software and corrected 
to β-2 microgoblulin (β2M mouse) or β-actin (rat) (housekeeping gene) specific levels.  
2.2.4. Quantitative reverse transcriptase PCR: qRT-PCR was performed as 
follows: cDNA was diluted to 25 ng/μl and a SYBR Green Supermix® master mix was 
prepared with the following constituents: 8.5 μl nuclease-free water, 1.0 μl forward 
primer (10 μM), 1 μl reverse primer (10 μM), 12.5 μl SYBR Green master mix for a total 
volume of 23 μl per reaction,  23 μl master mix was then aliquoted into 96 well plates and 
2 μl cDNA (50 ng) template from individual samples was aliquoted into individual wells.  
Quantitative analysis of mRNA for mouse specific primer pairs for T-bet, GATA3,  
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Table 2.1: Primer pair sequences: Primer sequences against mouse (Mus musculus) 
specific CYP2E1, GATA3, SMAD3, T-bet and , β2M and rat (Rattus norvegicus) 
CYP2E1 and β-actin were selected using Primer3 software. All primer sequences were 
BLAST analyzed to assure specificity.  
 
GENE Direction Sequence Product
Forward 5’ AGG CTG TCA AGG AGG TGC TA 3’ CYP2E1 
Mus musculus Reverse 5’ GGA AGT GTG CCT CTC TTT GG 3’ 
210 bp 
Forward 5’ GCA AAA AGG AGG GTT TAG GG 3’ GATA3 
 Reverse 5’ GTG GTC ACA CTC GGA TTC CT 3’ 
190 bp 
Forward 5’ GGG CCA ACA AGT CAA CAA GT 3’ SMAD3 
 Reverse 5’ CTG GCT GGC TAA GGA GTG AC 3’ 
232 bp 
Forward 5’ CCT GGA CCC AAC TGT CAA CT 3’ T-bet 
 Reverse 5’ AAC TGT GTT CCC GAG GTG TC 3’ 
173 bp 
 
Forward 5’ ATG GGA AGC CGA ACA TAC TG 3’ β2M 
 Reverse 5’ CAG TCT CAG TGG GGG TGA AT 3’ 
177 bp 
Forward 5’ CCT ACA TGG ATG CTG TGG TG 3’ CYP2E1 
Rattus norvegicus Reverse 5’ CTG GAA ACT CAT GGC TGT CA 3’ 
171 bp 
Forward 5’ GAG CTA TGA GCT GCC TGA CG 3’ Β-actin 
Reverse 5’ GGA TGT CAA CGT CAC ACT TC 3’ 
150 bp 
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SMAD3 (Table 2.1) were analyzed on a CFX96 Touch® real time PCR detection system 
(BioRad) using an annealing temperature of 54oC (Mantel et al., 2007; Yu et al., 2006). 
Samples were assayed in duplicate, and relative gene expression of each transcript was 
expressed as ΔcT and normalized to β-2 microgoblulin (housekeeping gene) from pair-
matched controls (Livak, 2001). 
2.3. Preparation of Tissue Lysates: 
2.3.1. Materials:  Hepes, sodium chloride (NaCl), magnesium chloride (MgCl2), 
Triton X-100, β-glycerophostate, sodium dodecyl sulfate (SDS), sodium deoxycholate, 
ethylenediaminetetraacetic acid (EDTA), KH2PO4, K2HPO4,2-(N-
morpholino)ethanesulfonic acid, Tris-HCl, dithiothreitol (DTT), sodium vanadate and 
Igepal CA-210 (nonident p40), and β-mercaptoethanol were all purchased from Sigma 
Aldrich (St. Louis, MO) complete protease inhibitor cocktail (PMSF, Leupeptin, 
Apotinin, Pepstatin) was purchased from Roche (Indianapolis, IN), Laemmli buffer was 
purchased from BioRad (Hercules, CA). 
2.3.2. Lysates from Animal Tissue:  Flash frozen Liver tissue (25 mg) was 
collected in the one of the buffer preparations (Table 2.2). Laemmli buffer (50 μl  β-
mercaptoethanol to every 950 μl Laemmli buffer was prepared for Western blots. Tissue 
was homogenized followed by 30 seconds of sonication, protein was quantified by BCA 
and equalized appropriate buffer.  
2.4.  Western Blot. 
2.4.1. Materials:  BCA Protein Assay Reagent Kit, CL-X Posure film and ECL 
detection reagents were purchased from Pierce Biotechnology (Rockford, IL).  Tris-base, 
glycine, ammonium persulfate (APS), TEMED, Tween-20, NaCl, 12M hydrochloric acid  
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Table 2.2:  Buffers used for preparation of tissue lysates:  List of buffers used with 
chemical components required for each preparation. 
Buffer Constituents Concentration 
Tris-HCL 50 mM 
Nonident p40 (Igepal) 1% (v/v) 
Sodium deoxycholate 0.25% (w/v) 
Sodium chloride 150 mM 
Radioimmunoprecipitation 
assay (RIPA) buffer 
 
 
EDTA 1 mM 
Buffer prepared in ultra pure H2O as a stock solution, protease inhibitors added to 
working solution.  
Hepes 25 mM 
NaCl 0.3 M 
MgCl2 1.5 mM 
Triton X 100 1% (v/v) 
β-glycerophostate 20 mM 
Sodium Dodecyl sulfate (SDS) 0.1% 
Sodium deoxycholate 0.5% (w/v) 
mitogen activated protein 
kinase  (MAPK) lysis buffer 
 
EDTA 0.25 mM 
Buffer prepared in ultra pure H2O as a stock solution, protease inhibitors added to 
working solution 
Tris-HCL 50 mM 
2-(N-morpholino) ethanesulfonic acid 50 mM 
EDTA 0.5 mM 
2-(N-morpholino) 
ethanesulfonic acid (MES) 
buffer 
Sodium Dodecyl sulfate (SDS) 0.1% (w/v) 
Buffer prepared in ultra pure H2O as a stock solution, protease inhibitors added to 
working solution 
K2HPO4 1 M 0.1M Potassium phosphate 
buffer pH 6.8 KH2PO4 1 M 
49.7 mL of 1M K2HPO4 with 50.3 mL of KH2PO4 diluted to 1L in ultra pure H2O 
Protease Inhibitors: Phenylmethylsuflonyl fluoride 
(PMSF) 
1 mM 
 Na3VO4 1 mM 
 NaF 1 mM 
Stock solutions prepared  0.1 mM/μl added to working solutions to final concentration as 
indicated with complete protease inhibitor tablets purchased from Roche 
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(HCL), β-mercaptoethanol (BME), methanol and SDS were all purchased from Sigma-
Aldrich (St. Louis, MO).  Laemmli buffer, bis-Acrylamide (30%), mini-Protran 
electrophoresis system, min-Trans-Blot module and blotting grade non-fat dry milk 
(NFDM) were purchased from BioRad Laboratories (Hercules, CA). Nitrocellulose 
membrane was purchased from Amersham Biosciences (Piscataway, NJ). See Blue Plus 
II pre-stained protein molecular weight marker was purchased from Invitrogen Life 
Sciences (Carlsbad, CA). X-ray film was developed using a Konica SRX-101 Medical 
film developer (Mahwah, NJ). Densitometry was determined using ImageJ imaging 
software from the NIH (Rasband, 1997-2011). Molecular Devices SpectraMax 5e plate 
reader (Sunnyvale, CA). Electrophoresis running buffer (25 mM Tris, 0.2 M glycine and 
3.5 mM SDS). Electrophoresis transfer buffer (25 mM Tris, 0.2 M glycine, 20% (v/v) 
methanol). Tween-TBS was prepared with TBS with 0.05% (v/v) Tween 20.  
2.4.2. BCA Protein Assay:  Protein concentrations were determined using a BCA 
protein assay kit, as per manufacturer’s protocol.  Protein standards (0-2000 µg/mL) were 
prepared using bovine serum albumin (BCA kit) diluted in RIPA buffer (prepared as 
describe in Section 2.2, Table 2-2). Standards and sample lysates were assayed in 
duplicate using a 96 well microplate.  Working BA reagent was prepared by diluting 
reagent B with Reagent A mixture (1:50) for a 200 µl volume per analyte) and solution 
was added to each well containing standards and sample lysates. The plate was sealed 
and incubated at 37oC for 30 minutes.  Absorbance at 562 nM was measured on a 
SpectraMax 5e plate reader. The mean absorbance was corrected to zero standard 
absorbance and plotted versus protein concentration. The resulting standard curve was 
used to calculate the protein concentration of unknown samples. Protein concentrations 
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from individual samples were equalized by standard buffers and diluted to a final 
concentration of 2μg/μl, or alternately equal concentrations of protein from individual 
samples in each group were pooled and normalized to final concentration of 2μg/μl in 
prepared Laemmli (section 2.4.2) and boiled for 5 minutes. 
 2.4.3. Preparation of SDS-PAGE/ Western blot gels:  SDS-PAGE gels were 
prepared using the mini-protean 3 electrophoresis system.  The lower gel (resolving)  
contained 10-15% (v/v) 30% (w/v)  bisacrylamide solution made with 1.5 M Tris buffer 
(1.5 M Tris, 15 mM SDS, pH 8.8), ultra-pure water, APS (0.75 mM) and TEMED 
(7mM).  The upper gel (stacking) contained 13.5% (v/v) 30% (w/v) bisacrylamide 
solution , 32% (v/v) SDS PAGE lower buffer (0.5 M Tris, 14 mM SDS, pH 6.8), 
ultrapure water, APS (0.75mM) and TEMED (7 mM).  Wells for protein loading were 
created in the upper gel using performed combs. 
 2.4.4. Methods immunoblot:   Sample protein lysates were prepared in RIPA 
buffer, concentrations were equalized in Laemmli buffer and boiled for 5 minutes prior to 
loading (25-40 µg) on SDS-PAGE gel. See-blue marker plus II (10 µl) was loaded into 
the gel.  Proteins were electrophoresed using the Mini-Protean 3 electrophoresis system 
and electrophoresis buffer.  Proteins were transferred to nitrocellulose membranes in a 
Mini-Trans Blot module on ice using electrophoresis buffer. Membranes were blocked 
with blocking solution (5% NFDM w/v in TBS) for 1 hour at room temperature (RT) with 
rocking. Following blocking, membranes were washed 3 x 10 minutes each wash in 
TBS/Tween-20. Membranes were incubated overnight with primary antibody (1:1000 
dilution) in blocking solution.  After incubation with primary antibody, membranes were 
washed 3x 10 minutes each wash in TBS/Tween-20 followed by 2 hour incubation at RT 
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with appropriate peroxidase conjugated secondary antibody diluted 1:5000 or 1:1000 in 
blocking solution with rocking.  Membranes underwent a final set of 3 – 10 minute 
washes and were incubated with ECL detection system and exposed to X-ray film before 
processing in Konica medical film developer. Films were scanned on an Epson scanner 
and digitally stored for analysis of optical integrated volume using ImageJ software.  
 2.4.5. Antibodies:  Monoclonal anti-phosphorylated ERK 1/2 Thr202/Tyr204, 
Thr185/Try187 (AW39R) and polyclonal Anti-cytochrome P450 Enzyme 2E1 (CYP2E1) 
(AB1252) was purchased form Millipore (Temecula, CA), Anti-alcohol dehydrogenase 
(ADH) (SC-22750), -aldehyde dehydrogenase (ALDH 1/2)(SC-50385), Anti-Actin 
(SC1616), anti-extracellular regulated kinase (ERK1)(SC-93) were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). Anti-rabbit biotinylated secondary antibody and 
anti-goat HRP conjugated secondary antibody were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). 
 2.4.6. Densitometry and statistical analysis: All densitometry was performed 
using ImageJ (Rasband, 1997-2011). All statistics were calculated and charts created 
using Prism5, Graphpad (La Jolla, CA). 
2.5. Histology, Immunohistochemistry, and TUNEL: 
2.5.1. H&E and Picrosirius Red staining         
2.5.1.1. Materials Histology: Superfrost plus slides 75 x 25 mm were purchased 
from Cardinal Health, (Dublin, OH), cover slips and permamount were purchased from 
Fisher Scientific (Waltham, MA). Modified Mayer’s Hemotoxylin, Eosin and Picrosirius 
Red were purchased from American MasterTech Scientific (Lodi, CA). Xylene, hydrogen 
peroxide, and phosphate buffered saline were purchased from Sigma Aldrich, (St. Louis, 
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MO). Graded ethanol (70%, 95% and 100% (v/v)) were purchased from Pharmo Products 
(Brookfield, CT) 
2.5.1.2. Methods H&E and Picrosirius Red: Tissue sections from multiple liver 
lobes were mounted on slides and stained with Hemotoxylin and Eosin (H&E) for 
morphology and Picrosirius red stained for collagen deposition. Hepatic tissue was 
collected at sacrifice and stored in 10% neutral buffered formalin (section 2.1.4) for at 
least 24 hours at RT. Liver tissue was sectioned and transferred to an appropriate tissue 
mold. Tissue in mold was dehydrated by a series of graded ethanol washes and processed 
into paraffin blocks by a series of xylene washes followed by paraffin embedding in an 
automated tissue processor machine. The resulting embedded blocks were cut to 4 μm 
sections and each section adhered to a positively charged glass slide. Mounted sections 
were heated to 60oC for 20 minutes, and paraffin was removed and sections rehydrated in 
a series of xylene, graded ethanol and water washes at RT as follows: xylene (3 washes 3 
minutes per wash), graded ethanol (2 washes 3 minutes/ 100% ethanol (v/v), 1 wash 3 
minutes/70% (v/v) ethanol), slides were placed in distilled water (2 washes 2 minutes per 
wash or until clear). Rehydrated, deparaffinized sections were stained at RT in Meyer’s 
modified Hematoxylin (4 minutes), rinsed under running water until clear and placed in a 
coplin jar with fresh dH2O for final rinse prior to Eosin stain (45 seconds). Alternately, 
sections were stained in modified Meyer’s hemtoxylin (5 minutes) for nuclear staining, 
Picrosirius red (1 hour) and followed by subsequent washing steps. After staining, 
sections were rinsed and dehydrated in a series of graded ethanol and xylene washes 
before coverslip mounting.  
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2.5.1.3. Scoring H&E and Picrosirius Red:  Sections were imaged on an Olympus 
1X70 microscope and digital images recorded at 100x magnification. A minimum of 10 
fields per liver from multiple lobes were imaged.  H&E stained slides were blind scored 
by three independent reviewers per modified criteria previously reported (Table 2.3) 
(French et al., 1993; Morgan et al., 2002). Picrosirius red staining for collagen was 
quantified using ImageJ software (Rasband, 1997-2011). Images were first converted to 
grayscale and scale was set to 200 μm as and scale bar on micrograph was measured to 
establish scale. Image was stacked into red, blue and green channels threshold was 
adjusted in green channel which demonstrated the best contrast, and set for use in all 
slides, % Sirius red staining as a measure of collagen was calculated.  
2.5.2.  Immunohistochemistry 
2.5.2.1. Materials Immunohistochemistry: Superfrost plus slides 75 x 25 mm were 
purchased from Cardinal Health, (Dublin, OH), cover slips and permamount were 
purchased from Fisher Scientific (Waltham, MA). Proteinase K, phosphate buffered 
saline (PBS) and, hydrogen peroxide were purchased from Sigma Aldrich (St. Louis, 
MO), 10mM citrate buffer (pH 6.0), and methyl green stain were purchased from Poly 
Scientific (Bay Shore, NY), Modified Mayer’s Hemotoxylin, was purchased from 
American MasterTech Scientific (Lodi, CA). Graded ethanol (95% and 100% (v/v)) were 
purchased from Pharmo Products (Brookfield, CT), ABC staining kit and goat or rabbit 
normal serum were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Steamer was purchased from Black & Decker (Towson, MD). Tissue processor model 
(ATP1) was purchased from Triangle biomedical Sciences (Durham, NC). Rodent  
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Table 2-3:  Pathological scoring criteria: Scoring criteria employed in blind scoring of 
hisotology slides after H&E and Picro sirius red staining. Modified from standards as 
reported in (French et al., 1993; Morgan et al., 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Score Pathological 
parameter 0 1 2 3 4 
Steatosis Normal 
liver 
Micro-vesicular 
fat, vesicles in 
<10% of 
hepatocytes 
Micro/macro-
vesicular fat 
vesicles, present 
in 10-30% of 
hepatocytes 
Micro & macro-
vesicular fat 
vesicles, present 
in >30% of 
hepatocytes 
Macro-vesicular 
fat vesicles, 
present in 
multiple zones 
with bridging   
Necrosis Normal 
liver 
Individual 
scattered 
necrotic cells 
Scattered 
necrotic cell 
clusters <10 
cells 
Scattered 
necrotic cell 
clusters > 10 
cells 
Multiple 
necrotic cell 
clusters within 
field 
inflammation Normal 
liver 
Scattered 
inflammatory 
cells  
Scattered small 
cells 
inflammatory 
cells, hepatocyte 
damage in zones 
1-3 
Scattered small 
inflammatory 
cell collections, 
hepatocyte 
damage multiple 
zones 
Large, multiple 
scattered small 
inflammatory 
cell collections 
extensive 
hepatocyte 
damage 
Fibrosis Normal 
liver 
0-4% 5-9% 10-14% >15% 
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Decloaker, rodent block, Tris-buffered saline (TBS), goat or rabbit polymer kit, 
denaturing solution  Betazoid, Bajoran Purple and Vulcan fast Red DAB chromagen, 
were purchased from Biocare Medical (Concord, CA). A fluorescein In situ cell death 
terminal dUTP nick end label (TUNEL) detection kit was purchased from Roche 
(Indianapolis, IN). Olympus IX70 fluorescent microscope was used for imaging. 
2.5.2.2. Methods GSTpi staining:  Section (4 μm) from formalin fixed, paraffin 
embedded tissues were cut and mounted on Superfrost Plus slides. Sections were air dried 
overnight and baked in an oven at 60oC for 20 minutes, after cooling they were 
deparaffinized and rehydrated (as described Section 2.6.1.2). After rehydration slides 
were placed in a staining dish containing 10 mM citrate buffer and staining dish was 
placed in a Black& Decker steamer (1 hour). Sections were cooled to RT and treated with 
3% H2O2 to quench endogenous peroxidase activity for 3 minutes followed by 2x wash 
with dH2O (1 minute). Sections were placed in a humidified chamber at RT and blocked 
with goat serum (30 minutes). Sections were incubated with anti-glutathione S-
transferase placental isoform (GSTpi) (1:100 dilution). Detection was performed using an 
ABC kit counterstained with Mayer’s hematoxylin for GSTpi. Sections were imaged at 
100x magnification on Olympus IX70 microscope and digital images captured, minimum 
of 10 sections per liver. Area (mm2) and multiplicity of altered hepatic foci (AHF) were 
determined by counting clusters (>2) of GSTpi positive cells (multiplicity) or alternately, 
measuring clusters (mm2) using ImageJ software (Rasband, 1997-2011). 
2.5.2.3. Methods PCNA staining:  Sections (4 μm) from formalin fixed, paraffin 
embedded tissues were cut and mounted on Superfrost Plus slides. Sections were air dried 
overnight and baked in an oven at 60oC for 20 minutes, after cooling they were 
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deparaffinized and rehydrated (as described Section 2.5.2.1). Sections were treated with 
3% H2O2 to quench endogenous peroxidase activity and washed 2x with dH2O (1 minute 
each). After rehydration slides were placed in a staining dish containing antigen retrieval 
solution (Rodent decloaker) and heated in a Black&Decker steamer (40 minutes).  After 
cooling on a bench for 20 minute, slides were rinsed 2x in dH2O.  Slides were laid flat in 
a humid chamber and Rodent Block M was applied for 20 minutes followed by two 
rinses with Tris-PBS (TBS). Primary goat polyclonal Anti-PCNA antibody was applied 
and incubated at RT for 30 minutes followed by 2 rinses with TBS. Goat probe and goat 
polymer were applied for 10 minutes each with TBS rinses between applications. 
Betazoid, DAB chromagen was applied and allowed to develop for 1 minute followed by 
2x rinses dH2O. Sectons were counterstained with methyl green for nuclear visualization, 
rinsed and slides were mounted with coverslips. Sections were imaged at 200 x 
magnification on an Olympus IX70 microscope.  
2.5.2.4. Methods in situ TUNEL assay: An In situ TUNEL assay was performed 
and sections counterstained with 4'-6-Diamidino-2-phenylindole (DAPI) for nuclear 
visualization. Sections (10 μm) from formalin fixed, paraffin embedded tissues were cut 
and mounted on Superfrost Plus slides. Sections were air dried overnight and baked in an 
oven at 60oC for 20 minutes, after cooling they were deparaffinized and rehydrated 
(section 2.6.1.3) and stored in dH2O. Sections were treated with 3% H2O2 to quench 
endogenous peroxidase activity an washed 2x with dH2O followed by Proteinase K (20 
μg/ml) in Tris-PBS buffer at 37oC (30 minutes). Slides were laid flat in a humid chamber 
and covered with enzyme-probe solution, incubated at 37oC (1 hour) after which a final 
 
 
61
wash series 3x in PBS. Slides were mounted with DAPI coverslips. Sections were imaged 
at 200 x magnification on an Olympus IX70 microscope.  
2.5.2.5. Scoring: A minimum of 5 sections per lobe, 2 lobes/liver were viewed 
and digital images captured. PCNA positive and negative cells were quantified using cell 
counting features of ImageJ software and established as % PCNA positive cells 
(Rasband, 1997-2011). Positive control for PCNA was mouse spleen. A minimum of 5 
sections per lobe, 2 lobes/liver were viewed and digital images captured. Images were 
analyzed using ImageJ software. Image for in situ slides was first converted to grayscale 
and RBG stacked. Threshold was set in green channel and TUNEL positive cells were 
counted in a minimum of 5 sections per lobe, 2 lobes/liver. To confirm antibody 
specificity embryonic tissue was used as positive control and enzyme-free probe as 
negative. 
2.6.      BioPlex Cytokine Assay: 
2.6.1. Materials:  A custom BioPlex suspension array of 7 cytokines key to 
development or maintenance of specific T-effector responses or those implicated in liver 
injury and HCC (Th1 – Il-1b, IFNγ, IL-12p70, Th2 – IL-13, T-regulatory – IL-10 and 
cytokines implicated in liver injury – IL-6 and TNFα) was purchased from BioRad 
(Hercules, CA). Mouse serum diluent, standards, 96 well filtration plate, BioPlex wash 
buffer, pre-mixed beads coated with target antibodies were all supplied by the 
manufacturer. 
2.6.2. Methods:  To access and compare cytokine expression patterns in male and 
female mice at both early (24wk) and late (48wk) HCC development, a Bio-Plex custom 
murine cytokine array for simultaneous quantification of  7 cytokines involved in 
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inflammatory and effector T- cell responses (TNFα, IL-6, IFNγ, IL-12p70, IL-1b, IL-10, 
IL-13) was performed. Pooled serum from each treatment group was diluted 1:4 in 
proprietary serum sample diluents. Premixed standards were reconstituted in 0.5 ml of 
murine serum diluent, generating a stock concentration of 32,000 pg/ml for each cytokine 
and serially diluted to generate a standard curve.  The assay was performed in a 96-well 
filtration plate supplied with the assay kit and pre-wetted with 100 µl Bio-Plex assay 
buffer.  Premixed beads (50 µl) coated with target capture antibodies were transferred to 
each well of the filter plate (5000 beads per well per cytokine) and washed twice with 
Bio-Plex wash buffer. Premixed standards or diluted samples (50 µl in Bio-Plex assay 
buffer were added to each well containing washed beads. The plate was shaken (1100 
rpm) for 30 sec, followed by 60 min room temperature incubation with continued shaking 
(300 rpm). Following incubation, premixed detection antibodies (25 µl, final 
concentration 2 µg/ml) were added to each well.  Incubation was terminated after an 
additional 30 min with shaking (1100 rpm, 30 sec reduced to 300 rpm) at room 
temperature; beads were washed 3 times in Bio-plex wash buffer, buffer removed by 
vacuum filtration. Streptavidin-PE (50 µl) and shaking as previously for 10 min and 
washed 3 times with Bio-plex wash buffer, buffer removed by vacuum filtration. Beads 
were resuspended in 125 µl Bio-Plex assay buffer and shaken (1100 rpm) for 30 sec 
before being read on the Bio-Plex suspension array system and analyzed using Bio-Plex 
manager software. 
2.7.  Serum ALT/AST:  
2.7.1. Materials:  Serum alanine-aminotransferase (ALT) and serum aspartate-
aminotransferase (AST) were measured using an ALT/GPT or AST/GOT 2-part reagent 
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(Thermoscientific, Pittsburg, PA) in a SpectraMax 5e plate reader, (Molecular Devices 
Sunnyvale, CA).  
2.7.2. Methods:  Mouse serum was collected and stored at -80oC as described 
(section 2.1.4). Aliquots stored for measuring serum ALT/AST. Serum analysis was 
conducted as per the manufacturer’s protocol. Briefly, ALT/AST infinity reagent was 
warmed to 37oC, individual serum samples were diluted 1:10 (25 μl sample:250 μl 
infinity reagent).  250μl was loaded into 96 well plates and 25 μl of serum or dH2O were 
added to wells in duplicate. Absorbance at 340 nm was read at 0, 1, 2 and 3 minutes and 
the average change (decrease) was calculated over time. Serum concentration of 
ALT/AST was calculated by the following formula:  
 U/L = ((ΔAbs x 0.275 mL) x 1000)/(0.025 mL x 6.3 x 1) 
Activity in U/L as determined by mean change in absorbance per minute x factor where 
the factor is calculated as total reaction volume in mL x 1000 divided by sample volume 
in mL x coefficient of NADH at 340 nm (6.3) x path length (1 cm). Absorbance was first 
corrected by subtracting absorbance of blank well (reagent + water). An internal standard 
from rat serum calculated to be between 11-14 U/L was run in parallel with each assay.  
2.8. Blood Alcohol Content: 
2.8.1. Materials BAC mouse serum:  EnzyChrom ™ Ethanol assay kit BioAssay 
systems. SpectraMax 5e plate reader, Molecular Devices (Sunnyvale, CA). This is a 
colorimetric assay used to determine serum ethanol concentration. Assay is based on 
alcohol dehydrogenase activity catalyzed oxidation of ethanol in which NADH is coupled 
to formazan (MTT) chromagen.  The intensity of the color product measured at 565 nm is 
proportional to ethanol concentration.  
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2.8.2. Methods BAC mouse serum:  Mouse serum was collected and stored at -
80oC as described (section 2.1.4). Aliquots were stored for measuring serum BAC. Serum 
analysis was conducted as per the manufacturer’s protocol. Standards were prepared from 
a 1% ethanol standard provided in assay kit (1 vol % ethanol = 170 mM or 785 mg/dL) 0-
1% range. A working reagent was prepared as follows: for each reaction 80 μl Assay 
buffer, 1 μl enzyme mix, 2.5 μl NAD and 14 μl MTT was prepared a total volume of 90 
μl per well working reagent was added to 96 well plates with 10 μl standard or sample in 
duplicate and blank wells consisting of working reagent with dH2O. The plate was tapped 
gently to mix and incubated at RT for 30 minutes and100 μl of stop reagent was added to 
each well. The plate was placed in plate reader, and following a 15 second mixing stage, 
absorbance was read at 565 nm. Concentration of ethanol was calculated as  
[EtOH] =  Abs (sample) – Abs (Blank) divided by slope of standard curve. 
2.9.    TBARS for malondialdehyde:   
2.9.1. Materials TBARS:  A thiobarbituric acid reactive species (TBARS) assay 
kit was purchased from Cayman Chemical.  This is a colormetric assay that measures 
thiobarbituric acid reactive substances to assess lipid peroxidation, malondialdehyde 
(MDA) levels in plasma, serum, urine or tissue homogenates. A SpectraMax 5e plate 
reader, (Molecular Devices;Sunnyvale, CA). 13 x 110 mm snap cap glass test tubes were 
purchased from VWR. 
2.9.2. Methods TBARS from animal tissue:  A TBARS assay was performed on 
lysates from liver tissue. Liver tissue from individual animals was weighed with lysates 
prepared from 25 mg of tissue in 100 μl of RIPA buffer as described (section 2.3.2, table 
1) and sonicated (15 seconds) at 40 V over ice. Lysates were centrifuged at 1600 x g for 
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10 minutes at 4oC, and supernatant collected for analysis. Assay was conducted as per the 
manufactuer’s protocol. MDA standards (0-400 μM MDA) were prepared from MDA 
stock solution provided in assay kit and diluted in RIPA buffer. Test tubes 13 X 110 mm 
with snap caps were labeled and 100 μl of supernatant was added to each tube with 100 
μl SDS solution and 4 mL prepared color reagent supplied with kit. Tubes were capped 
and placed upright in 1000 mL beaker submerged to the volume of the sample and 
regents in vigorously boiling water (1 hour). At termination tubes were immediately 
placed in ice bath to stop reaction and placed on ice (10 minutes). Tubes were centrifuged 
for 10 minutes at 1600 x g, 4oC. An aliquot (150 μl) of each sample and standard were 
loaded into 96 well plates in duplicate, and absorbance was read at 540 nm. Average 
absorbance of each well was calculated and absorbance for standard (0 MDA) was 
subtracted.  A linear curve was plotted based on Abs verses MDA concentration.  
Concentration of MDA was calculated as follows: 
 MDA μm = corrected absorbance – y intercept divided by slope.  
2.10     Tissue Content Glutathione: 
2.10.1. Materials GSH assay:  Glutathione (GSH) assay kit Cayman Chemical.  
GSH serves as a nucleophilic co-substrate to glutathione transferases in the detoxification 
of xenobiotics. Metaphosphoric acid, triethanolamine were purchased from Sigma 
Aldrich (St. Louis, MO). This is a colormetric assay that measures total glutathione 
(GSH/GSSG) levels in tissue homogenates. SpectraMax 5e plate reader, Molecular 
Devices (Sunnyvale, CA). 
2.10.2. Methods GSH assay:  50 mg of liver tissue was lysed  and prepared in 1 
mL of MES buffer as previously described (section 2.4.2). Lysates were centrifuged at 
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10,000 x g , 15 minutes at 4oC, and supernatant removed.  Supernatant was deproteinated 
as per manufacturer’s protocol. MPA reagent, consisting of 5 g of metaphosphoric acid 
was dissolved in 50 mL water, TEAM reagent: consisting of 4 M solution of 
triethanolamine 531 μl in 459 μl of water. 500 μl of each sample was added to an equal 
volume of MPA reagent in 1.5 mL microcentrifuge tubes and vortexed, samples were 
then centrifuged at 2,000 x g, 2 minutes.  
Supernatant was removed and placed in a 2 mL screw cap centrifuge tube with 50 
μl of TEAM reagent. Solution was vortexed and used to determine total GSH. GSH 
standards were prepared in MES buffer 0-16 μM GSH.  All reagents were allowed to 
equilibrate to room temperature prior to the start of the assay. An aliquot of 50 μl of 
samples and standards were loaded into 96 well plates in duplicate. Assay cocktails 
consisting of the following constituents:  MES buffer (11.25 mL), reconstituted cofactor 
mixture, prepared as per manufacturer’s protocol (0.45 mL), and reconsititued enzyme 
mixture (2.1 mL), water (2.3 mL) and reconstituted DTNB (0.45 mL)/per 96 well 
plate.150 μl of assay cocktail was added to each well containing standards and samples, 
plate was wrapped in foil and placed on an orbital shaker.. Absorbance at 405 nm was 
measured at 25 minutes. A linear curve was plotted based on Abs verses GSH 
concentration. Concentration of GSH was calculated as follows  
GSH μm = corrected absorbance – y intercept divided by slope.  
2.11.  CYP2E1 Activity:  
2.11.1. Materials hydroxylation of p-nitrophenol: Chemicals, p-nitrophenol, 4-
nitrocatechol, 60% 1N perchloric acid, sodium hydroxide (NaOH), and β-Nicotinamide 
adenine dinucleotide phosphate hydrate (NADP+) were purchased from Sigma Aldrich 
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(St. Louis, MO). Absorbance was read on a SpectraMax 5e plate reader (Molecular 
Devices (Sunnyvale, CA). 
2.11.2. Methods hydroxylation of p-nitrophenol:  CYP2E1 activity was 
determined based on the hydroxylation of p-nitrophenol to 4-nitrocatechol(Koop, 1986). 
A 0.5 mL reaction mixture was prepared as follows: protein from individual liver tissue 
lysates was equalized to provide 50μg total protein/reaction with (100 μmol p-nitrophenol 
and 1mmol NADP cofactor) added to each sample to a total reaction volume of 0.5 ml. 
Stock solutions of p-nitrophenol (1.0 mmol) in potassium phosphate buffer and NADP 
cofactor (10 mmol) prepared in 10 mmol NaOH solution. Reaction mixture was 
incubated for 10 minutes at 37oC. The reaction was stopped by the addition of 300μl 60% 
(v/v) 1N perchloric acid. Samples were centrifuged at 10,000 x g for 5 minutes at RT. The 
supernatant was then removed, and 100μl of 10M NaOH was added. An aliquot of 250μl 
of samples and standards were loaded in duplicate into 96 well plates and read on a 
spectrophotometer at 540nm. Activity was then calculated as the amount of  p-
nitrophenol metabolized against a standard curve of known 4-nitrocatechol. Standards of 
4-nitrocatechol (0-1 μmol) were prepared in potassium phosphate buffer from a 1 μmol 
stock solution and used to generate a standard curve to calculate the amount of p-
nitrophenol hydroxylation/ μg total protein/minute from the following equation: 
nmol/μg protein  =  corrected absorbance – y intercept divided by slope
 
 
 
 
 
 
 
 
CHAPTER 3: SILIBININ INHIBITS CYP2E1 MEDIATED ETHANOL 
METABOLISM AND ETHANOL MEDIATED PROLIFERATION IN H4IIE CELLS 
 
 
3.1. Introduction:  
 Hepatocellular carcinoma is the most rapidly increasing type of cancer diagnosed 
in the United States, and represents a major health burden on a global scale (El-Serag, 
2007). Chronic ethanol consumption has been identified as a major causative factor 
(carcinogen) for HCC development (McKillop, 2005; Seitz and Becker, 2007) and acts 
synergistically with other know HCC risk factors (Farazi and DePinho, 2006). Prognosis 
for HCC remains poor due to the cryptic nature of the disease and long latency between 
onset and diagnosis, combined with a lack of viable treatment options (McKillop, 2006; 
McKillop and Schrum, 2009). Increasing clinical and experimental evidence suggest that, 
following consumption, many of the detrimental hepatic effects of ethanol are attributed 
to hepatic ethanol metabolism (Albano, 2008; McKillop, 2005; Seitz and Becker, 2007).  
Ethanol and ethanol metabolism exert direct and indirect effects on hepatic 
pathology. The majority of hepatic ethanol metabolism occurs in the hepatocytes, by way 
of two primary metabolic pathways (Lieber, 1997b; McKillop, 2005; Seitz and Becker, 
2007). In the setting of moderate/acute consumption, the majority of ethanol is 
metabolized by alcohol dehydrogenase (ADH) to acetaldehyde, a highly reactive 
carcinogen that is in turn rapidly metabolized to acetate by acetaldehyde dehydrogenase 
(ALDH) (McKillop, 2005; Seitz and Becker, 2007). In the setting of chronic ethanol 
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consumption, hepatic cytochrome P4502E1 (CYP2E1) is induced (Lieber, 1997b; Lu, 
2008; McKillop, 2005). Induction of CYP2E1 is associated with an imbalance in ALDH-
acetaldehyde oxidation, which favors the accumulation of acetaldehyde. In addition to 
increased acetaldehyde, CYP2E1-dependent ethanol metabolism is poorly coupled and 
generates partially reduced oxygen and reactive oxygen species (ROS) leading to 
intrahepatic oxidative stress (Albano, 2006). These factors increase the likelihood of 
genetic damage and alterations in the integrity of signaling pathways that regulate and 
maintain cell function (Lu, 2008). Additionally, CYP2E1 induction has been identified as 
an important factor in the (predominately hepatic) activation of pro-carcinogens (Lu, 
2008). Oxidative stress, lipid peroxidation and pro-carcinogen activation influence other 
hepatic and non-hepatic cell types that contribute toward progressive hepatic diseases 
(Lieber, 2000; McKillop, 2005).  
 The identification of ethanol metabolism and ROS generation/oxidative stress as 
major components in mediating the effects of ethanol in the liver has led to increased 
interest in the use of antioxidants to blunt the deleterious effects of ethanol on hepatic 
function (Arteel, 2003).  S-adenosyl-L-methionine (SAMe) is a precursor in the synthesis 
of the primary endogenous hepatic antioxidant glutathione (GSH) (Garcia-Ruiz and 
Fernandez-Checa, 2006). Supplementation with SAMe has been reported to exert 
hepatoprotective effects in a wide range of animal models of hepatic disease (Karaa et al., 
2008; Lu and Mato, 2008; Mato and Lu, 2007). However, the use of SAMe in clinical 
trials has been controversial and the results less conclusive (Ramhaldi, 2001). This has 
led to renewed interest in alternative therapies based on naturally occurring, plant-derived 
compounds including those such as silibinin, a biologically active flavinoligand derived 
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from the milk thistle plant (S. marianum) (Dhiman and Chawla, 2005; Ramasamy and 
Agarwal, 2008; Saller, 2007).  
 The aims of the current study were to determine the effects of silibinin on ethanol 
metabolism and enzyme expression in HCC cells, and whether ethanol and/or silibinin 
could act to alter the rate of HCC cell proliferation in vitro. In doing so we also sought to 
identify underlying mechanism(s) by which silibinin may act to slow the rate of HCC 
progression in the absence or presence of ethanol.  
3.2    Materials:  
3.2.1. Cell lines:  H4IIE cells and human HepG2 (ATCC, Bethesda, MD), and 
HepG2 cells that had undergone mock transfection (C37-HepG2) or transfection to 
express constitutively active CYP2E1 (E47-HepG2) were used (C37- and E47- HepG2 
cell lines were a kind gift from the laboratory of Dr A. Cederbaum, Mount Sinai School 
of Medicine, New York, NY). 
3.2.2. General materials: Fetal bovine serum (FBS), TRIZOL ®, Minimum 
essential media (MEMα) cell culture medium (Gibco), fungizone, 
penicillin/streptomyacin (Pen/Strep), sodium bicarbonate (7.5% w/v), trypsin-
ethylenediaminetetraacetic acid (EDTA; 0.25% (w/v)), G418, and Image-iT® LIVE 
Green-ROS detection assay kit were purchased from Invitrogen (Carlsbad, CA). 500mL 
filtering system with 0.22 μm pore filter, 50 mL filtering conicals with 0.22 μm pore 
filter, a “Mr. Frosty” Cryo 1oC freezing container (Nalgene, Rochester, NY), sterile tissue 
culture flasks and 6 well plates were purchased from VWR (West Chester, PA). Trypan 
blue, Chloroform, isopropyl alcohol, dimethylsulphoxide (DMSO), ethanol, and silibinin 
were purchased from Sigma Aldrich (St. Louis, MO).  A bright line hemocytometer was 
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purchased from Hausser Scientific (Horsham, PA). A Countess , Invitrogen (Carlsbad, 
CA). Antibodies against ADH, ALDH, and -actin were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Antibodies specific against CYP2E1, and total/active 
(phosphorylated) extracellular signal regulated kinase 1/2 (ERK/pERK) were purchased 
from Millipore (Temecula, CA). The Lipid Peroxidation Assay kit was purchased from 
Calbiochem/EMD Biosciences (San Diego, CA). 
3.3. Methods: 
3.3.1. Culture Medium Preparation:  Culture medium was prepared in a sterile, 
laminar flow hood. Medium constituents were combined in the filter (0.22 μm pore filter) 
container of a 500ml flask (MEMα, 10% (v/v) or 0.1% (v/v) FBS, fungizone, pen/strep) 
and vacuum filtered. Stock concentrations of filtered (0.22 μm pore filter) EtOH 1 mM/μl 
in PBS and a stock solution of silibinin (10 mmol) was prepared by dissolving silibinin in 
dimethyl sulfoxide (DMSO; 0.01% (v/v)). Freezing medium was prepared in a 50 mL 
filtering conical tube with 0.22 μm pore filter as follows: 55.5% FBS, 33.3% MEMα, 
11.1% DMSO (v/v) and vacuum filtered. Cells placed in storage were detached using 
trypsin-EDTA, and following centrifugation, the cell pellet was suspended in freezing 
medium solution and aliquoted into cryo vials (1 mL/vial). Vials were placed in a “Mr. 
Frosty” cryo 1oC freezing container and stored in a -80oC overnight. Cryo vials were 
removed from the freezer container and placed in liquid nitrogen for long term storage. 
3.3.2. Cell Culture Conditions and Treatments:  Vials of frozen H4IIE or HepG2 
cells, were removed from liquid nitrogen storage, and rapidly thawed in a 37oC 
waterbath. The cell suspension was transferred to a 15 mL conical tube and centrifuged at 
700 x g for 5 minutes at RT. Supernatant was aspirated and pelleted cells suspended in 
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10% FBS MEMα medium (v/v). The cell suspension was instilled into culture flasks with 
10% FBS MEMα medium (v/v). Monolayer cell cultures were removed from culture 
flasks using trypsin-EDTA.  Initially, medium was aspirated from culture vessel, 
monolayer was washed one time with PBS, and 5 mL trypsin-EDTA/ cm2 of 0.25% 
trypsin-EDTA (v/v) was instilled into flasks and incubated at 37oC for 5 minutes. Cell 
suspension was collected in a 15 mL conical tube and centrifuged at 700 x g for 5 
minutes at room temperature. Supernatant was aspirated and cells suspended into fresh 
10% FBS MEMα medium (v/v) and aliquoted into appropriate culture flasks or 6 well 
plates.  
The rat H4IIE hepatoma cell line (ATCC, Bethesda, MD) was cultured in MEM 
medium supplemented with FBS (10% v/v) to 75-80% confluence. At this point cells 
were made quiescent by replacing the culture medium with low serum MEMα (LSM; 
0.1% (v/v) FBS) for 36 hours. For cells exposed to alcohol, an aliquot of culture medium 
was removed and 200-proof alcohol (diluted in PBS) was added such that the final 
culture medium concentration (0-75 mmol/L) was achieved. In experiments employing 
silibinin a stock solution (10mmol) was prepared by dissolving silibinin in dimethyl 
sulfoxide (DMSO) and cells were pre-treated (2 hours, 0-10mol) prior to alcohol 
treatment (0-75mmol/L). Control experiments were performed in which vehicle alone 
(DMSO; 0.01% v/v) was added in place of silibinin. Culture conditions for HepG2-C37 
and HepG2-C47 were identical to those for HepG2 with the exception that G418 was 
added to culture medium (4mg/mL).   
3.3.3. Cell proliferation: Cell proliferation was initially assessed by performing 
sequential cell counts over a 96 hour period as previously described (Moran, 2006). 
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Briefly, cells were made quiescent in LSM for 24 hours then pre-treated with silibinin 
(10mol) or vehicle (DMSO; 0.1% (v/v)) for 2 hours. At the end of this period the culture 
medium was removed and replaced with MEMα containing 1% (v/v) FBS alone or 1% 
(v/v) FBS, 10M silibinin and/or 25mmol/L alcohol. Cells were then detached and 
counted at 24 hour intervals using a Countess™ cell counter (Invitrogen, Carlsbad, CA). 
Cell numbers were averaged for 5 independent experiments. In studies lasting >24 hours, 
culture medium was removed and replaced at 24 hour intervals with fresh medium 
containing alcohol and/or silibinin. To confirm cell count data were due to proliferation 
per se, a parallel series of experiments were performed using MTT 
reduction/proliferation assay. Briefly, cells were counted and plated at 105 cells/well onto 
96-well plates. Cells were then either pre-treated with silibinin (10μmol) or vehicle 
(DMSO; 0.01% (v/v)) for 90 minutes followed by alcohol (25mmol/L), or treated with 
alcohol alone (25mmol/L). The MTT assay was then performed according to the 
manufacturer’s instructions (Invitrogen, Carlsbad, CA).   
3.3.4. mRNA analysis: Following H4IIE cell treatment total RNA was extracted 
using TRIZOL ®. Cells were removed by trypsin-EDTA and centrifuged at 700 x g for 5 
minutes at room temperature. The cell pellet was suspended in 0.75 ml of TRIZOL 
reagent and pipetted several times. 150 μl of chloroform was added to TRIZOL and the 
mixture vortexed gently. The suspension was incubated at RT for 5 minutes, followed by 
centrifugation at 4oC for 10 minutes at 12,000 x g.  The aqueous phase was transferred to 
a clean microcentrifuge tube and 15 μl sodium acetate (pH 5.5) in 500 μl ice-cold (-20oC) 
isopropyl alcohol was added. The mixture was vortexed and placed at -20oC overnight. 
The suspension was removed from -20oC and centrifuged at at 12,000 x g for 30 minutes, 
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4oC. Isopropyl alcohol was aspirated and the pellet rinsed in 750 μl ice-cold (-20oC) 75% 
ethanol (v/v), and the mixture vortexed. The suspension was centrifuged at 7,500 x g, for 
5 minutes at 4oC, ethanol aspirated, and the pellet resuspended in 35 μl RNase free water.  
To perform RT-PCR, 1μg of total RNA was reverse transcribed by Improm IITM 
(Promega) using random hexamers to generate complementary DNA (cDNA), cDNA 
was precipitated and resuspended in nuclease-free water to be used in PCR reactions (as 
described, Section 2.2.3). Briefly, 100ng of cDNA was used in each reaction with the 
CYP2E1 gene specific primers (Section 2, Table 1). PCR reactions consisted of 95oC for 
2 minutes followed by 35 cycles of 95oC, 55oC and 72oC for 45 seconds each with a final 
elongation at 72oC for 2 minutes.  Amplified products were resolved using a 1.5% (w/v) 
Agarose gel and stained with ethidium bromide before conversion to digital images. The 
level of each PCR product was then semi-quantitatively determined using Quantity One 
software.  
3.3.5. Western Blot Analysis: Following treatment, cells were washed with PBS 
(4oC) and lysates prepared using RIPA buffer (ADH, ALDH and CYP2E1 analysis) or 
MAPK lysis buffer for ERK 1/2 (Kovach et al., 2001) (as described Section 2.3.2). In 
both instances lysates were aliquoted and stored at -80oC and protein levels equalized 
prior to analysis. Protein expression was determined by Western blot whereby cell lysates 
were resolved by 12.5% SDS-PAGE as previously reported (Kovach et al., 2001). 
Primary antibodies were diluted 1:1000 in 5% (w/v) nonfat dry milk dissolved in 0.05% 
(v/v) Tween-20/Tris-buffered saline (TBS). Signal intensity was determined using NIH-
ImageJ and equal protein loading confirmed by stripping/re-probing membranes using a 
β-actin antibody. 
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3.3.6. Analysis of ethanol metabolism: Aliquots (100μl) of culture medium were 
sequentially removed (0-24 hours) and stored at -80oC prior to analysis. Alcohol 
concentration was determined using an EnzyChrom ethanol assay according to 
manufacturer’s protocol and described (section 2.8.2)(Brandon-Warner et al., 2010a). To 
assess ethanol loss due to evaporation, cell free culture flasks containing medium plus 
ethanol were assayed in parallel.  
3.3.7. Analysis of lipid peroxidation, ROS/oxidative stress:  Lipid peroxidation 
was determined using the Lipid Peroxidation Assay kit as per the manufacturer’s 
instructions. Changes in cellular oxidative stress/ROS generation were determined using 
an Image-iT® LIVE Green Reactive Oxygen Species Assay in conjunction with Hoechst 
33342 (for cell/nuclear localization) as per the manufacturer’s instructions. Using this 
approach cells were either plated to single-well cover slips for microscopic analysis or 
into 96-well plates for quantitative analysis (at 485nm excitation-530nm emission). 
Untreated cells were assigned an arbitrary value of 1 and relative ROS production 
expressed as % carboxy-DCF fluorescence ± SEM. 
3.3.8. Analysis of CYP2E1 activity: To assess whether the effects of silibinin on 
CYP2E1 responsiveness to alcohol treatment in HCC cells were due to direct or indirect 
mechanisms. To perform these studies human HepG2 cells and HepG2 cells that had 
undergone mock transfection (C37-HepG2) or transfection to express constitutively 
active CYP2E1 (E47-HepG2) were used. Cells were grown to 75-80% confluence and 
made quiescent in LSM prior to the addition of alcohol (25 mmol/L). 100μl aliquots of 
culture medium were sequentially removed (0-24 hours) and stored at -80oC prior to 
analysis for alcohol concentration using the EnzyChrom ethanol assay. To determine 
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the contribution of CYP2E1 activity during these events we next measured the rate of 
hydroxylation of p-nitrophenol to 4-nitrocatechol in H4IIE and HepG2-E47 cells in the 
presence or absence of silibinin following alcohol treatment (Koop, 1986). Briefly, cells 
were grown to 70% confluence and treated with silibinin and/or alcohol as previously. 24 
hours later cells were washed with PBS (4oC), collected in KH2PO4 (pH 6.8, 4
oC), 
sonicated, and stored at -80oC prior to analysis. Following total protein determination and 
correction (to100 μg/ml) hydroxylation of p-nitrophenol was performed (described 
section 2.12.2). 
3.3.9. Statistical analysis: Data are expressed as mean ± SEM. Statistical analysis 
was performed using a Student t-test or one-way ANOVA with Tukey’s or Dunnett’s 
multiple comparison post tests (as appropriate) between control and treatment groups. 
p<0.05 was considered significant. 
3.4. Results: 
3.4.1. Ethanol metabolizing enzyme expression: Western blot analysis of ADH 
and ALDH expression in H4IIE cells demonstrated no significant difference in 
expression of either enzyme following alcohol treatment (0-75mM, 24 hours) in the 
absence or presence of silibinin (10M) (Figure 3.1a, n=4 separate experiments). In 
contrast alcohol treatment caused a dose dependent increase in CYP2E1 expression, a 
significant increase being detected at 10mmol/L increasing to a maximum at 25mmol/L 
(Figure 3.1a, n=4 separate experiments, p<0.05 versus untreated). Of note, at higher 
doses of alcohol (50 and 75mM), CYP2E1 expression was lower than that observed at 
25mM. To address the possibility of alcohol exerting a toxic effect at higher doses we 
performed a trypan blue exclusion assay. These studies demonstrated a significant 
 
 
77
decrease in cells excluding trypan blue at alcohol concentrations of 50mmol/L (73.49 ± 
2.23%) and 75mmol/L (66.05% ± 2.89%) compared to cells treated with 25mmol/L 
alcohol (93.10% ± 2.86). Pretreatment of cells with silibinin (10 M, 2Hrs) followed by 
alcohol (10 or 25mmol/L) significantly inhibited alcohol-induced increases in CYP2E1 
expression (Figure 3.1b, n=4 separate experiments, p<0.05).   
 In light of data demonstrating the effects of ethanol on CYP2E1 protein 
expression in the absence and presence of silibinin, we next sought to determine whether 
these changes were also manifest at the mRNA level. RT-PCR analysis using primers 
specific against rat CYP2E1 mRNA demonstrated significantly increased CYP2E1 
mRNA expression following treatment of H4IIE cells with ethanol (25 mmol/L) as 
compared to untreated cells (Figure 3.2, n=4 separate experiments, p<0.05). Furthermore, 
pre-treatment of H4IIE cells with silibinin (10 M, 2 h) abrogated ethanol-dependent 
increases in CYP2E1 mRNA expression (Figure 3.2, n=3 separate experiments). To 
determine the functional significance of the effects of silibinin on CYP2E1 expression 
and alcohol metabolism, we analyzed culture medium alcohol content in the absence or 
presence of silibinin pretreatment (10M, 2Hrs). These data demonstrate significant 
alcohol metabolism in H4IIE cells over a 24 Hr time period (Figure 3.3a, n=4 separate 
experiments, samples analyzed in triplicate, p<0.05 versus alcohol in medium alone ([no 
cells]). Pre-treatment of cells with silibinin significantly inhibited the rate of alcohol 
metabolism in H4IIE cells such that at the end of the 24 Hr period 28.11.7% percent of 
the initial alcohol added remained in silibinin pre-treated cells verses 16.41.1% in cells 
treated with alcohol alone (Figure 3.3b, n=4 separate experiments, samples analyzed in 
triplicate, p<0.01). 
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Figure 3.1: Ethanol stimulates cytochrome P4502E1 expression in H4IIE cells, an 
effect inhibited by silibinin pretreatment. a). Representative immunoblots 
demonstrating the effect of increasing doses of ethanol (EtOH) on the expression of 
cytochrome P4502E1 (CYP2E1), alcohol dehydrogenase (ADH), and acetaldehyde 
dehydrogenase (ALDH) in the H4IIE HCC cell line 24 hours after EtOH addition (0-
75mM/L). Equal protein loading was confirmed using an antibody specific against -
actin. The effect of EtOH on CYP2E1 expression was then analyzed by optical integrated 
volume for repeat experiments and data expressed as fold change versus untreated 
(0mM/L EtOH, lower panel). n=4 separate experiments, *p<0.05versus untreated cells. 
b) Representative immunoblots demonstrating the effect of EtOH (10 and 25mM/L) on 
the expression of CYP2E1, ADH, ALDH in the H4IIE HCC cell line in the presence and 
absence of silibinin (10M). Equal protein loading was confirmed using an antibody 
specific against -actin. The effect of EtOH in the absence and presence of silibinin 
(10M) on CYP2E1 expression was then analyzed by optical integrated volume for 
repeat experiments and data expressed as fold change versus untreated (0mM/L EtOH). 
n=4 separate experiments, *p<0.05 versus untreated cells, #p<0.05 EtOH + Sil versus 
EtOH alone. 
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Figure 3.2:  Ethanol stimulates CYP2E1 mRNA expression, an effect inhibited by 
silibinin pre-treatment:  Representative RT-PCR analysis demonstrating the effect of 
EtOH (10 and 25 mmol/L) on the expression of CYP2E1 mRNA in the presences and 
absence of silibinin 10 μM. CYP2E1 mRNA expression was analyzed by optical 
integrated volume for repeat experiments and data expressed a fold change verses 
untreated (0 mmol/L EtOH). n= 3 separate experiments, *p<0.05 EtOH+Sil versus EtOH 
alone.   
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 3.4.2. H4IIE Cell Proliferation:  H4IIE cell proliferation was determined for cells 
cultured in 1% FBS (v/v) culture medium in the absence and presence of 25mmol/L 
alcohol with or without silibinin pretreatment (10M, 2Hrs) over a 96 Hr period. In 
untreated cells total viable cell counts increased by a factor of 4.05 ± 0.31 fold compared 
to viable cell number at day 0 (Figure 3.4, n=5 independent experiments, p<0.01). No 
significant changes in the rate of proliferation were observed in H4IIE cells treated with 
silibinin or vehicle (DMSO, 01% (v/v)) only (Figure 3.4, n=5 independent experiments). 
In contrast, daily treatment with alcohol (25mmol/L) led to a significant increase in 
viable cell number as compared to 1% FBS (v/v) medium or 1% FBS (v/v) with silibinin 
(10M) or vehicle (Figure 3.4, n=5 independent experiments, p<0.05 alcohol versus 
alcohol + Silibinin). 
3.4.3. ERK 1/2 activity in H4IIE cells:  The ERK-MAPK signaling pathway has been 
identified as a central pathway in mediating cell proliferation in H4IIE (and other) cells 
(McKillop et al., 1997; Roberts and Der, 2007). Western blot analysis of H4IIE cells 
treated with alcohol demonstrated active ERK1/2 (pERK 1/2) increased significantly 10 
mins after addition (Figure 3.5 a and b, 4.46 ± 0.56 fold versus 3.22 ± 0.61 in untreated 
cells, n=5 separate experiments, p<0.05). Pretreatment of cells with silibinin (10M) 
failed to significantly alter the magnitude or time course of ERK1/2 activity following 
treatment with alcohol as compared to alcohol alone (Figure 3.5 a and b, n=5 separate 
experiments) 
3.4.4. Lipid peroxidation and ROS:  Malondialdehyde (MDA) levels were 
significantly higher in cells exposed to 10 or 25mmol/L alcohol versus untreated cells 
(Figure 3.6a, n= 4 separate experiments, p<0.05). Pretreatment of cells with silibinin 
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Figure 3.3: a) H4IIE cells metabolize ethanol, an effect inhibited by silibinin 
pretreatment. Ethanol (EtOH) content in cell culture medium was determined in the 
absence () or presence () of silibinin (Sil; 10mol) over a 24 Hr period 
following the initial addition of 25mmol EtOH to H4IIE cell cultures. n=4 separate 
experiments analyzed in duplicate, *p<0.05 EtOH + Sil versus EtOH alone. To ensure 
changes in culture medium EtOH concentration were not due to evaporation, parallel 
experiments were performed in which EtOH containing (25mmol) culture medium was 
placed in cell culture flasks in the absence of H4IIE HCC cells (). b) The 
percentage of EtOH remaining in culture medium following the addition of 25mmol/L 
EtOH to H4IIE cells in the absence or presence of silibinin. n=4 separate experiments, 
*p<0.05. 
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Figure 3.4: Silibinin inhibits ethanol-stimulated cell proliferation in H4IIE HCC 
cells. a) H4IIE HCC cells were cultured in medium containing 1% FBS in the presence or 
absence of silibinin (Sil; 10mol) for 96 Hrs. Following cell counts the number of cells 
was calculated as a fold change versus the number of cells at day 0. n=5 separate 
experiments, *p<0.05 versus control (C; 1% FBS alone), #p<0.05 EtOH (25mmol/L) 
versus EtOH (25mmol/L) + Sil (10mol). To ensure that DMSO (vehicle for dissolving 
Sil) did not affect proliferation parallel experiments were performed in which cells were 
treated with 1% FBS + 0.1% (v/v) DMSO (V). b) H4IIE HCC cells were cultured in 
medium in the presence or absence of silibinin pretreatment (Sil; 10mol, 2 Hrs) prior to 
exposure to ethanol (EtOH, 0, 10 or 25 mmol/L) and an MTT proliferation assay 
performed. Data are expressed as fold change versus control (untreated; C). n=4 separate 
experiments analyzed in duplicate, *p<0.05 versus control (C), #p<0.05 EtOH 
(25mmol/L) + Sil (10mol) versus EtOH (25mmol/L) only. To ensure that DMSO 
(vehicle for dissolving Sil) did not affect proliferation parallel experiments were 
performed in which cells were treated with 0.1% (v/v) DMSO (V). 
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Figure 3.5: Silibinin does not affect ethanol-dependent ERK1/2 activation in H4IIE 
HCC cells. a) Representative immunoblots demonstrating the effect of ethanol (EtOH; 
25mmol/L) on the activation (phosphorylation) of ERK1/2 in the absence (upper panel) 
or presence (lower panel) of silibinin (10mol). b) Following analysis of pERK1/2 
expression, membranes were stripped and probed for total ERK1 expression. The ratio of 
pERK1/2:ERK1 expression was then analyzed by optical integrated volume for repeat 
experiments and data expressed as fold change versus untreated. n=5 separate 
experiments, *p<0.05 versus untreated cells.  
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followed by alcohol (10 or 25mmol/Lt) significantly inhibited increases in MDA levels 
measured in cells treated with alcohol alone to levels not significantly different to 
untreated cells (Figure 3.6a, n=4 separate experiments, P<0.05 alcohol treated versus 
silibinin + alcohol). Silibinin alone did not significantly alter basal MDA levels in 
untreated cells (Figure 3.6a). 
To further evaluate the effect of silibinin on alcohol-dependent increases in 
oxidative stress we next used the carboxy-H2 DCFDA assay as a marker of intracellular 
peroxide levels. To perform quantitative analysis, experiments were performed using 
cells seeded to 96-well plates. These data confirmed that alcohol (25mmol/L) treatment 
led to a 3.55 ± 0.68 fold increase in fluorescence/ROS production compared to untreated 
cells (Figure 3.6b, n=4 separate experiments, p<0.05). Furthermore, pretreatment of cells 
with silibinin abolished the effects of alcohol on fluorescence/ROS production to levels 
not significantly different to untreated cells or, cells treated with silibinin alone. 
Treatment of cells with vehicle (DMSO, 0.1% (v/v) did not significantly alter 
fluorescence /ROS production compared to untreated cells (data not shown). Using a 
microscopic analysis approach, in parallel, relatively low fluorescence/ROS was detected 
in untreated cells and those treated with silibinin alone (Figure 3.6c). Conversely, a 
dramatic increase in fluorescence/ROS was observed following alcohol treatment (Figure 
3.6c), an effect that was abrogated by pretreatment with silibinin (Figure 3.6c, n=4 
separate experiments, p<0.05 silibinin+alcohol versus alcohol only).  
3.4.5. Effect of silibinin on CYP2E1 activity and ethanol metabolism:  To 
determine whether silibinin affects CYP2E1 induction, as compared to activity, we next 
employed the human HepG2 cell line in conjunction with HepG2 cells transfected to 
 
 
85
       
0
0.5
1.0
1.5
2.0
[M
D
A
] 
(μ
M
)
2.5
0 mM
[ETOH] (mM)
Sil
(10M)
- + - + - +
10mM 25mM
*
*
*#
#
EtOH
+Sil
0
0.5
1.0
1.5
2.0
F
lu
o
re
sc
en
ce
(F
o
ld
 Δ
V
e
rs
u
s 
C
)
2.5
C Sil EtOH
*#
*
[M
D
A
] 
(μ
M
)
[M
D
A
] 
(μ
M
)
F
lu
o
re
sc
en
ce
(F
o
ld
 Δ
V
e
rs
u
s 
C
)
F
lu
o
re
sc
en
ce
(F
o
ld
 Δ
V
e
rs
u
s 
C
)
F
lu
o
re
sc
en
ce
(F
o
ld
 Δ
V
e
rs
u
s 
C
)
F
lu
o
re
sc
en
ce
(F
o
ld
 Δ
V
e
rs
u
s 
C
)
F
lu
o
re
sc
en
ce
(F
o
ld
 Δ
V
e
rs
u
s 
C
)
 
                      
Figure 3.6: Silibinin inhibits ethanol-dependent oxidative stress in H4IIE HCC cells. 
a). Malondialdehyde (MDA) levels were determined in H4IIE HCC cells following 
treatment with ethanol (EtOH, 10 and 25mmol/L) in the absence (-) and presence (+) of 
silibinin (Sil; 10mol). n=4 separate experiments,*p<0.05 EtOH versus no EtOH, 
#p<0.05 EtOH + Sil versus EtOH – Sil. b) Quantitative analysis of the carboxy-H2 
DCFDA assay was performed using a 96-well plate assay as described in the Methods. 
n=4 separate c) Representative immunofluorescent cytochemistry images of H4IIE HCC 
cells treated with EtOH (25mmol/L) in the absence or presence of silibinin (Sil; 10mol) 
analyzed for ROS/peroxide generation using a carboxy-H2 DCFDA assay in parallel 
studies. ROS/peroxide was detected as green fluorescence. Cells were counterstained 
with DAPI (blue) for nuclear localization. experiments analyzed in duplicate, *p<0.05 
versus control (C; untreated), # p<0.05 EtOH treated (25mmol/L) versus EtOH 
(25mmol/L) + Sil (10mol) treated.  
C Sil
EtOH EtOH
+Sil
a) 
c) 
b) 
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express CYP2E1 (E47) or an empty vector control (C37). These data demonstrated 
significant alcohol metabolism by the HepG2 and C37 cell lines over a 24 Hr period, an 
effect that was not significantly different in the presence of silibinin (10µM) (Figure 3.7a 
and b). Conversely, while the rate of ethanol metabolism was significantly accelerated in 
the E47 (CYP2E1 expressing) HepG2 cell line, this effect was abrogated by pretreatment 
with silibinin to a level not significantly different to untransfected/C37 HepG2 cells 
(Figure 3.7c and d, p<0.05 alcohol metabolism in E47 versus HepG2 and C37 HepG2 
cells). 
3.5. Discussion and conclusions:  
 Ethanol has been identified as a causative agent in the development of several 
cancers including HCC (Baan et al., 2007; Seitz and Becker, 2007). The effects of 
ethanol on liver function and hepatic disease initiation and progression can be both direct 
and indirect in nature (Freeman et al., 2005; Seitz and Becker, 2007). However, 
considerable evidence suggests many of the intrahepatic effects of ethanol are due to 
metabolism in the hepatocyte and the associated increases in acetaldehyde production and 
oxidative stress (Seitz and Becker, 2007). The identification of oxidative stress as a major 
factor in the progression of liver disease towards cirrhosis and HCC has led to intense 
interest in the therapeutic  
The current study utilized the rat H4IIE HCC cell line. Previous studies by our 
group show that this cell line expresses ADH and ALDH, is capable of 
metabolizing ethanol, and that this metabolism can be significantly inhibited using 4-
methylpyrazole (Kovach et al., 2001). In the current study we demonstrate that exposure  
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Figure 3.7: Silibinin inhibits ethanol metabolism in human HepG2 HCC cells 
transfected to express CYP2E1 and CYP2E1 activity in HCC cells. a) Human HepG2 
HCC cells were treated with ethanol (EtOH; 25mmol/L) in the absence () or 
presence () of silibinin (Sil; 10mol) for 24 Hrs and EtOH content in the culture 
medium determined. b) Human HepG2 HCC cells transfected with empty vector (C37-
HepG2 cells) were treated with EtOH (25mmol/L) in the absence () or presence 
() of Sil (10mol) for 24 Hrs and EtOH content in the culture medium determined. 
c) Human HepG2 HCC transfected to express CYP2E1 (E47-HepG2 cells) were treated 
with ethanol (EtOH; 25mmol/L) in the absence () or presence () of silibinin 
(Sil; 10mol) for 24 Hrs and EtOH content in the culture medium determined. n=4 
separate experiments analyzed in duplicate, *p<0.05 versus time 0, #p<0.05 cells treated 
with Sil (10mol) and EtOH versus EtOH alone. d) Rat H4IIE and human E47-HepG2 
cells were cultured in the presence and absence of ethanol (EtOH; 25mmol/L) and/or 
silibinin pretreatment (Sil; 10mol) and CYP2E1 activity determined by measurement of 
p-nitrophenol hydroxylation to 4-nitrocatechol. n=4 separate experiments, *p<0.05 versus 
untreated H4IIE cells, #p<0.05 cells treated with Sil (10mol) and EtOH versus EtOH 
alone. 
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to ethanol at doses similar to blood ethanol content observed in the setting of moderate 
ethanol use of antioxidants (Albano, 2008; Lu and Mato, 2008; Mato and Lu, 2007; 
Ramasamy and Agarwal, 2008). 
consumption (10-25mmol/L), leads to a significant increase in CYP2E1 expression in the 
absence of changes in ADH or ALDH expression in vitro. Furthermore, CYP2E1 
induction and the rate of ethanol metabolism are significantly inhibited by the 
pretreatment of cells with silibinin (10mol). These data correspond to the inhibition of 
ethanol-dependent increases in cell proliferation in the H4IIE cell line in vitro. This 
evidence would suggest that, even in the setting of moderate ethanol consumption, HCC 
cells that express CYP2E1 may be subject to increased CYP2E1 induction and that these 
changes may significantly affect the rate of cell proliferation. Indeed, this may be of 
particular importance in considering the “two hit” model of hepatocarcinogenesis in 
which transformation and progression may be regulated by independent 
pathophysiological stimuli. However, it is important to highlight that the effects observed 
in vitro may not be similarly manifest in the in vivo setting in which the non-tumorigenic 
liver mass will, more than likely, play a more significant role in ethanol metabolism. 
Similarly, the concentrations and time of exposure to ethanol that the tumor mass is likely 
to experience in vivo will differ to that of a static in vitro culture employing HCC cell 
populations. 
Previous studies demonstrate that silibinin inhibits human HCC cell proliferation 
in vitro (Lah et al., 2007; Momeny et al., 2008) and does so via inhibition of ERK-MAPK 
signaling in the (human) HepG2 cell line (Momeny et al., 2008). In contrast, we failed to 
detect a significant effect of silibinin on cell proliferation or ERK-MAPK activity profiles 
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in H4IIE cells treated with silibinin alone. However, studies by Momeny et al. (Momeny 
et al., 2008) and Lah et al. (Lah et al., 2007) demonstrated significant inhibitory effects of 
silibinin at doses of 50-75mol and 120-240mol respectively, whereas our studies 
employed silibinin at 10mol final culture medium concentration. Indeed, both of these 
studies failed to observe significant effects of silibinin on proliferation and/or ERK-
MAPK activity at this dose (Lah et al., 2007; Momeny et al., 2008). While our data raise 
the possibility that the dose of silibinin used in the current studies was too low to affect 
ERK-MAPK signaling and/or proliferation, we were cognizant of not using higher doses 
in vitro due to data regarding the bioavailability of silibinin following oral ingestion in 
animal models and humans in vivo (Kidd and Head, 2005; Wu et al., 2007). In addition to 
the potential effects of silibinin on an ERK-MAPK signaling cascade other signaling 
mechanisms have been identified whereby silibinin may act to inhibit net cell 
accumulation. Using the human HepG2 and Hep3B cell line Varghese et al report silybin 
treatment inhibits the expression of a range of cyclins and cyclin-dependent kinases and, 
in the case of the Hep3B line, inhibits regulators of proteins involved in transition 
between the G2-M phases (Meeran and Katiyar, 2008; Varghese, 2005). Conversely, 
silibinin has also been reported to exert pro-apoptotic effects (albeit at higher doses than 
those that inhibit ERK-MAPK signaling) in other cancer cells (Ramasamy and Agarwal, 
2008; Singh and Agarwal, 2004), an effect that, in combination with inhibition of cell 
cycle progression, would result in decreased net cell accumulation (Ramasamy and 
Agarwal, 2008).   
As with many complimentary/alternative medicines the efficacy and mechanisms 
of action whereby the active constituents of milk thistle exert their effects remain 
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controversial. Several recent reviews suggest that the clinical benefits of milk thistle for a 
range of hepatic (and other) disease states is difficult to assess due to a lack of high-
quality, adequately conducted/reported clinical trials (Rambaldi et al., 2007; Saller, 
2007). Similarly, increasing evidence indicates that, much like ethanol consumption, the 
systemic effects of silibinin following ingestion may play as important a role in 
influencing the hepatoprotective effects as the direct actions in the liver (Rambaldi et al., 
2007; Varghese, 2005). The antioxidant/free radical scavenging capacity of milk thistle 
derivatives, including silibinin, appears to be directly related to the flavinoligand 
chemical structure(s) (Ramasamy and Agarwal, 2008). Currently no evidence has been 
presented to indicate silibinin acts to alter the rate of GSH synthesis although, the 
presence of silibinin has been demonstrated to reduce GSH depletion in isolated 
hepatocytes exposed to allyl alcohol (Miguez et al., 1994). Indeed, these data are 
supported by our findings that pre-treatment of cells with silibinin effectively decreases 
ROS/oxidative stress in H4IIE cells associated with ethanol metabolism. Specifically, 
data from our studies suggests that the ability to reduce oxidative stress is due to the 
ability to inhibit CYP2E1 induction/activity rather than affecting ADH-dependent ethanol 
metabolism. These data are consistent with ethanol metabolism studies that report the 
majority of hepatic oxidative stress associated with chronic ethanol consumption is due to 
CYP2E1 induction and the generation of ROS, including hydroxyethyl radicals (Albano, 
2008; Lu, 2008). However, while our studies using E47-HepG2 cells (transfected to 
express constitutively active CYP2E1) raise the possibility that silibinin may interact 
directly with the CYP2E1 enzyme to inhibit activity, these data contradict previous 
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studies by Miguez et al that failed to provide evidence for the involvement of CYP2E1 as 
an underlying mechanism for the effects of silymarin (Miguez et al., 1994).  
The effects of ethanol on hepatocyte integrity, and liver function as a whole, can 
be both direct and indirect in nature (Crabb and Liangpunsakul, 2007; McKillop, 2005; 
Seitz and Becker, 2007).  Similarly, oral ingestion of silibinin can exert indirect and 
direct effects, the net result of which are hepatoprotective. For example, chronic ethanol 
consumption is documented to stimulate a hepatic immune responses due, at least in part, 
to changes in the balance of the bacterial flora of the GI-tract and increased permeability 
of the GI tract to LPS resulting in Kupffer cell activation (Bode and Bode, 2005). In this 
regard silibinin has been demonstrated to inhibit the transcription and DNA binding 
activity of NFκB, (Manna, 1999; Saliou, 2001) a key factor in regulating and 
coordinating the hepatic inflammatory response (Tacke et al., 2009). In addition to 
modulating the immune response silibinin, and other flavinoligands, have been reported 
to modulate steroid hormone receptor-dependent gene expression (Mueller, 2004; 
Seidlova-Wuttke et al., 2003). This may be of particular significance in alcoholic liver 
disease given the relationship between the liver and the regulation of sex hormone 
levels/activity and the effects of chronic ethanol consumption on hepatic sex hormone 
regulation and signaling (Kovacs, 2002; Ronis et al., 2007). Similarly, the progression of 
hepatic foci to HCC and subsequent tumor expansion is dependent on neoangiogenesis 
and, silibinin is reported to inhibit angiogenesis due to inhibition of vascular endothelial 
growth factor VEGF-dependent signaling (Singh et al., 2008).  
In conclusion, data presented in this study demonstrate silibinin inhibits CYP2E1 
induction/ethanol metabolism and cell proliferation in a rat HCC cell line in vitro and 
 
 
92
does so at doses lower than those described in other (human) HCC cell lines. Our data 
suggest that the underlying mechanisms by which silibinin exerts these effects are due to 
decreased CYP2E1-dependent ROS generation, possibly via direct interaction with the 
CYP2E1 enzyme. While these data provide an insight into possible mechanisms whereby 
silibinin may slow the rate of HCC progression the wide spread systemic effects of both 
ethanol and silibinin are such that further studies are required to determine whether these 
mechanisms are equally important in vivo.  
 
 
 
 
 
 
 
 
CHAPTER 4: CHRONIC ETHANOL FEEDING ACCELERATES 
HEPATOCELLULAR CARCINOMA PROGRESSION IN A SEX-DEPENDENT 
MANNER IN A MOUSE MODEL OF HEPATOCARCINOGENESIS 
 
 
4.1. Introduction:   
On a global scale hepatocellular carcinoma (HCC) is the most common primary 
liver cancer diagnosed, the fifth most common cancer diagnosed overall, and the third 
leading cause of cancer-related mortality (Altekruse, 2009; El-Serag, 2007). Unlike many 
other common cancers in which hereditary risk factors have been identified, similar 
patterns of incidence are not evidenced for HCC. Rather, incidence of HCC is directly 
linked to exposure to known risk factors, of which viral hepatitis B and C, aflatoxin, and 
chronic, heavy ethanol consumption are the most common (Altekruse, 2009). Despite the 
varied nature of these insults, exposure is most commonly linked to progressive liver 
disease toward hepatic cirrhosis, the most common precursor to HCC development (Yang 
and Roberts, 2010; Zaman et al., 1985). Similarly, while each factor alone represents a 
significant risk for progression to cirrhosis and HCC, these agents act synergistically to 
enhance the probability of eventual HCC. 
  The increasing prevalence of viral hepatitis infection represents a burgeoning 
health problem globally. In developed countries chronic ethanol intake, in the absence or 
presence of underlying viral hepatitis, remains an important risk factor for hepatic 
cirrhosis and progression to HCC (Yang and Roberts, 2010). Significant advances have 
been made in our understanding of how ethanol affects the liver. Following ingestion, 
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≈80% of ethanol is metabolized in the liver. Ethanol metabolism occurs (predominantly) 
in hepatocytes via three pathways; alcohol dehydrogenase (ADH), cytochrome P4502E1 
(CYP2E1) and catalase (Crabb, 1995; McKillop and Schrum, 2009). In the setting of 
moderate and/or infrequent ethanol consumption, the majority of ethanol is oxidized by 
ADH to acetaldehyde that is, in turn, rapidly metabolized by acetaldehyde dehydrogenase 
(ALDH) to acetate (Crabb, 1995; McKillop and Schrum, 2009). Acetaldehyde represents 
a highly reactive compound capable of binding to cell constituents, including DNA, to 
form adducts. While direct DNA damage is a significant factor in ethanol toxicity, 
acetaldehyde also depletes glutathione (GSH), the main cellular antioxidant involved in 
detoxification (Albano et al., 1999; Lieber, 1997b). However, chronic, heavy ethanol 
ingestion leads to microsomal CYP2E1 induction (Crabb, 1995; McKillop and Schrum, 
2009). CYP2E1-mediated metabolism induces direct cellular damage due to production 
of reactive oxygen species (ROS) /oxidative stress, as well as elevated acetaldehyde 
production and acetaldehyde-dependent cellular damage. Additionally, CYP2E1 
induction has been reported to alter cell cycle progression, pro-carcinogen activation, and 
immune responses (Crabb, 1995; Ekstrom and Ingelman-Sundberg, 1989; McKillop and 
Schrum, 2009; Muller and Sies, 1987). 
Ethanol metabolism profoundly affects hepatocyte integrity, as well as that of 
other hepatic cells. However, increasing evidence indicates that the effects of ethanol 
(metabolism) on hepatic cells are further augmented by other, systemic events. Prolonged 
ethanol intake causes a hepatic inflammatory response due to increased GI-permeability 
to LPS (Enomoto et al., 2001; Jirillo et al., 2002). Elevated intrahepatic LPS promotes 
pro-inflammatory cytokine release from Kupffer cells (KCs) and neutrophil/macrophage 
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infiltration, leading to increased cytokine release and apoptosis (Jirillo et al., 2002; 
Mathurin et al., 2000). Stimulation of stress-activated cytokine cascades also increases 
ROS formation which, given ethanol-related GSH depletion, further enhances stress 
responses, incidence of DNA damage, apoptosis, and compensatory regeneration (Jirillo 
et al., 2002; Mathurin et al., 2000). If the liver cannot compensate, necrosis occurs and a 
positive feedback loop of damage-regeneration is initiated.  
Several studies in humans and animal models of HCC have identified sexual 
dimorphism during ALD development and progression. Differences in gene expression 
encoding for ethanol metabolizing enzymes influences predisposition to ethanol 
sensitivity, and ALD development/progression (Gramenzi et al., 2006). Differences in 
ADH activity exist between males and females, activity being lower in males than 
females, resulting in less acetaldehyde accumulation (Harada et al., 1998). Studies also 
report estrogens positively influence both ADH and CYP2E1, suggesting ethanol should 
be more rapidly metabolized in females vs. males (Harada et al., 1998). Yet this is not the 
case, and BACs following ethanol ingestion are not lower in females. Nonetheless, sex 
differences in ALD are well documented; women are more susceptible to the deleterious 
effects of ethanol than men, and are thus more likely to develop liver disease earlier 
(Muller, 2006). Several mechanisms have been proposed to explain this phenomena 
including different ADH activities in the stomach and liver, higher concentrations of 
toxic byproducts (from ethanol metabolism), and increases in estrogen (E2)-induced 
inflammation due to ethanol (Muller, 2006). Despite higher susceptibility of women to 
ethanol-induced liver damage, development of cirrhosis is more common in men than 
women (Zaman et al., 1985).  
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A considerable body of research has addressed the role of ethanol in ALD 
development and hepatocyte transformation. In comparison, relatively few studies have 
addressed potential mechanisms whereby ethanol may affect progression of hepatic 
tumorigenesis. In this study we sought to determine the effects of chronic ethanol intake 
on hepatocarcinogenesis in a well-described mouse model of HCC development 
generated via neonatal initiation with diethylnitrosamine (DEN). Additionally, we 
employed male and female mice for these studies in an attempt to identify potential 
sexual dimorphism in HCC progression in response to chronic ethanol feeding. 
4.2. Materials & Methods: 
 4.2.1. Materials In vivo model of hepatocarcinogenesis:  As listed in Section 2.1.2.  
4.2.2. Methods In vivo model of hepatocarcinogenesis: B6C3 mice (21-25 days 
old) were randomized, weighed, and injected with a single dose of DEN (1mg/Kg body 
weight, (i.p.)) dissolved in sterile olive oil (DEN group; D) or vehicle (olive oil (i.p.)), 
control group; C) as described in Section 2.1.3. Animals receiving DEN or vehicle were 
randomized to receive control or ethanol feeding regimes for early (16-24-weeks) or late 
(40-48-weeks) hepato-carcinogenesis studies. Animals were allowed free access to 
AIN93M rodent chow until specialized diets were introduced.  
4.2.3. Ethanol Drinking Water:  Animals assigned to ethanol-feeding groups were 
weaned on to an ethanol-drinking water (EtOH-DW) regime as described in Section 
2.1.4. For animals assigned to the early (16-24-weeks) hepatocarcinogenesis studies 
initiation of EtOH-DW began at 15 -weeks and ceased at 24-weeks. For animals assigned 
to the late (40-48-weeks) hepatocarcinogenesis studies initiation of EtOH -DW began at 
39-weeks and ceased at 48-weeks. All animals were weighed twice weekly. 
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4.2.4. Necropsy:  At 24 or 48-weeks (depending on pre-assigned groups) mice 
were weighed, anesthetized (isofluorane by inhalation), examined grossly and sacrificed 
as described in Section 2.1.5.   
4.2.5. Histology:  Multiple liver lobes (minimum of 2 lobes per animal) were 
sectioned (4-6m) and stained with Mayer’s hematoxylin and eosin (H & E) or 
Picrosirius red as described section 2.5.1.2. Representative sections (5 random 
fields/lobe) were examined microscopically (100x magnification) and blind-scored for 
steatosis (0-4), necrosis (0-4), inflammation (0-4), and/or fibrosis (0-4) using modified 
scoring scales reported by others (French et al., 1993; Morgan et al., 2002). Degree of 
fibrosis (mean % Picrosirius red staining) was performed using ImageJ software (NIH, 
Bethesda, MD). The four independent scores were combined to generate a total liver 
injury score (TLIS) as described Section 2.5.1.3.  
4.2.6. Immunohistochemistry:  For immunohistochemistry (IHC) sections (4-
6m) of fixed liver were immunostained following deparaffinization, rehydration and 
antigen retrieval. Sections were incubated with anti-glutathione S-transferase placental 
isoform (GSTpi; 1:100 dilution), as described in Section 2.5.2.1, or anti-proliferating cell 
nuclear antigen (PCNA; 1:1000 dilution), as described in Section 2.5.2.2. Five random 
fields/lobe (minimum of 2 lobes) were examined microscopically (200x magnification), 
photographed, and analyzed for number of foci and AHF area (mm2), or number of 
PCNA positive nuclei (dark brown staining) using ImageJ software. To measure 
apoptosis, an in situ TUNEL assay was performed as per the manufacturer’s instructions 
and sections counterstained with 4'-6-Diamidino-2-phenylindole (DAPI) for nuclear 
visualization, as described in section 2.5.2.3. To confirm antibody specificity mouse 
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spleen and embryonic tissue were used as positive controls (PCNA and TUNEL 
respectively). Negative control for TUNEL employed enzyme free probe. 
4.2.7. PCR and quantitative RT-PCR:  Total RNA was extracted from liver tissue, 
as described in Section 2.2.2. cDNA was synthesized from random hexamers, as 
described in Section 2.2.3 and used to perform PCR for CYP2E1 mRNA expression 
performed using mouse specific CYP2E1 primer pairs as listed in Table 1, Section 2.2 
(Brandon-Warner et al., 2010b). Final product was semi-quantified using NIH-ImageJ 
software and corrected to β-2 microgoblulin (housekeeping gene) levels. qRT-PCR was 
performed using cDNA followed by SYBR Green Supermix using mouse specific primer 
pairs for T-bet, GATA3, or SMAD3, listed in Table 1, Section 2.2. Reactions were 
prefomed in an iCycler IQ™ real time PCR detection system (BioRad) as described 
section 2.2.4. Samples were assayed in duplicate, and relative gene expression of each 
transcript was expressed as Ct and normalized to pair-matched controls. 
4.2.8. Western Blot Analysis:  Liver tissue (≈100mg) was homogenized RIPA 
buffer, the resulting homogenate sonicated (40C), protein levels measured, and 
normalized using RIPA buffer as described in Section 2.3.2. Protein detection was 
performed by immunoblot using antibodies specific against ADH, ALDH, CYP2E1 or 
cyclin D1 as described in Section 2.4.3 (Brandon-Warner et al., 2010b). Signal intensity 
was determined using NIH-ImageJ software and equal protein loading confirmed by 
stripping/re-probing membranes with an anti-β-actin (housekeeping protein) antibody.  
4.2.9. Liver Function and Oxidative Stress Status:  Serum alanine-
aminotransferase (ALT) was measured using an ALT/GPT 2-part reagent as described 
section 2.7.2. Hepatic lipid peroxidation was measured using a TBARS kit on liver tissue 
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homogenates, section 2.9.2. Hepatic GSH levels were determined by colorimetric 
analysis from liver tissue lysates collected in 2-(N-morpholino) ethanesulfonic acid 
(MES) buffer using a GHS assay kit, section 2.10.2. 
4.2.10. Ethanol Assay:  Aliquots (50μl) of serum were collected and stored at -
80oC prior to measurement of ethanol concentration, as described section 2.8.2 (Brandon-
Warner et al., 2010b).  
4.2.11. Cytochrome P4502E1 Activity:  CYP2E1 activity was measured as the 
rate of oxidation of ρ-nitrophenol to 4-nitrocatechol in the presence of NADPH and O2, 
as described 2.11.2 (Brandon-Warner et al., 2010b).  
4.2.12. Serum Cytokine Levels:  To evaluate and compare cytokine expression 
patterns a custom (7) Plex murine cytokine array purchased from BioRad, Hercules, CA) 
was performed as described in Section 2.6.2. Cytokines were selected to reflect changes 
in T-effector responses (Th1-IFNγ, IL1b, IL12p70 and Th2-IL13, T-reg-IL10) and 
inflammation-liver disease (TNFα and IL-6). Pooled serum (12.5μL) from each group 
was diluted 1:4 in proprietary serum sample diluents. Premixed standards were used to 
generate a standard curve. The assay was performed in a 96-well filtration plate supplied 
with the assay kit as per the manufacturer’s instructions, before being read on the Bio-
Plex suspension array system and analyzed using Bio-Plex manager software.  
4.2.13. Statistical Analysis:  Comparisons of tumor positive animals in each group 
were made by Fisher’s exact test. Comparisons of tumor size (mm2), multiplicity,  
ALT/AST, TBARS and GSH levels were made by either one-way ANOVA followed by 
Tukey’s or Dunnet’s post-hoc test, as appropriate or two-way ANOVA followed by 
Bonferonni correction.  
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4.3. Results:  
 4.3.1. Mortality, body-liver weight, and necropsy:  Male and female mice 
tolerated the EtOH-DW regime well either without, or with prior DEN initiation. Male 
mice were significantly heavier than female counterparts at all time points (Table 4.1, and 
Figure 4.1). Overall no significant difference in body weight was measured within male 
or female groups maintained on control (C) versus EtOH-DW regimes (E), nor between 
these groups and pair matched animals initiated with DEN alone (D), or DEN 
concomitant with EtOH-DW (D+E) (Table 4.1, and Figure 4.1). Of note, male mice in 
the D and D+E group (48 -weeks) exhibited significantly lower body weight compared to 
pair-matched male C or E groups at the end of the 48-week experimental period (Figure 
4.1A and Table 4.1). No mortality occurred in any of the experimental groups in the 24-
week group. Within the 48-week group, 1 male DEN and 1 female DEN+EtOH animal 
died prior to time course completion (47-weeks and 13-weeks respectively).  
At necropsy, livers were resected, photographed, and weights recorded. Upon 
gross examination no visible lesions were observed in any of the groups at 24-weeks 
(Table 4.1). By 48-weeks visible lesions were observed in both male and female mice 
initiated with DEN, a significantly greater number being visible in males (87.5% versus 
44.4%, male versus female, p<0.05, Figure 4.2, Table 4.1). In male mice (48-weeks) the 
effect of DEN was exacerbated by chronic ethanol feeding (93.7% (D+E) versus 87.5% 
(D)), whereas fewer visible lesions were observed in DEN-initiated females maintained 
on the EtOH-DW regime than DEN-initiated alone (35.7% (D+E) versus 44.4% (D); 
Figure 4.2 and Table 4.1). Calculation of liver-body weight ratios (L:BW) demonstrated 
no significant difference between male and female mice in pair-matched groups. 
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Figure 4.1:  Ethanol alone or with DEN did not alter growth of male or female mice. 
Growth curves for both male and female mice in experimental groups, EtOH-DW (E), 
DEN-initiation (D) or DEN+EtOH-DW (D+E) were not significantly different from same 
sex control (C) animals, with the exception that D and D+E male mice demonstrated a 
significant decrease in body weight at 48 weeks versus male C and E treatment groups. 
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However, by 48-weeks, male D and D+E mice exhibited a significantly higher L:BW 
ratio as compared to C and E groups, and D+E versus DEN-initiated alone (p<0.01, Table 
4.1). Conversely only DEN-initiated female mice in the 48-week groups, demonstrated 
significantly higher L:BW ratios. In comparing these data, differences in liver weight and 
L:BW ratios were attributed to increased size/number of tumors in the male (D and DE 
groups) and the female (D group) compared to control and ethanol only groups (Figure 
4.2, Table 4.1). 
 4.3.2. Liver pathology and tumor burden:  Total liver injury scores (TLIS) 
were generated following blind scoring for total fat, necrosis, inflammatory cell 
infiltration, and collagen deposition (Figure 4.3A; male and 4.3B; female 48-week 
images shown). Using this approach, increased injury was identified in male EtOH, DEN 
and DEN+EtOH mice in all lobes at both 24 and 48-weeks (Figure 4.3C). Conversely, 
pair-matched female mice were observed to exhibit more localized liver injury that was 
typically identified in only one or two lobes. Moderate, though significant, liver injury 
was measured in both male and female mice maintained on EtOH alone (E) compared to 
controls (C) at both 24 and 48-week time points (Figure 4.3C). Additional analysis 
demonstrated DEN-initiation alone (D) significantly increased the TLIS in both male and 
female mice at 24 and 48-week time points compared to C and E groups (Figure 4.3C, 
p<0.05). Within the 24-week group, maintenance on the EtOH-DW regime led to 
significantly greater TLIS in male mice compared to female (Figure 4.3C, p<0.05). This 
effect was further magnified in the 48- week study groups in which EtOH-DW 
significantly increased TLIS in male mice versus pair-matched female animals and male 
DEN-only initiated animals (Figure 4.3C, p<0.01). Finally, when comparing 24 to 48- 
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Figure 4.2: Ethanol feeding enhances DEN-induced hepatocarcinogenesis in male 
mice. Representative images of livers resected from male and female mice (48 weeks) 
initiated with DEN (D) or DEN with ethanol feeding (D+E) 
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Figure 4.3: Ethanol feeding promotes hepatic injury in a DEN model of 
hepatocarcinogenesis in male mice A) Representative images (x100 magnification) of 
sections from control (C) male mice (48 weeks) and pair-matched male mice maintained 
on ethanol feeding (E), initiated with DEN (D), or initiated with DEN and ethanol fed 
(D+E). Sections were stained with H&E, Picrosirius Red or an antibody against 
Glutathione S-transferase placental isoform (GSTpi). B) Cumulative total liver injury 
score (TLIS) was blind scored from representative sections (2 lobes/mouse, 5 fields/lobe) 
from each experimental group (male and female, 24- and 48-weeks; C, E, D, D+E). 
*p<0.05 versus respective male or female controls (C), #p<0.05 D+E (male or female) 
versus D mice, §p<0.05 male versus female within same treatment group/time points. 
Minimum n = 8 independent mice/group. 
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week groups, no significant difference in TLIS was measured between pair-matched 
groups in female mice (Figure 4.3C). Conversely, the effects of D or D+E had 
significantly greater impact on TLIS in male mice at 48 -weeks compared to 24 -weeks 
(Figure 4.3C, p<0.05).  
Analysis of individual components of the TLIS revealed that the primary mode of 
hepatic injury was lipid accumulation in DEN-initiated groups at both 24 and 48 -weeks, 
and lipid scoring was further increased by EtOH exposure, this effect being more 
pronounced in male compared to female mice (Table 4.2).   
  4.3.3. Immunohistochemistry (IHC):  was initially performed using an antibody 
against GSTpi to identify altered hepatic foci (AHF). Using this approach AHF was 
significantly greater in female D versus male groups at 24-weeks (p<0.05) (Figure 4.4A). 
Conversely, by 48-weeks, number of AHF/field was significantly greater in male D+E 
mice versus female counterparts (Figure 4.4B, p<0.005). Area of AHF were next 
calculated and expressed as mean foci area (MFA; mm2). These data demonstrated 
significantly greater MFA in D and D+E groups compared to E and C in males and 
females at 24 and 48 -weeks (Figure 4.4A and B, p<0.05). In analyzing male versus 
female DEN-initiated animals, greater MFA were measured in males compared to 
females in D+E mice (24 weeks) and in D and D+E mice groups (48 weeks) (Figure 
4.4B, p<0.05).  
  4.3.4. Proliferation:  To assess mitogenesis a second series of IHC was performed 
using an antibody specific against proliferating cell nuclear antigen (PCNA;Figure 4.5A). 
Quantification of these results demonstrated significantly increased PCNA staining in  
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Figure 4.4: Ethanol feeding promotes hepatic tumor incidence and size 
preferentially in male mice A) Mean number of altered hepatic foci (AHF)/field and 
mean foci area (MFA) were calculated from glutathione S-transferase placental isoform 
(GSTpi) positive cells in microscopic fields (x200 magnification, 2 lobes/mouse, 5 
fields/lobe) from control (C) male and female mice, and mice undergoing ethanol feeding 
(E), DEN-initiation (D) or DEN initiation followed by 8 weeks of ethanol feeding (D+E). 
*p<0.05 versus respective male or female E, #p<0.05 D+E versus respective male or 
female D mice, §p<0.05 male versus female within same treatment group/time points. 
Minimum n = 8 independent mice/group. B) Mean AHF and mean area occupied by foci 
were calculated from GSTpi+ cells from microscopic fields (x200 magnification, 2 
lobes/mouse, 5 fields/lobe) from control (C) male and female mice, and mice undergoing 
E, D, or D+E. *p<0.05 versus respective male or female E, #p<0.05 D+E versus 
respective male or female D mice, §p<0.05 male versus female within same treatment 
group/time points. Minimum n = 8 independent mice/group. 
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male and female mice initiated with DEN (D) or DEN+EtOH (D+E) compared to control 
(C), or EtOH-only (E) groups at 24 and 48-weeks (Figure 4.5B, p<0.05). Furthermore, 
significantly increased PCNA staining was measured in male D+E mice versus D in both 
24 and 48-week groups (Figure 4.5B, p<0.05). Finally, PCNA staining in D and D+E was 
significantly higher in male and female mice from 48-week groups compared to the 24-
week groups (Figure 4.5B, p<0.05). Since increased PCNA staining is also associated 
with DNA repair (Essers, 2005), we performed immunoblot analysis of cyclin D1 in 
hepatic tissue lysates. These data showed significantly increased cyclin D1 expression in 
D+E male and female mice compared to other groups (Figure 4.5B, p<0.05). 
Furthermore, higher cyclin D1 expression was apparent in male D+E mice at 48-weeks 
compared to pair-matched female counterparts (Figure 4.5C, p<0.05).  
4.3.5. Apoptosis:  An in situ TUNEL assay was performed and TUNEL positive 
nuclei/field (T+) calculated. These data demonstrated a significant increase in T+ nuclei 
in male D+E versus D only at both 24 and 48-weeks (Figure 4.6, p<0.05). Of interest, the 
number of T+ nuclei was significantly greater in female D+E mice at 24 -weeks 
compared to all other groups (Figure 4.6), and in female D-only mice compared to male 
counterparts in the 48-week group (Figure 4.6B, p<0.05). 
4.3.6. Blood-alcohol content (BAC), Liver Function and REDOX Status:  As anticipated, 
blood alcohol content (BAC) was elevated in animals maintained on the EtOH-DW 
regime, a range of 10.4  1.0 to 14.3  1.2mmol/L being detected (Table 4.3). No 
significant differences were measured between male and female DEN-initiated animals 
maintained on ethanol (D+E) compared to ethanol alone (E), and no significant 
differences were measured between respective groups at 24 versus 48-weeks (Table 4.3).  
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Figure 4.5: Ethanol feeding promotes hepatic tumorigenesis preferentially in male 
mice A) Representative proliferating cell nuclear antigen (PCNA) immunohistochmistry 
of hepatic sections (x200 magnification) from control (C) mice, or mice maintained on 
ethanol (E), DEN-initiation (D), or DEN and ethanol (D+E) at 24 or 48 weeks. B) 
Number of PCNA positive cells per microscopic field (x200 magnification) were 
measured in representative sections (2 lobes/mouse, 5 fields/lobe) from individual male 
and female mice on different treatment regimes (24 and 48 weeks) and mean values (± 
SEM) were calculated. *p<0.05 versus respective male or female E, #p<0.05 D+E versus 
respective male or female D mice, §p<0.05 male versus female within same treatment 
group/time points. Minimum n = 8 independent mice/group.  
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Figure 4.5: Ethanol feeding promotes hepatic tumorigenesis preferentially in male 
mice C) Representative immunoblots of cyclin D1 expression in hepatic tissue lysates 
from male and female mice on different treatment regimes at 24 and 48 weeks. Optical 
integrated volume was calculated, corrected for sample loading (stripping-re-probing 
membranes with anti-β-actin (β-Act)) and expressed as mean values (arbitrary units) ± 
SEM (lower panel). *p<0.05 versus respective male or female E, #p<0.05 D+E versus 
respective male or female D mice, §p<0.05 male versus female within same treatment 
group/time points. Minimum n = 6 independent samples per group. 
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Figure 4.6:  Ethanol feeding promotes cell death in hepatic tumorigenesis 
preferentially in female mice A) Fluorescein In situ cell death detection assay was 
performed on representative sections of control male and female mice (C) and mice 
maintained on ethanol (E), DEN-initiated (D), or DEN-initiated followed by ethanol 
feeding (D+E) at A) 24 and B) 48 weeks. Number of TUNEL positive cells per 
microscopic field (x200 magnification) were measured in representative sections 
(minimum of 2 lobes/mouse, 5 fields/lobe) and mean values (± SEM) calculated. *p<0.05 
versus respective male or female E, #p<0.05 D+E versus respective male or female D 
mice, §p<0.05 male versus female within same treatment group/time points. Minimum n 
= 8 independent mice/group. 
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As an indicator of liver injury/function serum alanine transferase (ALT) levelsNo 
significant differences were measured between male and female DEN-initiated animals 
maintained on ethanol (D+E) compared to ethanol alone (E), and no significant 
differences were measured between respective groups at 24 versus 48-weeks (Table 4.3).  
As an indicator of liver injury/function serum alanine transferase (ALT) levels 
were measured. Within the 24-week groups ALT levels were significantly elevated in all 
three treatment groups (E, D and E+D) compared to control, although these levels 
remained within the normal range expected for ALT levels in mice (11-70U/L) (Yan and 
Stanley, 2001). Of note, ALT levels in both male and female mice initiated with DEN 
and maintained on EtOH-DW (D+E) were significantly higher than either D, or E alone 
at 24-weeks (Table 4.3, p<0.05). In the 48-week groups ALT was again significantly 
greater in E, D and D+E groups compared to control (Table 4.3, p<0.05). Furthermore, in 
male mice, D+E and D alone caused significant increases in ALT levels compared to E 
alone at 24- and 48-weeks, while in female animals this effect was only evident in the 48-
week mice (Table 4.3, p<0.05). In both instances, ALT levels were significantly higher 
than in corresponding groups at 24-weeks (Table 4.3, p<0.05). 
 To measure hepatic REDOX status tissue lipid peroxidation (maliondialdehyde; 
MDA) and glutathione levels were measured. These data demonstrated significantly 
increased MDA levels in E, D and D+E groups at both 24 and 48-weeks compared to 
control (Table 4.3, p<0.05). Within the 24-week treatment groups no significant 
difference was measured between MDA levels between the different treatment regimes, 
or between male and female mice. Conversely, in the 48-week groups, MDA levels were 
significantly higher in the D+E groups compared to all other groups, and MDA levels 
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were significantly higher in male D+E animals compared to females (Table 4.3, p<0.05). 
Analysis of GSH levels revealed and inverse correlation to MDA data; all three treatment 
groups (E, D and D+E) exhibited significantly less GSH compared to controls, the most 
significant differences being measured in the D+E groups at both 24 and 48 -weeks. 
Additionally, the most pronounced effect on GSH depletion was measured in the male 
D+E group at 48-weeks (Table 4.3, p<0.05).  
4.3.7. Ethanol metabolizing enzyme expression and activity:  Expression of ADH, 
ALDH and CYP2E1 were measured by immunnoblot using liver tissue lysates. These 
data demonstrated no significant differences in ADH or ALDH expression within the 
groups analyzed at 24 or 48-week time points (Figure 4.7A). Conversely, analysis of 
CYP2E1 protein demonstrated increased CYP2E1 expression in E and D+E versus C and 
D mice at 24 weeks. In contrast CYP2E1 expression was only significantly increased in E 
and D+E versus C and D counterparts (Figure 4.7B). Additionally, there was no 
significant difference in CYP2E1 expression between DEN-initiated animals (D) 
compared to C, nor between male and female mice within the C and D groups at either 24 
or 48 weeks time points (Figure 4.7B). To further understand these differences, CYP2E1 
mRNA expression was measured by RT-PCR. Using this approach no differences in 
CYP2E1 mRNA were detected in male or female animals in any of the groups at either 
24- or 48-weeks (Figure 4.7D). To determine whether biochemical differences in 
CYP2E1 activity existed p-nitrophenol hydroxylation was measured. This approach 
demonstrated ρ-nitrophenol hydroxylation was significantly higher in E male and female 
mice compared to C and D at 24 and 48-weeks (Figure 4.7E, p<0.05). Furthermore, 
CYP2E1 activity was significantly higher in D+E versus E mice at 24- and 48-weeks 
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Figure 4.7. Ethanol induces cytochrome P4502E1 expression and activity 
preferentially in male mice. A) Representative immunoblots for ADH and ALDH 
expression in pooled hepatic tissue lysates from male and female control (C) and pair-
matched animals maintained on ethanol (E), DEN-initiated (D), or DEN-initiated 
followed by ethanol feeding (D+E) at 24 and 48 weeks B) Immunoblots of cytochrome 
P4502E1 (CYP2E1) expression in hepatic tissue lysates from male and female mice from 
each experimental group. C) Optical integrated volume was calculated, corrected for 
sample loading (stripping-re-probing membranes with anti-β-actin (β-Act)) and expressed 
as mean values (arbitrary units) ± SEM. *p<0.05 versus respective male or female E, 
#p<0.05 D+E versus respective male or female D mice, §p<0.05 male versus female 
within same treatment group/time points. Minimum n = 6 independent samples per 
group. D) RT-PCR analysis of CYP2E1 mRNA expression from pooled total mRNA 
samples from male and female mice on the different treatment regimes indicated at 24 
and 48 weeks. E) p-nitrophenol hydroxylation was measured as a marker of CYP2E1 
activity in hepatic lystaes from male and female mice on different treatment regimes at 24 
and 48 weeks. *p<0.05 versus respective male or female E, #p<0.05 D+E versus 
respective male or female D mice, §p<0.05 male versus female within same treatment 
group/time points. 
 
 
 
119
(male and female), and by 48-weeks CYP2E1 activity was significantly higher in male 
versus female D+E mice (Figure 4.7E, p<0.05).  
 4.3.8. Immunological status:  To identify changes in hepatic immune responses, 
we performed qRT-PCR analysis of hepatic T-bet, GATA3, and SMAD3 mRNA 
expression (Levings et al., 2002). These data demonstrated significantly increased T-bet 
and GATA3 mRNA expression in female experimental groups (E, D, and D+E) 
compared to control (Figure 4.8A, p<0.05, in all groups versus C) and compared to male 
counterparts, with the exception of GATA3 mRNA expression in DEN-only initiated 
animals (Figure 4.8A). Furthermore, T-bet and GATA3 mRNA expression were 
significantly decreased in male E and D+E mice versus control and DEN-only male 
counterparts (Figure 4.8A, p<0.05).  Concomitant with decreased T-bet/GATA3 mRNA 
expression, male mice demonstrated significantly increased SMAD3 mRNA expression 
in all experimental groups (E, D, and D+E) compared to control (Figure 4.8A, p<0.05, all 
groups versus C). Hepatic SMAD3 mRNA expression was in turn significantly increased 
in D and D+E male mice compared to E-only counterparts (Figure 4.8A, p<0.05). 
Conversely, SMAD3 mRNA was significantly decreased in female mice treatment 
groups as compared to male counterparts and female controls (Figure 4.8A, p<0.05).  
In an attempt to further understand changes in hepatic markers of immune status a 
custom mouse bioplex assay for 7 immunological cytokines (IL-6, TNFα, IL-10, IL-13, 
IL12p70, IL1b, and IFNγ) was performed in serum pooled from C, E, D, and D+E, 48-
week animals. IL-6 was not detectable in serum from any of the experimental groups 
(Figure 4.8B). In male animals, chronic ethanol feeding (E) did not alter cytokine levels 
as compared to control (C). However, serum levels of the 6 detectable cytokines 
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increased by 1.6-2.8 fold in DEN-initiated (D) males compared to pair-matched C and E 
mice. Conversely, levels of all 6 cytokines decreased in D+E mice to levels equal or 
lower than those measured in C and E mice (Figure 4.8B). Analysis of serum from 
female mice demonstrated E alone led to a 1.65 fold increase in IL-13 as compared to C, 
no notable differences being measured for the other detectable cytokines between E and 
C (Figure 4-8B). Unlike their male counterparts DEN-initiation (D) did not lead to any 
notable changes in detectable cytokine levels as compared to C (Figure 4.8B). However, 
female D+E mice demonstrated a substantial decreased IL-10, IL-13, IL-1b, and IFNγ as 
compared to C, E and D-only mice. Of particular note, IL-10 was ≈5.0 fold lower in 
female D+E mice compared to C, E or D mice, as well as pair-matched males, without 
any notable change in IL-12p70 or TNF (D+E versus C, E and D, Figure 4.8B). 
4.4. Discussion and Conclusions: 
Chronic ethanol abuse, in the absence or presence of other factors, is a significant risk 
factor for developing HCC (Yang and Roberts, 2010). Considerable evidence points to 
many of the deleterious effects of ethanol arising from metabolic byproducts and ROS 
produced during ethanol metabolism. Similarly, epidemiological evidence points to 
sexual dimorphism for HCC development. To date though, relatively few studies have 
addressed the effects of ethanol on promotion of hepatocarcinogenesis, and the potential 
role that the gender plays in these disparities. 
Epidemiological data report chronic, heavy ethanol consumption is a significant 
risk factor for the development of hepatic cirrhosis, the leading precursor to HCC 
development. However, experimental approaches to better understand these mechanisms 
report disparate results depending on the model employed. Using HCC cells in vitro, 
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Figure 4.8. Ethanol feeding differentially affects immune responses in male versus 
female mice in the setting of hepatocarcinogenesis. A. Quantitative real time PCR 
(qRT-PCR) analysis of T-bet, GATA3, and SMAD3 mRNA expression in total hepatic 
mRNA isolated from C, E, D, and D+E mice at 48 week time points. *p<0.05 versus C, 
#p<0.05 versus respective male or female E mice, §p<0.05 male versus female within 
same treatment group/time points. B. custom BioPlex assay was used to determine 
cytokine expression in pooled serum samples from control male (left) and female (right) 
mice (C), and pair matched animals maintained on ethanol (E), DEN-initiated (D), or 
DEN-initiated followed by ethanol feeding (D+E) at 48 weeks. Minimum n = 8 
independent samples per group.  
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ethanol is reported to either increase (Brandon-Warner et al., 2010b) or inhibit 
(Castañeda and Kinne, 2000) and Kinne, 2000) proliferation depending on the cell line 
employed. Studies aimed at evaluating the promotional effects of ethanol on 
hepatocarcinogenesis in vivo report similarly diverse results, whereby no effect, co-
carcinogenesis, or promotional effects occur (Mandl, 1989; Schwarz, 1983; Takada, 
1986). However, these studies were limited to male animals such that the role of gender 
has not previously been examined. Additionally, these models commonly utilize 
nutritional deficits (low methionine diet) or partial hepatectomy as a means to promote 
hepatocyte proliferation concomitant with ethanol feeding (Mandl, 1989; Schwarz, 1983; 
Takada, 1986). In doing so, it is possible that differences in timing, duration of ethanol 
exposure (relative to DEN initiation), and/or the effects of partial hepatectomy/altered 
nutritional may significantly affect outcome.  
 In this study DEN was administered to neonatal mice and dysplastic foci were 
allowed to develop prior to ethanol administration in the absence of nutritional deficits or 
partial hepatectomy. Following administration DEN, like ethanol, induces hepatic 
CYP2E1 resulting in hepatocyte transformation. As the animal/liver develops so, DEN-
induced hepatic DNA damage is magnified (Goldsworthy, 2002; Kang, 2007). As the 
animal matures hepatic tumors form that exhibit a high proliferative index, a subtype 
genetically similar to that of human HCC, and correspondingly poor prognostic outcomes 
(Fausto and Campbell, 2010). To ensure that the effects of DEN did not interfere with 
effects of chronic ethanol feeding on CYP2E1 induction, DEN-initiation was performed 
in neonatal mice (21-24 days old) 13 or 37 weeks prior to commencing ethanol feeding. 
In this way ethanol feeding was timed to coincide with hepatic foci (16 weeks) or HCC 
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(40 week) formation (following neonatal DEN injection) (Fausto and Campbell, 2010; 
Goldfarb et al., 1983; Goldsworthy, 2002; Kang, 2007).  
 In this study, rate of HCC for males to females was ≈2:1 in DEN-only mice and 
2.6:1 in DEN+EtOH mice at 48-weeks. Additionally increased incidence and size of 
tumors was measured in DEN-initiated male mice maintained on EtOH-DW (E+D) 
compared to DEN-initiation alone (D). In contrast, female mice maintenance on the 
EtOH-DW regime exhibited a decrease in both tumor size and burden. Of note, PCNA 
was higher in DEN-only female mice, while there was no apparent difference in cyclin 
D1 expression (compared to pair-matched males) in this group. This disparity may 
indicate changes in PCNA expression in female mice occurs, in part, due to activation of 
DNA repair mechanisms. That is, chemical carcinogens induce DNA damage that can, in 
turn, activate endogenous repair pathways, PCNA having been reported to accumulate at 
sites of DNA damage as a requirement for DNA repair (Essers, 2005). Given the 
importance of oxyradicals and changes in cellular REDOX balance during ethanol 
metabolism (Albano et al., 1999; Hoek, 2002), the differences in DNA repair 
mechanisms between male and female mice may thus be of significance in hepatic 
tumorigenesis in the setting of chronic ethanol feeding in a model pre-disposed to hepatic 
tumor formation. No differences in PCNA were detected between male and female E-
only mice, but female D+E mice had significantly lower PCNA staining compared to 
pair-matched males with significant increases in TUNEL positive cells. This may indicate 
that females eliminate cells with ethanol-induced DNA-damage, and that these 
differences in apoptosis are more efficient during early hepatocarcinogenesis than late, 
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although apoptosis (as indicated by TUNEL+ cells) remains higher in females than males 
in E and D+E groups, even at 48 wks. 
 In addition to differences in timing of DEN administration and/or nutritional or 
surgical promotion, our model employed an ethanol-drinking water (EtOH-DW) feeding 
regime. Several models of chronic ethanol feeding have been described, including the 
Lieber DeCarli (LDC) liquid diet, the Tsukamoto-French intra-gastric model, daily 
gavage, and exposure to ethanol vapor (Tabakoff and Hoffman, 2000). Each of these 
models has advantages and potential limitations depending on study design and duration. 
The choice of the EtOH-DW model for our studies was based on practical and 
experimental considerations. While the LDC and intra-gastric approaches are most 
commonly reported for studying alcoholic liver disease (Nanji and French, 2003; 
Tabakoff and Hoffman, 2000), the number of animals in our study group, the use of 
calorically pair-matched control animals, and the feeding period (8-weeks) made this 
approach unfeasible. Rather preliminary data from pilot studies, and data generated from 
our experimental series, demonstrated no significant differences in body weight in 
animals maintained on EtOH-DW compared to pair-matched DW-only animals, with 
BACs of ≈10-14mmol/L. 
Measures of morbidity (ALT, pathology scores: steatosis, necro-inflammatory 
changes) corresponded to tumor burden and incidence in male and females and was 
affected by ethanol. Serum ALT, was elevated in animals maintained on EtOH-DW, 
without or in addition to DEN-initiation, at both 24 and 48-weeks. Additionally, ALT 
levels were several fold higher in late (48-week) stage models while only modest 
increases over normal levels (11-70U/L) were identified at early time points (24-week). 
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To directly compare degrees of hepatic injury, we presented our data as total liver injury 
score (TLIS). Using this approach, data demonstrate TLIS are (generally) commensurate 
with ALT data. However, it is of interest to note that both male and female D and D+E 
mice had significantly elevated ALT values (compared to C or E counterparts), yet TLIS 
were significantly lower in female D+E mice versus male D+E mice. The most likely 
explanation for this disparity is the difference in tumor burden between the two groups; in 
females, HCC formation was most commonly restricted to 1 or 2 lobes, whereas in males 
tumors formed throughout all hepatic lobes. As such histological examination using 2 
randomly assigned lobes (5 fields/lobe scored) is more likely to encounter/score non-
tumor tissue in females compared to males resulting in a lower TLIS. Additionally, when 
considering the individual components used to compile TLIS, lipid deposition is observed 
as the most pronounced individual factor influencing TLIS at both early and late time 
points. Of further note, in the 24-week animals lipid scoring (male and female) was 
comprised primarily of microvessicular lipid droplets indicative of active lipid loading. 
However, by the 48-week time point lipid deposition was primarily large globules 
indicative of steady state steatosis. Additionally, male mice had high levels of foamy 
degeneration of cells with large areas of necrosis, effects exacerbated by ethanol 
exposure in DEN-initiated animals. Overall, scores for individual criteria were generally 
lower in female mice, the only exception being the presence of more infiltrating immune 
cells in female DEN-initiated mice at 24 and 48-weeks compared to pair matched males.  
The differences we detected in hepatic injury are most likely to be related to 
changes in cell REDOX state due to ethanol metabolism, generation of ROS, and changes 
in cellular GSH. Induction of CYP2E1 accentuates the imbalance in acetaldehyde/ALDH 
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and contributes to the generation of ROS with subsequent depletion of GSH and 
oxidative injury. Male and female mice maintained on the EtOH-DW regime had 
consistently higher levels of MDA compared to control or DEN-initiated only mice at 24-
weeks. Conversely, GSH levels were decreased in both male and female animals. 
However, female mice exhibited consistently higher GSH levels than males in both 24 
and 48-week groups. These data suggest that, despite the increased potential for injury in 
females, greater GSH levels may protect against hepatic ROS/oxidative injury.  
 Hepatic inflammatory responses to ethanol, and their influence on the tumor 
microenvironment have been identified as important factors during hepatocarcinogenesis 
(Kakumu et al., 2000; Mandrekar and Szabo, 2009).  mRNA analysis of transcription 
factors for Th1 (T-bet) and Th2 (GATA3)  T-effector responses demonstrated that 
females maintained higher expression of both T-bet and GATA3 compared to pair-
matched males in E, D and D+E groups. Furthermore, ETOH-DW alone or EtOH-DW in 
DEN-initiated male mice acted to suppress T-bet and GAT3 expression below that of c 
levels. Thee events also occurred in the presence of increased SMAD3 mRNA expression 
in male experimental mice compared to their female counterparts. Collectively, these data 
suggest females maintain a more robust inflammation response, a property reflected by 
lower tumor incidence and burden as compared to male counterparts. Indeed, as indicated 
by TUNEL analysis, increased apoptosis was detected in female E and D+E groups 
compared to male counterparts (24 weeks), an event that may be indicative of more 
efficient immunosurveillance and or clearance of transformed cells in females; factors 
that will directly contribute to subsequent decreases in hepatic tumor size and burden in 
females at later time point (48 weeks). Of further note, we also detected increased 
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SMAD3 mRNA in E, D and D+E male mice, a factor that may indicated increased 
activation of a T-regulatory response through TGF signaling and immunosuppression in 
male versus female mice.  
Cytokine profiles within the tumor milieu can have critical effects on tumor 
promotion and progression. Data presented herein demonstrated that DEN-initiation led 
to increased expression of all measured cytokines in male mice compared to control. In 
contrast, no such increase in serum cytokines were measured in DEN-initiated female 
mice, an effect that is likely attributable to the increased incidence and tumor burden in 
male DEN mice compared to female. Ethanol alone did not noticeably alter cytokine 
expression in male mice, yet serum IL-13 was increased by a factor of 1.65 in female E-
only mice compared to control and did correlate to increased GATA3 identified in this 
group. Serum cytokine levels were not completely reflective of hepatic gene expression, 
but indicate systemic immune responses. As such, they can be influenced by many 
factors outside the liver, including sex-hormone levels, blood LPS, and overall oxidative 
stress. It was also noted that male D+E mice exhibited an increased ratio of IL10/low 
IL12p70 expression relative to C that was not detected in female mice. This is significant 
as high IL-10/low IL-12p70 has been reported to influence alternative activation of 
macrophages which can in-turn impair dendritic cell (DC) maturation Endogenous IL-12 
p70 is important for host response to tumors, and is reported to inhibit tumoriogenesis 
(Lin and Karin, 2007) by promoting the maturation of dendritic cell (DC) maturation 
(Corinti et al., 2001). This is associated with conversion of macrophages from an 
inflammatory (M1) phenotype, to a tumor associated (M2) phenotype that promotes 
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tumor progression. It is noteworthy, that suppression of dendritic cell function has been 
reported in human cases of HCC  
 Multiple factors influence cytokine expression, and this is particularly true in the 
setting of chronic ethanol consumption. For example, a significant component of hepatic 
immune responses are attributed to oxidative stress arising from ethanol metabolism 
(Crabb, 1995; Hoek, 2002). Additionally, there are indirect effects of ethanol on intestinal 
permeability, as well as composition of the gut flora that are equally important in 
defining Kupffer cell (KC) activation and intrahepatic immune signaling (Enomoto et al., 
2001; Mandrekar and Szabo, 2009). As such, changes in serum cytokine levels we report 
may not accurately reflect specific immune responses within the milieu of tumor per se, 
or for that matter the environment around the tumor. Similarly, this type of cytokine 
panel does not allow us to address the potential role of the multiple cell types likely to be 
contributing to change in systemic cytokine levels (e.g. KCs, stellate cells, endothelial 
cells, monocytes and/or T/B-cell populations). However, gender differences are reported 
in cytokine signaling as well as recruitment of neutrophils and macrophages to the site of 
injury (Bird, 2008; Naugler, 2007). The potential to differentially effect DC activation, 
immunosuppression and modulation of T-regulatory cells described herein thus raises 
intriguing questions regarding the potential role of cytokines/immune responses in 
mediating inherent differences in male and female responses during EtOH-dependent 
changes in tumor promotion (Butura, 2009; Hoek, 2002; Lin and Karin, 2007).  
 While differences in immune system responsiveness are likely to be important 
mediators of the gender specific effects of ethanol on tumor promotion, other factors 
must also be considered. Most notable amongst these are the likely effects of ethanol on 
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sex hormone signaling. While our study did not measure androgen or estrogen levels, or 
signaling pathways regulated by these sex hormones, a considerable body of data 
indicates ethanol plays a significant role in regulating the synthesis and action of sex 
hormones in the liver and other organs. Gender specific differences have been identified 
in IL-6 expression, and transcriptional activation through NFkB, p38, AP-1 and STAT3 
that may influence HCC progression and immune response (Karin, 2009).  Additionally, 
small molecule mediators such as adeponectin have been demonstrated to possess 
hepatoprotective and anti-tumor qualities and exhibit sex-dependent differences in 
expression (Shen et al., 2010; You and Rogers, 2009).  
Indeed, it seems increasingly likely that future studies of the dynamic between sex 
hormone synthesis, metabolism and signaling, and the intra and extra-hepatic immune 
system responses will prove central to fully understanding the dramatic gender 
differences that occur during hepatic tumorigenesis in the setting of chronic ethanol 
intake. These data demonstrate ethanol promotes hepatocarcinogenesis in a mouse model 
primed to develop HCC, but this activity is more pronounced in males than females. 
Additionally, this is accompanied by increases in MDA and measures of oxidative stress 
combined with depletion of cellular GSH in males compared to their female counterparts.   
These data demonstrate that ethanol promotes HCC progression in male mice, and 
that male mice exposed to ethanol after DEN initiation have inherently higher levels of 
oxidative stress with depletion of antioxidant defenses (GSH) when compared to female 
counterparts. Theses changes in REDOX status are associated with increased tumor size 
and burden. This suggests that antioxidant therapy may be beneficial in ameliorating 
these effects and preventing ethanol mediated promotion of HCC. Our in vitro studies 
 
 
130
using a rat hepatoma cells (H4IIE) demonstrated that pre-treatment of ethanol exposed 
cells with silibinin deceased the rate of cell proliferation and improved measures of 
oxidative stress. These data supported a mechanism of direct interaction between silibinin 
and CYP2E1 that altered ethanol metabolism thereby decreasing the associated toxic 
effects while inhibiting proliferation. Further studies remain to determine if silibinin 
would confer any protective effects in this mouse model of HCC and if these effects 
occur differently in male and female mice. Additionally, we can determine if anti-cancer 
properties attributed to silibinin could reduce the rate of tumor promotion or progression 
in the absence of ethanol exposure.
 
 
 
 
 
 
 
 
CHAPTER 5:  DIETARY SILIBININ POTENIATES THE PROMOTIONAL EFFECTS 
OF ETHANOL ON HEPATOCARCINOGENESIS IN AN INVIVO MOUSE MODEL 
 
 
5.1. Introduction:   
Hepatocellular carcinoma (HCC) is a significant global health burden. In the 
United States (US) rates for HCC have doubled over the last three decades (Altekruse, 
2009). HCC most commonly occurs in the context of chronic inflammation leading to 
fibrosis and cirrhosis (McKillop, 2005). In the US nearly 18 million people abuse 
ethanol, making this a major risk for development of hepatic cirrhosis, the leading risk for 
subsequent HCC development (Altekruse, 2009; El-Serag, 2002; McKillop, 2005). The 
mechanisms by which chronic ethanol consumption leads to cirrhosis and HCC remain 
poorly defined. Ethanol is not considered a hepatic carcinogen per se; rather injury is 
thought to be related to its metabolism in hepatocytes. Additionally, ethanol works 
synergistically with other risk factors to further increase incidence and severity of disease 
onset (El-Serag, 2007; McKillop and Schrum, 2009).  
Within the liver, hepatocytes account for the majority of ethanol metabolism to 
acetaldehyde via ADH and/or CYP2E1 dependent pathways (Lieber, 2000; McKillop, 
2005). Acetaldehyde is in turn oxidized by acetaldehyde dehydrogenase (ALDH) to 
acetate, which enters the Kreb’s cycle. With infrequent, moderate consumption, the 
ADH/ALDH pathway accounts for most ethanol oxidation. However, in the setting of 
chronic, long term, ethanol exposure induction of CYP2E1 occurs and acetaldehyde 
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production is increased (Lieber, 1997b; McKillop, 2005). Acetaldehyde is a toxic, 
volatile intermediate that can rapidly bind to DNA, proteins and lipid membranes 
(Muller, 1987). These interactions produce DNA and protein adducts, or lipid 
peroxidation, which leads to additional toxic aldehyde products (e.g.  malondialdehyde 
(MDA) and 4-hydroxynonenol (HNE)). In addition, CYP2E1 enzyme is also poorly 
coupled to oxygen leading to partially reduced ethanol; hydroxylethyl radical (HER), and 
reactive oxygen species (ROS) that combine to further exacerbate the genotoxic and 
cytotoxic effects of ethanol metabolites (Albano, 2006; Wu and Cederbaum, 2003). 
Cumulative effects of these events can be the generation of genetic changes that drive 
malignant transformation. Additionally, ethanol/ethanol metabolism influences cell 
signaling pathways, affecting proliferation, DNA repair, and apoptosis (Albano, 2006). In 
doing so, ethanol may act as a promoting agent on select transformed cells allowing for 
clonal expansion.  
The underlying effects of ethanol are largely determined by the generation of 
toxic intermediates, such as ROS that lead to increased oxidative stress. Hepatic GSH 
serves as the major endogenous antioxidant involved in detoxification (Lu, 1998). Cell 
GSH levels can be depleted by chronic oxidative stress which generates an imbalance in 
ratio of GSH to its disulfide-oxidized form (GSSG). Structural changes in mitochondria 
occurring as a result of oxidative stress and ethanol exposure mediate effects on 
membrane permeability that impair GSH transport (Cunningham and Bailey, 2001). 
Oxidative stress is a key mediator of hepatic inflammation which can be critical in the 
promotion and progression of HCC (Albano, 2008; Lieber, 2001).This has led to 
numerous studies on the efficacy of utilizing antioxidant therapies to ameliorate oxidative 
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injury occurring from increased generation of oxygen radicals and loss of cellular 
REDOX homeostasis associated with chronic ethanol abuse.  
Antioxidants have been reported to reduce ethanol mediated double strand DNA 
breaks, and inhibit formation of lipid peroxidation byproducts (Bartsch, 2005; 
Navasumrit, 2000). Silybum marianum (Milk Thistle) has been used as an 
hepatoprotectant for (at least) several millennia. It is derived from plant seeds as 
silymarin, a mixture of flavinoligands consisting of silybin A, silybin B, isosilybin A and 
B, silychristin and silydianin (Saller, 2007). Of these, the most abundant and biologically 
active the diasteroisomers silybin A and B with exist in a 1:1 ratio, and collectively 
identified as silibinin (Lee, 2003; Saller, 2007). Silibinin is a potent scavenger of hydroxy 
radicals and is reported to stimulate increased synthesis of superoxide dismutase (SOD) 
(Mira et al., 1994; Pradeep et al., 2007). Additionally, other properties may act to inhibit 
cancer growth or progression. Ramakrishnan, et al. report that silymarin inhibits 
proliferation in HepG2 cells in a dose dependent manner, with a corresponding increase 
in apoptotic cells (Ramakrishnan et al., 2009). Protective effects of silibinin have also 
been reported in several in vivo studies of liver injury in which protection from oxidative 
injury, stellate cell activation and T-cell mediated liver injury is evidenced by oral 
silibinin (Pradeep et al., 2007; Schumann et al., 2003; Trappoliere et al., 2009).  
Data from previous chapters demonstrate ethanol promotes hepatic carcinogenesis 
in a DEN mouse model, effects restricted to males.  In this case a single dose of DEN (1 
mg/kg, i.p.) was administered to infant B6C3 mice (21-28 days) followed by chronic 
ethanol feeding at points predicted for foci (16 weeks), or HCC (40 weeks) development 
(Goldfarb et al., 1983; Vesselinovitch and Mihailovich, 1983).  Of specific note, these 
 
 
134
events were associated with sex-dependent differences in GSH-GSSG status between the 
sexes, while previous in vitro studies demonstrated silibinin inhibited the promotional 
effects of ethanol on HCC cell proliferation.  
In light of these data, the aims of the final set of studies for my dissertation were 
to determine the effects of dietary silibinin, in the absence and presence of chronic 
ethanol feeding on promotion and progression in a mouse model primed to develop HCC. 
As in previous studies, silibinin administration was timed to coincide with the kinetics of 
DEN initiated tumorigenesis (Goldfarb et al., 1983; Vesselinovitch and Mihailovich, 
1983).  
5.2. Materials and Methods: 
5.2.1. Materials:  Materials for the in vivo model of haptocarcinogensis as 
previously described (Section 2.1.2). Materials for immunohistochemistry studies were as 
described previously (Section 2.5.2.1). Additionally, anti-F4/80 and anti-CD3 antibodies 
were purchased from Abcam (Cambridge, MA). Rabbit HRP, DAB chromagen, Rat AP 
polymer kit, and Vulcan Fast Red were purchased from Biocare (Concord, CA). Antigen 
retrieval 1 mM EDTA was purchased from GibcoBRL (San Francisco, CA). Proteinase K 
was purchased from Qiagen (Valencia, CA). Materials for immunohisotchemistry 
Enzyme- Immuno-Assay (EIA) for detection of 8-OHdG was purchased from Cayman 
Chemical (Ann Arbor, MI). A DNA isolation kit and Monococcal nuclease were 
purchased from Zymo Research (Irvine, CA). Glycerol, Alkaline phospatase 2000 U/mL, 
MgCl2, CaCl2, EDTA, NaCl and Tris-HCL were purchased from Sigma Aldrich (St. 
Lousi, MO).  
5.2.2. Methods In vivo model of hepatocarcinogenesis:  B6C3 mice (21-28 days 
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old) were randomized, weighed, and injected with a single dose of DEN (1mg/kg body 
weight, (i.p.)) dissolved in sterile olive oil (DEN group; D) or vehicle (olive oil (i.p.)), 
control group; C) as described in Section 2.1.3. Animals receiving DEN or vehicle were 
randomized to receive control (AIN93-M) diet or diet supplemented with silibinin 
(AIN93-M+0.5% (w/w) silibinin). DEN-initiated animals designated to receive silibinin 
diet were further divided into groups designated to receive water or EtOH-DW regimes 
for early (16-24-weeks) or late (40-48-weeks) hepatocarcinogenesis studies. Prior to 
experimental treatments, animals were allowed free access to AIN93M rodent chow.  
5.2.3. Silibinin diet:  Animals assigned to groups receiving silibinin diet 
(AIN93M mouse chow + 0.5% silibinin (w/w) (silibinin diet alone (Sil)), DEN initiated + 
silibinin diet (D+Sil), or DEN-initiated + EtOH-DW + silibinin diet (D+E+Sil)) were 
introduced to diet at 15 weeks for early (24 week) or 39 weeks for late (48 week) 
hepatocarcinogenesis studies and maintained on diets for 9 weeks prior to necropsy 
(Section 2.1.4). All animals were weighed twice weekly and an n assessment of food 
intake was conducted during the second and sixth weeks in those studies. Six animals 
from male and female C, Sil, D+Sil, and D+E+Sil groups were randomly selected and 
cages isolated. Regular AIN93M mouse chow and AIN93M+Sil (0.5% w/w) mouse chow 
was weighed and placed into feeding chutes on cages. Cages were checked and remaining 
food weighed daily for 5 days.  Mean rate of consumption was calculated based on the 
amount of food consumed divided by number of animals.  
5.2.4. Necropsy:  At 24 or 48 weeks (depending on pre-assigned groups) mice 
were weighed, anesthetized (isofluorane by inhalation), examined grossly and sacrificed 
as described (Section 2.1.5).  
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5.2.5. Histology: Multiple liver lobes (minimum of 2 lobes per animal) were 
sectioned (4-6m) and stained with Mayer’s hematoxylin and eosin (H & E) or 
Picrosirius red as described (Section 2.5.1.2). Representative sections (5 random 
fields/lobe) were examined microscopically (100x magnification) and blind-scored for 
steatosis (0-4), necrosis (0-4), inflammation (0-4), and/or fibrosis (0-4) using modified 
scoring scales reported by others (French et al., 1993; Morgan et al., 2002). Degree of 
fibrosis (mean % Picrosirius red staining) was performed using ImageJ software (NIH, 
Bethesda, MD).  Four independent scores were combined to generate a total liver injury 
score (TLIS) as described previously (Section 2.5.1.3).  
5.2.6. Immunohistochemistry (IHC): Staining for anti-glutathione S-transferase 
placental isoform (GSTpi, 1:100 dilution), and proliferating cell nuclear antigen 
(PCNA1:1000 dilution) were conducted as previously described (Sections 2.5.2.1 and 
2.5.2.2).  
Additional sections were stained with an antibody specific for 8-hydroxy 
deoxyquanosine (8-OHdG) as an indicator of oxidative DNA damage. Sections (4-6m) 
of fixed liver were immunostained following deparaffinization, rehydration and antigen 
retrieval. Sections were examined microscopically (200x magnification), photographed 
and number of 8-OHdG positive nuclei (dark brown staining), positive and negative 
nuclei were counted using cell counter features of NIH ImageJ software, and stated as a 
percent positive. 
To assess immune cell infiltration sections (4-6 m) were dual stained for 
immune cell markers macrophage (F4/80, 1:250 dilution) and T-cells (CD3, 1:250 
dilution) positive cells. Sections (4-6 m) were immunostained following antigen 
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retrevial in 1mM EDTA. Immune cells were identified as positive stained macrophage 
(F4/80, DAB chromagen, dark brown staining) or T-cells (CD3, Vulcan fast-red 
chromagen) as number of positively stained cells/field, using cell counting feature of 
ImageJ as previously described. A total of 5 fields per section, 2 sections per liver were 
examined.  
5.2.7. Reverse trancriptase PCR and quantitative RT-PCR:  Total RNA was 
extracted from liver tissue, as described (Section 2.2.2), and cDNA was synthesized from 
random hexamers (Section 2.2.3) and used to perform PCR for CYP2E1 mRNA 
expression using mouse specific CYP2E1 primer pairs (Table 1, Section 2.2 (Brandon-
Warner et al., 2010b)). Final product was semi-quantified using NIH-ImageJ software 
and corrected to β-2 microgoblulin (housekeeping gene) levels. qRT-PCR was performed 
with cDNA followed by SYBR Green Supermix using mouse specific primer pairs for T-
bet, GATA3, or SMAD3, listed in Table 1 (Section 2.2). Reactions were preformed in an 
iCycler IQ™ real time PCR detection system (BioRad) as described section 2.2.4. 
Samples were assayed in duplicate, and relative gene expression of each transcript was 
expressed as Ct and normalized to pair-matched controls (Baker et al., 2010; Livak, 
2001). 
5.2.8. Western Blot Analysis: Liver tissue (≈100mg) was homogenized in RIPA 
buffer, the resulting homogenate sonicated (4oC), protein levels measured, and 
normalized using RIPA buffer. Protein detection was performed by immunoblot using 
antibodies specific against ADH, ALDH, CYP2E1 or cyclin D1 (Section 2.4.3) 
(Brandon-Warner et al., 2010b). Signal intensity was determined using NIH-ImageJ 
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software and equal protein loading confirmed by stripping/re-probing membranes with an 
anti-β-actin (housekeeping protein) antibody.  
5.2.9. Liver function and REDOX status: Serum alanine-aminotransferase (ALT) 
was measured using an ALT/GPT 2-part reagent (Section 2.7.2). Hepatic lipid 
peroxidation was measured in liver tissue homogenates based on thiobarbituric acid 
reactive species (TBARS). Hepatic GSH levels were determined by colorimetric analysis 
from liver tissue lysates collected in 2-(N-morpholino) ethanesulfonic acid (MES) buffer 
using a GHS assay kit. 
5.2.10. Ethanol assay: Aliquots (50μl) of serum were collected and stored at  
-80oC prior to measurement of ethanol concentration, as previously described section 
2.8.2 (Brandon-Warner et al., 2010b).  
5.2.11. Cytochrome P4502E1 activity: CYP2E1 activity was measured as the rate 
of oxidation of ρ-nitrophenol to 4-nitrocatechol in the presence of NADPH and O2 
(Section 2.11.2) (Brandon-Warner et al., 2010b).  
5.2.12. Measurements of serum cytokine levels: To evaluate and compare 
cytokine expression patterns a custom (7) Plex murine cytokine array (BioRad, Hercules, 
CA) was preformed.  
5.2.13. Silibinin levels: Determination of silibinin levels in serum and liver tissue 
were conducted at the David H. Murdock Research Institute (DHMRI) by mass 
spectrometry (LC-MS). Serum (pooled samples from each treatment group) and 
individual liver tissue samples (n=5) from each treatment group were collected as 
described Section 2.1.5. Liver tissue was prepared and homogenized in KCl (0.15 mol/L) 
or Tris HCl (pH 7.4) buffer.  Tissue homogenates were centrifuged and supernatants 
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collected for analysis. Total silibinin from both conjugated and un-conjugated fractions in 
serum and liver were initially digested with β-glucuronidase and sulphatase at 37oC for 
1.5 hours. After digestion, 3 volumes of internal standard (naringenin 10 μl/mL in 
acetonitrile) was added and mixtures centrifuged at 3,500 rpm for 20 minutes at RT. A 
UPLC-tandem MS system was used for silibinin quantification following 
chromatographic separation of 5 μl aliquot of each sample supernatant on an Acquity 
UPLC analytical column.  
5.2.14. Statistical analysis:  Comparisons of tumor positive animals in each group 
were made by Fisher’s exact test. Comparisons of pathological scoring, foci size and 
number, mRNA or protein expression, ALT, GSH, TBARS and silibinin were made by 
one-way ANOVA followed by Dunnet’s or Tukey’s post-hoc test,  as appropriate or two-
way ANOVA followed by Bonferonni correction.  
5.3. Results: 
 5.3.1. Mortality, liver-body weight, necropsy:  No significant differences were 
measured in body weight of male and female mice in C or Sil groups during the course of 
the study (Figure 5.1). Male mice were significantly heavier than female counterparts at 
all time points (Figure 5.1, Table 5.1). Male mice maintained on EtOH-DW where 
significantly heavier than C at 24 weeks (Figure 5.1, Table 5.1, *p<0.05). Male D, D+E, 
and D+E+Sil demonstrated significant weight gain beginning at 24 weeks when 
compared to control, but after 44 weeks weight declined rapidly, and by necropsy they 
were significantly smaller than pair-matched C (Figure 5.1, Table 5.1, *p<0.05). No 
significant increase in liver weights were measured in male mice compared to control at 
24 weeks; however, liver:body weight (L:BW) ratio was significant in D+E mice  
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A)           B) 
 
 
 
 
 
 
 
 
 
C)            D) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:  Silibinin diet alone or with concomitant EtOH-DW in DEN-initiated mice 
had limited effects on growth rates in male and female mice.  Growth curves for both 
A) male and B) female mice in experimental groups, Silibinin diet (Sil), DEN-initiated 
only (D), DEN initiated + silibinin diet (9 weeks) (D+Sil) were not significantly different 
from same-sex control (C). Male D and D+Sil mice had significantly decreased body 
weight at 48 weeks compared to pair-matched C or Sil mice. C) male and D) female mice 
in experimental groups EtOH-DW (8 weeks) EtOH,  DEN initiated + EtOH-DW (8 
weeks) D+E, and DEN+EtOH-DW +Silibinin diet (D+E+Sil).  
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compared to control (Table 5.1). In 24 week female mice, liver weight and L:BW ratio 
were significantly increased in female DEN mice compared to C (Table 5.1, *p<0.05). 
Conversely, D+Sil group had significantly reduced liver weight compared to pair-
matched C and DEN-only animals, this corresponded to significantly reduced L:BW ratio 
compared to D (Table 5.1, #p<0.5 versus DEN). No differences in growth, liver weight, 
L:BW were identified in D+E or D+E+Sil female mice. In 48 week male mice liver 
weight and L:BW ratios in all DEN initiated groups were significantly increased 
compared to C (Table 5.1, *p<0.05). No differences were identified in D versus D+Sil or 
D+E versus D+E+Sil male groups. Conversely, in female mice only the DEN-initiated 
group had significantly increased liver weight and L:BW ratio compared to C (Table 5.1, 
*p<0.05). However, D+Sil females had significantly lower liver weight and L:BW ratio 
compared to D-only (Table 5.1, #p<0.05). These changes in liver weight and L:BW ratio, 
corresponded to tumor burden identified in male and female mice (Figure 5.2). 
Upon gross examination no visible lesions were identified in C or Sil male or 
female mice. Visible lesions were identified in male and female DEN initiated mice. 
There was no significant difference in the number of animals presenting with lesions at 
24 or 48 weeks (Table 5.1). No significant differences in the number of animals identified 
with visible lesions were detected in either male or female D versus D+Sil groups at 24 or 
48 weeks. Silibinin feeding concomitant with EtOH-DW did not significantly alter the 
number of male or female animals presenting with visible lesions at 24 or 48 weeks 
(Table 5.1).  
Male and female animals tolerated the silibinin diet well without, or with prior 
DEN initiation and in combination with EtOH-DW. Measures of dietary intake 
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Table 5.1: Liver/Animal weights and Liver:Body weight ratios at necropsy.  *p<0.05 
versus C, or  #p<0.05 versus DEN-only within male or female groups assayed at the 
matching timepoints (24 or 48 weeks).  
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Figure 5.2:  Silibinin feeding provided minimal or no protection in male and female 
DEN initiated mice, but exacerbated hepatocarcinogenesis when combined with 
EtOH-DW regime.  Representative images of livers resected from male and female mice 
(48 weeks) initiated with DEN (D) and DEN initiated mice maintained on silibinin diet 
(D+Sil), DEN initiated mice +EtOH-DW (D+E), and DEN initiated mice + EtOH-DW + 
Silibinin diet (D+E+Sil). 
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demonstrated no significant differences in consumption of AIN93M mouse chow plus 
silibinin (0.5% w/w), without (Sil) or with prior DEN initiation (D+Sil), and with 
DEN+EtOH-DW and silibinin diet (D+E+Sil), or AIN93M mouse chow only (C) without 
or with prior DEN initiation (D) in male or female mice. Male mice consumed 
3.52±.011g of food/mouse/day in animals maintained on silibinin diet versus to 
3.64±0.12g of food/mouse/day in control. Females consumed 3.12±0.12g of 
food/mouse/day in animals maintained on silibinin diet versus 3.04±0.08g of 
food/mouse/day in control. Of note, 1 male (D+Sil) mouse in the 24 wk group and 1 
female (D+Sil) mouse in the 48 wk group died three weeks post DEN initiation. 
5.3.2. Hepatic tissue and serum silibinin levels: Measures of silibinin in liver 
tissue were decreased in DEN-initiated female mice at 24 and 48 weeks, but appeared to 
have little effect on serum levels (Figure 5.3A). Measures of silibinin in liver tissue were 
decreased in D+Sil male mice at 24 weeks, this decrease was not identified in male 
D+EtOH+Sil mice (Figure 5.3A). At 48 weeks silibinin levels were significantly 
increased in all male DEN-initiated mice compared to those measured at 24 weeks, and 
this was enhanced by concomitant EtOH-DW. Increased serum levels detected in 48 
week male D+E+Sil animals corresponded to increased tissue levels (Figure 5.3B).  
5.3.3. Liver pathology:  Total liver injury scores (TLIS) were generated following 
blind scoring of H&E and Picrosirius red stained slides for total fat, necrosis, 
inflammatory cell infiltration and collagen deposition (Figure A.1-A.12, appendix A, 
representative images). Using this approach as a means of directly comparing groups,  
signficant increases in measures of hepatic injury were identified in all DEN initiated 
male and female groups (Figure 5.4A, *p<0.05) compared to C, Sil, or EtOH only 
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A)      B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3:  Tissue and serum silibinin levels were increased in 48 week DEN-
initiated mice and was further increased by concomitant EtOH-DW.  A) Silibinin 
levels in liver tissue following 9 weeks of silibinin supplemented AIN93M (0.5% w/w) 
mouse chow. No significant differences were measured between male and female mice 
without (Sil) or with prior DEN initiation (D+S) at 24 weeks, or with EtOH-DW regime 
(DES). Male mice measured increased tissue silibinin levels at 48 weeks. B) Silibinin 
levels in pooled serum measured in male and female mice with or without prior DEN 
initiation. Increased serum levels were identified in both male and female mice at 48 
weeks when compared to same sex groups at 24 weeks.  
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animals at 24 and 48 weeks. It is of note, male and female mice maintained on silibinin 
diet only had similar TLIS as those maintained on EtOH-DW alone. Males had increased 
TLIS in all DEN-initiated groups compared to females. Silibinin diet in D+Sil mice did 
not decrease TLIS compared to D-only in males or females; in fact, in 48 male mice 
TLIS was significantly increased compared to pair-matched DEN-only animals. Silibinin 
given with EtOH-DW (D+E+Sil) had no impact on liver injury at 24 or 48 weeks in 
either male or female mice when compared to D+E animals. 
Further examination of individual components of liver injury indicated that 
increased lipid deposition was associated with silibinin diet without or with prior DEN 
initiation in male and female mice. Increased total fat identified in D+Sil and D+E+Sil 
male mice at 48 weeks demonstrated a corresponding increase in foamy degeneration and 
necrosis with infiltration of inflammatory cells (Table A.1; appendix A). Scores for 
female mice indicated increased lipid deposition in D+Sil and D+E+Sil groups, however 
measures of necrosis were decreased and inflammation increased in these groups when 
compared to D or D+E respectively at 24 weeks. 
 5.3.4. Immunohistochemistry and tumor burden:  Immunohistochemistry (IHC) 
was initially performed using an antibody specific against GSTpi to identify multiplicity 
and area of altered hepatic foci (AHF). Using this approach, AHF were measured and 
counted as an indicator of tumor burden. Measures of tumor area were significant in male 
and female DEN-initiated experimental groups compared to respective male and female 
C, EtOH, or Sil only animals at 24 and 48 weeks (Figure 5.5A(24 week), 5.5B (48 week), 
*p<0.05). Male mice measured significantly increased area of AHF versus pair-matched 
female mice in all DEN-initiated experimental groups. At both 24 and 48 weeks silibinin  
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Figure 5.4: Silibinin feeding had no effect on TLIS in male or female mice.  A) 
Cumulative total liver injury score (TLIS) was blind scored from representative sections 
(total fat, inflammatory cell infiltration, necrosis and collagen – male and female 24 and 
48 weeks; C, Sil, E, D, D+E, D+Sil, D+). *p<0.05 versus respective male or female 
controls (C), EtOH-DW (E), or silibinin diet (Sil) only; #p<0.05 versus respective pair-
matched DEN-only (D). Minimum of n=8 independent mice/group. 
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A)       B)   
 
 
 
 
 
C)      D) 
 
 
 
 
 
 
 
 
 
Figure 5.5: Silibinin feeding decreased tumor size and burden preferentially in 
female mice during early hepatocarcinogenesis.  A) Measures of mean area (mm2) and 
multiplicity, mean number of altered hepatic foci/field (AHF) were calculated from 
glutathione S-transferase - placental isoform (GSTpi) positive cells (clusters of 2 or more 
cells) in a microscopic field (x200 magnification), 2 lobes/mouse 5 fields/lobe) from 
male and female, 24 and 48 weeks, control (C), 9 weeks silibinin diet (0.05% w/w) (Sil), 
DEN-initiated (D), and DEN+silibinin diet (D+SIL). *p<0.05 versus respective male or 
female C, #p<0.05, D+SIL versus respective male or female DEN (D)  B) Multiplicity of 
AHF as calculated by count of GSTpi positive cells (200x magnification, 2 lobes/mouse, 
5 lobes/field). *p<0.05 versus respective male or female C, #p<0.05, D+SIL versus 
respective male or female DEN (D). Minimum n=8 independent mice/group 
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feeding in D+Sil male mice did not significantly reduce tumor area versus D-only. 
Additionally, no differences in multiplicity were detected. Silibinin diet in combination 
with EtOH-DW regime (D+E+Sil) did not significantly reduce area of AHF versus D+E 
male mice. Conversely, female mice demonstrated a significant decrease in measured 
tumor area in D+Sil mice versus female DEN-only mice at 24 weeks (Figure 5.5A, 
#p<0.05). However, this effect was not evidenced in female mice at 48 weeks, although 
area measures of AHF in female D+Sil mice were smaller than DEN-only counterparts. 
Additionally, silibinin diet in combination with EtOH-DW regime did not significantly 
reduce area of AHF in female mice at 24 or 48 weeks.   
Multiplicity of AHF were increased in male and female mice at 24 and 48 weeks 
in all DEN-initiated experimental groups compared to pair-matched C, E, or Sil only 
mice (Figure 5.5C (24 week), 5.5 D (48 week), *p<0.05). Numbers of AHF were not 
significantly altered in D+Sil versus D or D+E+Sil versus D+E groups in either male or 
female pair-matched animals. 
5.3.5. Proliferation:  In order to assess mitogenesis, in light of increases in area 
measured in AHF, a series of IHC was performed using an antibody specific against 
proliferating cell nuclear antigen (PCNA; Figure  5.6A (24 weeks), 6C (48 weeks)). 
Quantification of these results demonstrated significantly increased PCNA staining in 
both male and female mice in all DEN-initiated experimental groups versus same-sex 
control animals at matching time points (Figure 5.6B-24, and D-48 weeks ,*p<0.05). 
Additionally, these data demonstrate that expression was not altered in D+Sil versus D,  
or D+E+Sil versus D+E male mice. Conversely, PCNA staining was reduced in female 
 D+Sil versus D mice at 24 weeks and this was decrease was significant at 48 weeks 
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 (Figure 5.6B, #p<0.05).  
Since PCNA localizes to sites of DNA damage, and is associated with activation 
of DNA repair pathways (Essers, 2005), we next performed immunoblot analysis of 
cyclin D1 in hepatic tissue lysates. These data demonstrate that cyclin D1 expression is 
increased in all male DEN-initiated experimental groups when compared to C at 24 and 
48 weeks (Figure 5.7A and B, *p<0.05). Additionally, in 24 week male mice cyclin D1 
expression is significantly increased in D+Sil male mice versus D-only animals (Figure 
5.7A, #p<0.05). However, no significant differences were identified in D versus D+Sil or 
D+E versus D+E+Sil in male or female groups at 48 weeks.   
5.3.6. Apoptosis: To identify differences in apoptosis, an in situ TUNEL assay 
was performed and TUNEL positive nuclei/field (T+) calculated. These data 
demonstrated significantly increased T+ nuclei in female mice maintained on EtOH-DW 
regime (E) or silibinin diet (Sil) without, or with prior DEN initiation (D+E, D+Sil, and 
D+E+Sil) at 24 and 48 weeks versus control (Figure 5.8A and B, *p<0.05), and this was 
significant compared to pair matched male mice (Figure 5.8A and B, §p<0.05). 
Furthermore, significantly increased T+ nuclei were identified in female  D+Sil mice 
versus D only (Figure 5.8A, #p<0.05).  
5.3.7. Liver injury and REDOX status:  Serum alanine transferase (ALT) levels 
were measured as an indicator of liver injury/function. In the 24 week groups ALT levels 
were elevated in male and female DEN-initiated mice compared control (Table 5.2, 
*p<0.05 versus C).  Silibinin feeding reduced serum ALT in DEN-initiated male and 
female in the absence or presence of concomitant EtOH-DW, this was significant in male 
D+Sil mice versus D (Table 5.2, #p<0.05 versus D). Within 48 week groups ALT levels 
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Figure 6 continued. 
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Figure 5.6: Silibinin feeding was associated with decreased PCNA expression in 
female mice during early and late hepatocarcinogenesis. A) 24 week and C) 48 week 
representative proliferating cell nuclear antigen (PCNA)  immunohistochemistry of 
hepatic sections (x200 magnification) from 24 week control male and female (C) mice, or 
mice maintained on EtOH-DW (E),  Silibinin diet (Sil), initiated with DEN (D), 
DEN+EtOH (D+E), DEN+Silibinin diet (D+SIL), and DEN+EtOH-DW+Silibinin diet, 
(D+E+Sil or DES) B) 24 week and D) 48 week; number of PCNA positive cells per 
microscopic field (x200 magnification) measured in representative sections (2 
lobes/mouse, 5 fields/lobe) from individual male and female mice from each 
experimental group with mean values ± SEM calculated. *p<0.05 versus respective C or 
Sil only animals, #p<0.05 versus respective male or female pair-matched DEN-initiated 
mice. Minimum n=8 independent mice/group. 
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Figure 5.7: Silibinin feeding was associated with increased cyclin D1 expression in 
male DEN-initiated mice during early hepatocarcinogenesis. A) Representative 
immunoblots of cyclin D1 expression in hepatic tissue lysates from male and female mice 
in each experimental group at 24 and 48 weeks. B)  24 week and C) 48 week animals 
optical integrated volume calculated, corrected for sample loading (stripping-re-probing 
membranes with anti-β-actin (β-act), and expressed as mean value (arbitrary units) ± 
SEM. p<0.05 versus respective C, or Sil only animals, #p<0.05 versus respective male or 
female pair-matched DEN-initiated mice. Minimum n=6 independent samples per group.  
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Figure 5.8: Silibinin feeding was associated with increased apoptotic cell death 
during early and late hepatocarcinogenesis in female DEN-initiated mice.  
Fluorescein In situ cell death detection assay was performed on representative sections 
from male and female Control (C), EtOH-EW (E), Silibinin diet regime (Sil), DEN 
initiated (D), DEN+EtOH-DW (D+E), and DEN initiated + silibinin diet (D+S) or 
DEN+EtOH-DW+Silibinin diet (DES) experimental groups at A) 24 weeks and B) 48 
weeks;  number of TUNEL positive cells per microscopic field (x400 magnification) 
were measured in representative sections (minimum of 2 lobes/mouse, 5 field/lobe) and 
mean values ± SEM calculated. *p<0.05 versus respective male or female C or Sil, 
#p<0.05 versus pair-matched male or female DEN+EtOH, §p<0.05 male versus female in 
pair-matched experimental group. 
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were significantly elevated in male and female DEN-initiated experimental groups versus 
same-sex controls (Table 5.2, *p<0.05 versus C).  Silibinin feeding did not significantly 
alter serum ALT in male DEN-initiated mice in the absence or presence of concomitant 
EtOH-DW; however ALT was significantly reduced in D+Sil female mice versus D 
(Table 5.2, #p<0.05 versus D).  
To further evaluate hepatic REDOX status, tissue thiobarbituric acid reactive 
species (TBARS) were measured as an indicator of (malondialdehyde; MDA) lipid 
peroxidation. These data demonstrated significantly increased MDA in experimental 
groups compared to C in male and female mice at 24 and 48 weeks (Table 5.2, *p<0.05 
versus C). Silibinin feeding significantly decreased MDA in male DEN-initiated mice 
presence of concomitant EtOH-DW, and in female D+Sil versus D-alone and in D+E+Sil 
versus D+E (Table 5.2, #p<0.05 versus D or D+E). Additionally, female mice measured 
significantly lower MDA levels in experimental groups (Sil, D, D+Sil, and D+E+Sil) 
compared to pair-matched male mice. Within the 48 week groups, male and female 
animals measured increased MDA in E-only and all DEN-initiated treatment groups 
compared to C (Table 5.2, *p<0.05). In male mice silibinin feeding did not significantly 
reduce MDA levels in DEN-initiated mice in the absence or presence of EtOH-DW. 
Conversely, silibinin feeding in DEN-initiated female mice measured  significantly 
decreased MDA in D+Sil versus D-only and D+E+Sil versus D+E mice (Table 5.2, 
#p<0.05 versus D or D+E). Measures of MDA were increased in male versus pair-
matched female mice. 
On analysis of GSH levels a similar pattern was observed at 24 weeks, GSH was 
significantly reduced in DEN-initiated experimental male and female mice (Table 5.2, 
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*p<0.05 versus C). Male GSH levels were decreased compared to pair-matched female 
mice. GSH in D+Sil female mice was significantly increased versus DEN-only female 
mice (Table 5.2, #p<0.05 versus D). In 48 week male and female groups GSH was 
significantly decreased in E, and all DEN-experimental groups compared to C (Table 5.2, 
*p<0.05). Female mice maintained increased GSH levels compared to pair-matched male 
mice. GSH levels in 48 week DEN-initiated male and female mice were not significantly 
altered by silibinin feeding in the absence or presence of EtOH-DW.  
To further assess oxidative DNA damage measures of hepatic anti-8-hydroxy-
deoxyguanosine (8-OHdG) were assessed by IHC on liver sections using an anti-8-OHdG 
specific antibody and a parallel assay by mouse-specific Enzyme Immuonassay (EIA) of 
purified, nuclease treated DNA were performed. IHC data demonstrated that increased 8-
OHdG staining was identified in DEN-initiated male and female mice at 24 and 48 
weeks. In addition, 8-OHdG positive staining was identified in male Sil only mice 
(Figure 5.9A). Analysis of EIA data demonstrated similar results, male and female mice 
had significantly increased 8-OHdG in DEN-initiated groups versus control at 24 and 48 
weeks (Figure 5.9B, *p<0.05). Levels in male DEN-initiated treatment groups were 
significantly increased versus pair-matched females in 48 week groups (Figure 5.9B, 
§p<0.05 male versus female).  Silibinin feeding did not significantly reduce 8-OHdG in 
D+Sil versus D-only male or female animals, but was associated with a significant 
decrease in female D+E+Sil mice versus pair matched D+E mice at 24 weeks (Figure 
5.9B, #p<0.05 versus D+E). No decreases in 8-OHdG were measured in silibinin fed 
male or female mice at 48 weeks. 
5.3.8. Blood alcohol content (BAC), ADH, ALDH, and CYP2E1 expression: 
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Table 2:  Measure of liver injury/function and REDOX status.  Alanine  
aminotransferase (ALT), malondialdehyde (MDA) and glutathione (GSH) levels at 
necropsy. *p<0.05 versus respective pair-matched C or Sil, #p<0.05 versus respective 
pair-matched DEN only, and §p<0.05 male versus female in pair-matched experimental 
group.  
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Figure 9:  Silibinin feeding was associated with decreased formation of 8-OHdG 
during early and late hepatocarcinogenesis in female mice.  A) Representative 8-
hydroxy-deoxyguanasine (8-OHdG) IHC of hepatic sections (200x magnification) from 
control (C) mice, mice maintained on silibinin diet (Sil), Den-initiated mice (D), DEN 
initiated mice on silibinin diet (D+S) experimental groups (48 week time point shown).  
IHC analysis was conducted by counting positively stained nuclei/field as a percent of 
total cells at 400x magnification, a minimum of 5 fields/lobe and 2 lobes per animal were 
examined. B) Parallel measures of 8-OHdG nucleoside concentrations per 1μg/DNA 
isolated from hepatic tissue, samples were assayed in duplicate by enzyme immunoassay 
(EIA) (24 week-left panel, 48 week –right panel). *p<0.05 versus respective male or 
female C, #p<0.05 versus pair-matched male or female DEN+EtOH-DW, §p<0.05 male 
versus female in pair-matched experimental group. Mimum n=6 independent mice/group. 
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Animals maintained on EtOH-DW regime, without or with prior DEN-initiation and with 
concomitant silibinin diet had elevated BAC versus pair-matched C.  Serum BAC ranges 
measured between 13.3±1.1 to 14.3±1.2 in male and from 10.4±1.1 to 11.4±1.2 in female 
E, D+E, and D+E+Sil mice at 24 weeks and ranges measured between 11.4±0.5 to 
14.2±0.8 in male and 10.9±0.6 to 13.1±0.8 in female E, D+E, and D+E+Sil mice at 48 
weeks. No significant differences were measured between male and female non- and 
DEN-initiated mice on EtOH-DW and in DEN-initiated mice in the absence or presence 
of silibinin diet. No significant differences were measured in male versus female mice in 
pair-matched groups at the same time points.  
 Expression of ADH, ALDH and CYP2E1 were determined by immunoblots using 
pooled liver tissue lysates. These data demonstrated no significant differences in ADH or 
ALDH expression within any experimental groups analyzed at 24 and 48-week time 
points (Figure 10A). However, analysis of CYP2E1 protein demonstrated increased 
CYP2E1 expression in male and female mice maintained on EtOH-DW regimes without 
(E) and with prior DEN initiation (D+E), and with silibinin diet  D+E+Sil at 24  and 48 
weeks (Figure 10A). To further understand changes in CYP2E1, immunoblots of lysates 
from individual animals (Minimum n=6) were analyzed for CYP2E1 expression. These 
data demonstrated significantly increased CYP2E1 in DEN-initiated male and female 
mice maintained on EtOH-DW regime at 24 and 48 weeks (Figure 10B, *p<0.05 versus 
C).  In addition, expression in male D+E and D+E+Sil was significantly increased 
compared to pair-matched female mice. Silibinin feeding with concomitant EtOH-DW 
did not significantly alter CYP2E1 expression in DEN-initiated males or female mice at 
24 or 48 weeks.  
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To further understand differences observed in CYP2E1 expression, we measured 
mRNA by RT-PCR. Using this approach we found lower mRNA levels in male and 
female Sil and D+S mice, but no differences were observed in any other groups at either 
24 or 48 weeks (Figure 10C).  
To determine if biochemical differences in CYP2E1 activity existed, 
hydroxylation of p-nitrophenol was measured. This approach demonstrated that p-
nitrophenol hydroxylation was significantly higher in ethanol fed male and female mice 
at 24 and 48 weeks versus respective C mice (Figure 5.10D, *p<0.05). Males 
demonstrated higher CYP2E1 activity than pair-matched female mice. Silibinin feeding 
with concomitant EtOH-DW had no effect on hydroxylation of p-nitrophenol in either 
male or female DEN-initiated mice at 24 or 48 weeks. 
5.3.9. Immunological profile: To evaluate how underlying immune response and 
cytokine levels may influence changes in pathology associated with HCC progression, we 
performed qRT-PCR analysis of hepatic T-bet, GATA3, and SMAD3 mRNA expression 
in an effort to determine dominant T-effector responses that may be present. These data 
were then analyzed by comparing C, Sil, DEN-initiated mice and D+Sil mice and 
alternately, C, EtOH, D+E and D+E+Sil experimental groups. These data demonstrate 
significant increases in expression of T-bet (Th1- effector Transcription factor) in female 
D and D+Sil mice (Figure 5.11A, *p<0.05 versus pair-matched control or Sil), and this 
was significant compared to pair-matched male animals (Figure 5.11 A, §p<0.05 male 
versus female).  Conversely, males demonstrated increased SMAD3 expression in D and 
D+Sil groups, and this was significant in D+Sil males (Figure 5.11A, *p<0.05 versus C 
or Sil) Differences in SMAD3 expression in male D and D+S mice was significant 
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Figure 10 continued. 
D) 
 
 
 
 
 
 
Figure 5.10: Ethanol induced cytochrome P450 2E1 expression and activity that was 
not abrogated by concomitant silibinin feeding.  A) Representative immunoblots for 
ADH, ALDH and CYP2E1 expression in pooled hepatic tissue lysates from male and 
female control (C), and pair-matched EtOH-DW (E), Silibinin diet (S), DEN-initiated 
(D), DEN+EtOH-DW (D+E), DEN+Silibinin diet (D+S), and DEN+EtOH-DW+Silibinin 
diet D+E+Sil (DES). B) Optical integrated volume was calculated, corrected for sample 
loading (stripping-re-probing membranes with anti-β-actin (β-act)) and expressed as 
mean value (arbitrary units)±SEM for immunoblots of CYP2E1 from lysates of minimum 
n=6 individual animals/group, normalized to β-act, *p<0.05 versus control, #p<0.05 
versus pair-matched DEN+EtOH-DW (D+E), and §p<0.05 male versus female at 
matching time points. C) Representative RT-PCR gels of CYP2E1 mRNA expression 
from pooled total mRNA from hepatic tissue in male and female mice on different 
experimental treatment regimes at 24 and 48 weeks  D) p-nitrophenol hydroxylation was 
measured as a marker of CYP2E1 activity in hepatic lysates from male and female mice 
on different experimental treatment regimes at 24 and 48 weeks. *p<0.05 versus control, 
#p<0.05 versus pair-matched EtOH-DW, and §p<0.05 male versus female at matching 
time points. 
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compared to pair-matched female mice (Figure 5.11A, §p<0.05 male versus female in 
pair-matched experimental groups).  Male and female D+Sil mice had significantly 
reduced GATA3 (Th-2-effector transcription factor), compared to DEN-only animals 
(Figure 5.11A, #p<0.05 versus male or female D).  
 Analysis of mRNA expression of T-bet, GATA3, and SMAD3 demonstrated 
similar differences between male and female mice on EtOH-DW regime in the presence 
or absence of silibinin diet.  Female mice measured increased T-bet in E and D+E+Sil 
groups compared to C (Figure 5.11C, *p<0.05 versus same-sex C), this was  
Significant in D+E+Sil female mice compared to pair-matched male mice (Figure 5.11C, 
§p<0.05). A significant  increase in T-bet mRNA was measured in male D+E+Sil mice 
compared to pair-matched C (Figure 5.11C, *p<0.05),  and this was significant versus 
DEN-only male mice (Figure 5.11C, #p<0.05). Female mice also demonstrated 
significantly increased GATA3 in EtOH fed groups (E and D+E) versus pair-matched C 
(Figure 5.11C, *p<0.05), this was significant versus male counterparts (Figure 11C, 
§p<0.05).  GATA3 expression was significantly reduced in ethanol feeding in male mice 
compared to C (Figure 5.11C, *p<0.05). However in D+E+Sil female mice GATA3 was 
significantly reduced compared to female D+E animals (Figure 5.11C, #p<0.05). GATA3 
expression was unchanged in male D+E and D+E+Sil groups.  Male mice demonstrated 
increased SMAD3 mRNA in all EtOH- fed groups, this was significant in D+E mice 
(Figure 5.11C, *p<0.05 versus C), and was versus pair-matched female mice (Figure 
5.11C, §p<0.05).  
 To analyze cytokine profiles, a custom mouse bioplex assay for 7 immunological 
cytokines (IL-6, TNFα, IL-10, IL-13, IL12p70, IL-1b, and IFNγ) was performed in serum 
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pooled from C, Sil, D, and D+Sil in 48 week animals. IL-6 was not detected in any 
experimental groups (Figure 5.11B and 5.11C). Silibinin did not alter cytokine levels in 
either male or female groups when compared to C (Figure 5.11B). Cytokine levels were 
increased in male DEN-initiated experimental groups compared to pair-matched female 
groups. Further, no change was identified in female DEN-only mice compared to C. 
Conversely, male mice demonstrated increased levels of all analyzed cytokines in D and 
D+Sil mice compared to C and Sil groups (Figure 5.11B). In analyzing cytokine 
expression in ethanol fed groups, IL-6 was not detected in either male or female groups 
(Figure 5.11D). Cytokines were increased in male D+E+Sil compared to all other groups. 
Variations in specific cytokines were detected. Increased TNFα was identified in all male 
and female EtOH groups (E, D+E, and D+E+Sil) when compared to C (Figure 5.11D). 
Females E and D+E+Sil animals had increased IL13, which was also elevated in 
D+E+Sil male mice, despite the low mRNA expression of GATA3.  
5.4. Discussion and Conclusions:     
 Hepatic cirrhosis is the primary underlying risk factor for subsequent 
development of HCC (El-Serag, 2007; McKillop, 2006; Vidali, 2007). Underlying 
mechanisms of hepatic injury leading to cirrhosis and HCC begin with chronic 
inflammation, dysregulation of lipid metabolism, and increased oxidative stress that 
arises from documented risk factors; Hepatitis C or B viral infection, aflatoxin, chronic 
ethanol abuse, and/or non-alcoholic fatty liver disease (El-Serag, 2007; McKillop, 2006). 
Chronic ethanol abuse is a major risk factor for hepatocarcinogenesis in the United 
States, but the deleterious effects of ethanol are primarily due to metabolic intermediates 
and ROS produced during metabolism (McKillop, 2005; Seitz and Becker, 2007). The 
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Figure 5.11 A and B: Silibinin feeding produced limited effects on immune response 
in male or female mice in the setting of hepatocarcinogenesis. A) Quantitative Real-
time PCR analysis of T-bet, GATA3, and SMAD3 mRNA expression in total hepatic 
mRNA isolated from male and female control (C) mice, mice maintained on silibinin diet 
(Sil), Den-initiated mice (D), DEN initiated mice on silibinin diet (D+S) experimental 
groups at 48 week time points *p<0.05, versus same-sex control or Sil, #p<0.05 D versus 
D+S in male or female and §p<0.05 male versus female in pair-matched experimental 
group. Minimum n=6 independent mice/group B) Custom 7 cytokine Bioplex assay was 
used to determine cytokine expression in pooled serum samples from C, Sil, D,  and D+S 
male (left) and female (right) mice. Minimum n=8 independent samples/group.  
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Figure 5.11 C and D: Cytokine levels were increased in DEN-initiated male mice 
maintained on silibinin feeding and concomitant EtOH-DW. C) Quantitative Real-
time PCR analysis of T-bet, GATA3, and SMAD3 mRNA expression in total hepatic 
mRNA isolated from male and female from control (C), EtOH-DW (E), DEN+EtOH-DW 
(D+E), DEN+EtOH+Silibinin diet (DES) at 48 weeks *p<0.05 versus respective male or 
female C or Sil, #p<0.05 DE versus DES in pair-matched male or female experimental 
groups,   §p<0.05 male versus female in pair-matched experimental group. Minimum n=6 
independent mice/group D) Custom 7 cytokine Bioplex assay was used to determine 
cytokine expression in pooled serum samples from C, E, D+E and DES, male (left) 
female (right). Minimum n=8 independent samples/group.  
 
 
 
 
 
 
 
 
 
 
 
168
link between oxidative stress mediated inflammation and promotion/progression has been 
established in many types of cancer (Karin and Greten, 2005; Lin and Karin, 2007; 
Reuter et al., 2010). Oxidative stress/ROS in the milieu of the tumor microenvironment 
can provide favorable conditions for promotion and progression during carcinogenesis 
(Balkwill et al., 2005; Dhanalakshmi et al., 2004). The mechanisms for these interactions 
have not been completely elucidated, but this relationship has been confirmed by the 
inhibitory effects achieved through the use of antioxidant and anti-inflammatory agents 
(Arteel, 2003; Reuter et al., 2010). In addition, individual variations based on sex, 
metabolic and nutritional differences, and modulation of immune responses may be 
critical factors in susceptibility to development and progression of cirrhosis to HCC.  
The relationship between oxidative stress and hepatocarcinogenesis has 
stimulated increased interest in the use of natural plant derived flavinoids as therapeutics 
to reduce oxidative stress/inflammation and potentially restrict HCC promotion and 
progression. Milk thistle (Silybum marianum) has demonstrated anti-oxidant and anti-
inflammatory activity, and has been used as a hepatoprotectant for thousands of years 
(Gazak, 2007; Saller, 2007). The extract derived from the seeds is composed of several 
flavinoligands, of which the major bioactive constituent is silibinin.  Silibinin is 
comprised of a 1:1 ratio of diastereoisomers silybin A and silybin B (Saller, 2007). 
Silibinin is a potent antioxidant; however, studies of the effects of silibinin in prostate, 
breast, and lung cancers have demonstrated that it possesses additional properties that 
influence  proliferation, apoptosis, angiogenesis, and immune modulation that interfere 
with cancer progression (Chen et al., 2005; Cheung et al., 2010; Lee et al., 2007; Singh, 
2004b).  
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 Epidemiological data indicates that males are three times more likely to develop 
HCC than females (El-Serag, 2007). Our previous studies reported that male mice were 
more susceptible to the promotional effects of ethanol than their female counterparts. 
These effects could occur through direct actions of ethanol on cell signaling pathways 
and immune function, or through increased oxidative stress and toxic metabolites 
generated, thereby creating a favorable environment for promotion and progression of 
HCC. Increased tumor mass and burden in DEN-initiated male mice maintained on 
EtOH-DW was accompanied by CYP2E1 induction, increased measures of oxidative 
stress and diminished GSH. Conversely, female mice demonstrated reduced tumor size 
and burden and maintained higher levels of GSH with decreased measures of hepatic 
injury and higher rates of apoptosis.  In females, this was associated with decreased 
CYP2E1 induction and activity. These data suggest that the promotional effects may be 
due to the oxidative stress generated by CYP2E1 mediated ethanol metabolism and 
accumulation of acetaldehyde, and byproducts of lipid peroxidation. Additionally, 
increased intestinal epithelial permeability associated with ethanol consumption elevates 
bacterial endotoxin (LPS) in the liver activating Kupffer cells to release TNFα, and ROS 
that can synergize with CYP2E1 to increase liver injury (Ferenci et al., 1989). 
 The goal of this study was to determine if silibinin could reduce oxidative stress 
and inflammatory responses to prevent tumor promotion and progression during early 
(16-24 week) and late (40-48 weeks) DEN-initiated carcinogenesis alone; and 
additionally, if silibinin could blunt the promotional effects of EtOH when administered 
in combination with chronic EtOH-DW regime. HCC was induced by administration of a 
single ip injection of DEN (1 mg/kg) to neonatal mice (21-28 days old). Experimental 
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treatment regimes were established to coincide with kinetics of DEN-initiated 
hepatocarcinogenesis and formation of early dysplastic foci (16 weeks) and late when 
HCC can be anticipated (44 weeks) (Fausto, 2010; Goldfarb et al., 1983). CYP2E1 is 
induced in conjunction with hepatic transformation, but subsides during growth and 
development of DEN-initiated infant mice. Hepatic DNA damage is amplified and 
populations of transformed cells expand as initiated mice grow and develop 
(Goldsworthy and Fransson-Steen, 2002; Kang, 2007). The neoplasia formed in this 
model display a phenotype similar to that of human HCC with a high proliferative index 
with poor prognostic outcome. To ensure the effects of DEN-initiation on CYP2E1 had 
abated, dysplastic foci were allowed to develop for 15 or 39 weeks prior to commencing 
silibinin (0.05% w/w, 9 week) feeding without or with EtOH-DW (10/20% v/v, 8 week) 
regime.  
 Silibinin is reported to have low toxicity, even at high doses (Yang et al., 2011). 
Previous studies have demonstrated that dietary feeding in rodent models provided a 
viable means for silibinin administration, and was well tolerated (Singh and Agarwal, 
2004; Zhao and Agarwal, 1999). Clearance of silibinin occurs through its conjugation to 
glucuronide and sulphate compounds followed by excretion in bile (Jacobs et al., 2002). 
Previous studies report that mice tolerated chronic EtOH exposure (8 weeks) via drinking 
water, and had measured BAC at levels comparable to moderate consumption in humans 
(Ishihara et al., 2010; Seitz, 2006). Dietary silibinin feeding paired well with EtOH-DW 
regime, and was practical and effective given the timing and duration of each 
experimental treatment.  
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 In this study male mice developed HCC at a rate ≈2:1 compared to female mice in 
DEN-initiated groups with silibinin feeding (0.05% w/w), (D+Sil). The rate in D+E+Sil 
decreased to ≈1.4:1. Silibinin feeding in DEN-initiated mice, in the absence or presence 
of EtOH-DW was associated with decreased ALT, MDA and 8-OHdG in all animals, 
while females maintained higher GSH levels. These improvements in measures of hepatic 
injury did not  result in significant histological improvement or decreases in collagen 
deposition when compared to DEN or DEN+EtOH mice. Females demonstrated less 
hepatic injury compared to pair-matched male mice, likely owing to decreased tumor 
burden identified in those animals. Additionally, hepatic lesions identified in females 
were restricted to one or two lobes, whereas male mice had extensive tumor burden 
affecting all lobes, this was exacerbated by EtOH-DW and further by combined EtOH-
DW and silibinin diet. 
 Tissue and serum levels of silibinin demonstrated that male mice had increased 
accumulation of silibinin in hepatic tissue during late HCC. This was most likely due to 
impaired hepatic function and decreased drug clearance with progressive liver injury and 
tumor burden. Silibinin clearance was impaired by concomitant EtOH-DW when 
compared to dietary silibinin alone in male DEN-initiated animals. Additionally, there 
was a corresponding increase in serum silibinin levels in D+E+Sil male mice. These 
effects were not evidenced in female mice, where silibinin levels were consistent at both 
time points. Clearance of silibinin was reflective of hepatic function and increased 
percentage of non-tumor liver present in females at both time points. Silibinin has been 
reported to interfere with glucuronosyltransferase activity through direct inhibition of 
cytochrome P450 3A4 and 2C9 (Sridar et al., 2004). This inhibition combined with 
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decreased liver function may have contributed to increased silibinin concentrations. 
Silibinin has been reported to have low toxicity even at high dosages, however changes in 
cellular effects have been reported to be dependent on tissue/serum concentration 
(Cheung et al., 2010; Schwarz et al., 1983).  
 Silibinin feeding was associated with a 48.4% decrease in tumor size in female 
D+Sil mice during early (24 week) hepatocarcinogenesis and 30.4% decrease during late 
(48 week) HCC. Decreases in tumor size and burden were associated with improvements 
in measures of hepatic injury. Anti-oxidant functions of silibinin likely contribute to 
decreased ALT, MDA, and oxidative DNA damage identified these animals. In addition 
to improvements in the measures of hepatic injury, female D+Sil had decreased liver 
mass and L:BW ratios. However, tumor size and burden were not decreased by silibinin 
feeding in DEN-initiated male mice. Measures of ALT decreased 1.2 fold in male D+Sil 
animals during early hepatocarcinogenesis, but this was without significant decreases in 
MDA, 8-OHdG or preservation of GSH levels. Similar improvements were not identified 
during late hepatocarcinogenesis in male mice. Antioxidant functions of silibinin likely 
explain modest improvements in hepatic injury and oxidative stress, but these effects 
were not sufficient to inhibit increases in tumor size and number. Additionally, silibinin 
feeding did not reduce TLIS in male or female D+Sil versus DEN-initiated animals. On 
histological examination male mice had higher measures of hepatic injury commensurate 
with increased tumor burden. Examination of individual components of liver injury 
demonstrated that lipid deposition, necrosis and inflammatory cell infiltration were 
increased in male D+Sil animals compared to DEN-initiated animals at 24 and 48 weeks. 
Increased lipid deposition and inflammatory cell infiltration were increased in female 
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mice. In 48 week male and female mice, increased Sirius red staining was also identified, 
indicative of fibrosis and collagen deposition.  
 Tumor incidence was associated with increases in proliferating cell nuclear 
antigen (PCNA) expression in all DEN-initiated male and female experimental groups, 
with higher levels identified in males compared to females. This corresponded to 
increased tumor size and burden in these animals. However, cyclin D1 was significantly 
higher in male D+Sil mice, indicating that PCNA expression was related to proliferation 
in males. However, in female mice PCNA may be due to increased activation of DNA 
repair mechanisms, as PCNA accumulates at sites of DNA damage (Essers, 2005). 
Expression of PCNA in female mice may indicate a prolonged cell cycle with activation 
of DNA repair pathways. In non-melanoma skin cancer silibinin was reported to increase 
S-phase arrest, allowing for DNA repair with concurrent up-regulation of mismatched-
base repair enzymes in response to UVB induced damage (Dhanalakshmi et al., 2004). 
Additionally, during early HCC, numbers of TUNEL positive cells were higher in female 
D+Sil animals. These data suggest that female mice have improved clearance of altered 
cells that may inhibit HCC promotion during early hepatocarcinogenesis. However, 
cyclin D1 levels in D+Sil female mice were comparable to those in DEN-initiated 
females during late HCC indicating that PCNA expression is likely due to proliferation 
during late HCC development. This suggests that inhibitory effects on HCC promotion 
identified during early HCC were dampened in late hepatocarcinogenesis. Male D+Sil 
mice demonstrated decreased TUNEL positive cells in D+Sil mice compared to DEN 
initiated mice during both early and late HCC. Loss of responsiveness to apoptotic 
signals in damaged cells is a hallmark of cancer progression (Hanahan and Weinberg, 
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2000). Necrotic cell death is an inflammatory process, unlike apoptosis.  On histological 
examination male D+Sil demonstrated increased steatosis and ballooning necrosis of 
hepatocytes, an effect that was more pronounced during late HCC.  
 The balance of inflammatory and anti-inflammatory cytokines during hepatitis 
can enhance or inhibit tumor promotion. Additionally, multiple cell types within the liver 
parenchyma contribute to inflammatory immune function. An assessment of immune 
cytokines demonstrated increased expression of all cytokines in DEN males, and these 
levels were increased further in D+Sil males. Conversely, in females TNFα, was elevated 
in DEN initiated mice, but decreased in D+Sil animals. Serum cytokine levels can be 
influenced by many factors and are reflective of systemic pathology and may not be 
indicative of specific immune responses within the liver, and tumor stroma. Additionally, 
assessing serum cytokine levels at a single time point at sacrifice does not adequately 
reflect the dynamic nature of immune response. However, despite decreases in 
inflammatory cytokines identified in females, there was increased T-bet mRNA. The 
presence of substances released by necrotic hepatocytes is an important inducer of NFκB 
in liver macrophages, Kupffer cells (KC) (Scaffidi et al., 2002). Activation of Kupffer 
cells is associated with increases in pro-inflammatory cytokines including TNFα, IL-6, 
which can activate other cell types in the liver (Maeda et al., 2005). Loss of hepatocytes 
as a result of increased necrotic cell death, as identified in male D and D+Sil mice may 
drive compensatory proliferation with increased expression of hepatic growth factors that 
contribute to promotion. Serum cytokine levels in D+Sil males were higher when 
compared to DEN-initiated animals. Despite increased expression of pro-inflammatory 
cytokines systemically, higher levels of SMAD3 mRNA were detected in liver tissue 
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from D+Sil animals. SMAD3 is a key mediator of TGFβ signaling during growth, 
differentiation, and apoptosis (Baldi et al., 1996; Imoto et al., 2005). Modulation of TGFβ 
can be critical during cancer development. In addition, androgen and estrogen are co-
regulators of SMAD3 induced transcription activation (Matsuda et al., 2001). Crosstalk 
between SMAD3 and estrogen/androgen signaling pathways appear to direct specific and 
differential actions in context of wound healing, estrogens accelerate healing associated 
with markedly reduction in inflammatory response and androgens inhibit repair and 
enhance leukocyte recruitment (Imoto et al., 2005). Signals mediated by TGFβ have roles 
in determining cell fate and growth control, as well as activation of fibrotic responses 
fundamental to liver disease, and are implicated in processes that mediate malignant 
progression (Ferenci et al.). Silibinin has been reported to inhibit nuclear factor κ B 
(NFκB) activation in hepatocytes during DEN-initiated hepatocarcinogenesis (Porta et 
al., 2009; Sakurai et al., 2006). Silibinin is reported to block nuclear translocation of 
NFκB, thereby blocking acute phase TNFα expression (Gharagozloo et al., 2010).  
Decreased TNFα expression identified in D+Sil females suggests that inhibiton of NFκB 
results in decreased expression of pro-inflammatory cytokines, TNFα, IL-1b, and IL-6 
(Kono et al., 2000; Mandrekar and Szabo, 2009). 
 Ethanol is a major source of hepatic oxidative stress, and chronic ethanol feeding 
leads to induction of CYP2E1. Ethanol resulted in an increase in CYP2E1 expression 
without, or with prior DEN initiation, and this occurred preferentially in male versus 
female mice. In addition, the promotional effects of ethanol on HCC corresponded to 
increased CYP2E1 expression and activity, oxidative stress, MDA and decreased GSH. 
In vitro studies on H4IIE rat hepatoma cells had suggested that silibinin could directly 
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interacted with CYP2E1 to inhibit ethanol metabolism (Brandon-Warner et al., 2010a).  
Silibinin has been reported to inhibit activity of other cytochrome P450 enzymes, 
reducing the associated oxidative stress that accompanies P450 mediated metabolism 
(Sridar et al., 2004). However, in this model EtOH-DW induced CYP2E1 expression 
without any changes in ADH or ALDH, but silibinin feeding had no effect on CYP2E1 
expression in D+E+Sil mice when compared to D+E mice in male or female animals. 
Interestingly, there was a decrease in mRNA message in male and female silibinin only 
and in D+S mice, but no changes in protein expression or activity were detected in 
silibinin fed groups without or with EtOH-DW. Ethanol metabolism mediated by 
CYP2E1 is a significant source of ROS and can facilitate the accumulation of 
acetaldehyde and contribute to lipid peroxidation and oxidative injury (Albano, 2006; 
Lieber, 1997a; McKillop, 2005; Wu and Cederbaum, 2003). In the context of initiatated 
cells, these factors can contribute to promotion and progression.  
 Promotional effects of ethanol previously identified in male D+E mice were not 
altered by concomitant silibinin feeding (D+E+Sil). Tumor area was reduced in these 
animals by ≈2.2% in early HCC, but was increased by ≈3.1% during late 
hepatocarcinogenesis, with increases in multiplicity at both time points. Measures of 
tumor area in female D+E+Sil mice were reduced by 30.4% in early, but only 8.5% 
during late stage when compare to D+E, however incidence was increased at both time 
points. Since both silibinin and ethanol treatments were postponed until HCC was 
expected to develop, it is likely that the accumulation of mutations had already 
progressed toward a malignant phenotype in 48 week animal groups. The combination of 
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EtOH-DW with silibinin at this point may have facilitated other changes in immune 
response, energy availability, or oxidative stress that served to enhance HCC progression.  
 Lesions identified in female mice were generally restricted to one or two lobes, 
the higher percent of non-tumor liver likely resulted in improved liver function, and when 
combined with anti-oxidant properties of silibinin was sufficient to decrease REDOX 
stress.  Measures of hepatic function (ALT) were improved over pair-matched D+E mice 
during early stage (24 week) hepatocarcinogenesis in males and females, but only in 
females during late stage (48 week) HCC. This improvement in females was 
accompanied by significant reductions in MDA, and modest preservation of cell GSH. 
Conversely, in male mice tumor burden was extensive, livers were grossly enlarged with 
significantly increased L:BW ratios. Increased tumor burden, with decreased hepatic 
function was reflected in higher ALT, MDA, 8-OHdG, and depleted GSH identified in 
D+E+Sil animals. Despite improvements in measures of hepatic function and oxidative 
stress, the highest liver injury scores were identified in male and female D+E+Sil mice at 
both 24 and 48 weeks. Increased tumor burden was associated with increased measures of 
PCNA in male and female D+E and D+E+Sil animals indentified in late (48 week) HCC. 
This increase in PCNA corresponded to increases in cyclin D1 expression in male 
animals. Conversely, female mice had higher numbers of TUNEL positive cells during 
late HCC compared to male mice in both D+E and D+E+Sil groups. This may indicate 
that females continue to eliminate damaged cells more effectively than their male 
counterparts.   
 Ethanol metabolism is a major source of oxidative stress, but it also enhances 
intestinal permeability allowing for the translocation of bacterial endotoxin (LPS) into the 
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liver. Bacterial endotoxin is a major stimulator of pro-inflammatory signals (Ferenci et 
al., 1989; Mandrekar and Szabo, 2009).  Females have been reported to sustain higher 
degrees of liver injury more rapidly in response to ethanol consumption, in part due to 
increased LPS and KC activation (Kono et al., 2000). Activation of KC occurs through 
LPS interaction with the CD14 receptor, leading to increased ROS, and production of 
pro-inflammatory cytokines. Pro-inflammatory mediators are increased in D+E+Sil male 
mice, but pathology and tumor burden were also increased, suggesting that increased 
inflammatory cytokines may be contributing to tumor progression. Ethanol can induce 
tolerance and sensitization of Kupffer cells by altering NFκB (Enomoto, 2001; 
Yamashina et al., 2005). Silibinin has been reported to increase lymphocyte proliferation, 
IFNγ, IL-4 and IL-10 secretion by inhibiting activation of NFκB in hepatocytes and 
Kupffer cells (Sakurai et al., 2006; Schwarz et al., 1983).  
 Tumor cells produce factors that can enhance their survival, direct alternate 
programming of macrophages within the tumor stroma (Mantovani et al., 2002; Porta et 
al., 2009). Liver macrophages are strategically located in the liver sinusoids where they 
are continually exposed to pathogen associated molecules. Conflicting signals mediated 
through ethanol, LPS or silibinin may alter the programming of  KC from an  M1 
phenotype with high production of nitric oxide and ROS effective in killing intracellular 
micro-organisms and tumor cells to an M2 phenotype that is more adept at scavenging 
debris, repair, tissue remodeling, and promotion of angiogenesis (Porta et al., 2009). 
Alternate programming of tumor associated macrophages is more permissive for tumor 
survival and may be part of inflammatory circuits that promote tumor progression. Male 
and female D+E+Sil mice demonstrated increased IL1B, IFNγ, TNFα and IL-13 levels, 
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cytokines which may contribute to polarization of macrophages to a tumor permissive 
(M2) phenotype.  Presence of Th2 cytokines with IL-10 are reported to direct this 
alternate activation (Mantovani et al., 2002). It is noteworthy that this cytokine profile is 
present in experimental groups with increased tumor burden. It seems likely that 
modulation of NFκB by ethanol and silibinin contribute to these effects. Further work 
remains to examine the role of NFκB activity or inhibition on HCC promotion and 
progression, and how these factors may be influenced by ethanol or silibinin. In light of 
the difference identified between male and female mice, it will be necessary to examine 
how sex-hormone signaling may also mitigate these processes.  
 These data demonstrated that silibinin was protective against oxidative injury and 
improved GSH levels in both D+Sil and D+E+Sil animals. Tumor size and burden were 
significantly reduced in D+Sil female mice, these protective effects were limited to early 
hepatocarcinogenesis and the effects were dampened in late HCC. Silibinin diet with 
concomitant ethanol feeding did not reduce tumor burden in male or female mice and 
silibinin may potentiate tumor promotion induced by ethanol. The effects of silibinin on 
promotion and progression in the absence or presence of ethanol raise questions about the 
safety of supplements, alone and in combination with other pharmacological agents. 
Many patients self medicate with natural herbal supplements, with the perception that 
even if they provide no benefit, they will do no harm, and most fail to share this 
information with their physicians. These data suggest there is a time-line for which 
supplements may provide some benefit in reducing measures of hepatic injury and that 
their effects can be mitigated by other interactions.  
 
 
 
 
 
 
 
CHAPTER 6: GENERAL DISCUSSION 
 
 
 Hepatocellular carcinoma (HCC) is a global health burden, and accounts for 
nearly ≈6% of all human cancers worldwide (Bosch et al., 2005). This cancer develops in 
the absence of specific familial or genetic markers, but instead from documented and 
largely preventable risk factors. These risks include Hepatitis B and C viral infection, 
aflatoxin B mycotoxin, non-alcoholic fatty liver disease, and chronic ethanol abuse (El-
Serag, 2007; McKillop, 2006; McKillop and Schrum, 2005). Most HCC occurs in Asia 
and sub-Saharan Africa. Incidence rates for many types of cancers have declined, but 
between 1975 and 2005, HCC rates in the United States have doubled (Altekruse, 2009). 
Epidemiological data report males to have an incidence of HCC that is 3-5 times higher 
than that of women (El-Serag, 2007).  Additionally, women present with a later onset of 
disease (El-Serag, 2007). Hepatitis C infection remains the principal risk factor 
associated with HCC. However, chronic ethanol abuse is a significant factor for HCC 
development in the United States, and it synergizes with other risk factors (El-Serag, 
2002). Regardless of underlying etiology, hepatocarcinogenesis is driven by 
inflammatory processes resulting from increased lipid deposition, hepatitis, leading to 
fibrosis and cirrhosis. Eighty to ninety percent of all HCC develops within the 
background of hepatic cirrhosis (Bartsch, 2005; El-Serag, 2007; McKillop, 2006; 
McKillop and Schrum, 2005). Clinical outcomes are dismal due to the lack of viable 
treatment options, an effect exacerbated by long disease latency. The time from onset to 
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clinical symptoms and diagnosis can be measured in decades (Okuda, 2000). 
Complicating diagnosis is the lack of biological markers. Currently, AFP and abdominal 
ultrasound are the initial tools used (Ferenci et al., 2010). Use of AFP as a diagnostic 
indicator has limitations as 40% of patients with HCC do not produce AFP, and many 
patients of African descent have normal AFP levels at 500 ng/mL (Ferenci et al., 2010).  
Development of HCC is a multistage process beginning with genetic mutations in 
isolated cells.  Over time selected cells clonally expand, accumulating additional genetic 
damage and mutations until they have overcome the barriers of growth inhibition, and 
apoptosis to become immortal, with a high proliferative index. These malignant cells 
have the ability to induce neo-vascularization and have increased invasion potential 
(Hanahan and Weinberg, 2000). Given the cryptic nature of the disease, diagnosis is often 
not made until late stage when treatment strategies are limited.  Staging is currently 
determined based on the Barcelona Clinic Liver Cancer (BCLC) guidelines. Treatment 
options are dependent on the stage designation at the time of diagnosis. Early stage 
cancer can be treated by tumor resection; intermediates stages are treated by ablation 
techniques designed to destroy tumor tissue or its blood supply; as staging progresses 
treatment is restricted to palliative care (Bruix and Sherman, 2005). Additionally, the 
only currently approved chemotherapy agent is Sorafenib, but this has only been 
demonstrated to improve life expectancy by a few months (Thomas and Zhu, 2005).  
Chronic ethanol abuse is a major cause of liver disease progressing to cirrhosis 
and eventual development of HCC, as liver hepatocytes are the primary site of ethanol 
metabolism (El-Serag, 2007; McKillop, 2005). Ethanol is not considered a 
hepatocarcinogen  per se, but contributes to  HCC through toxic metabolites, lipid 
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peroxidation and ROS generated during metabolism (Seitz, 2006). Oxidative stress is an 
important mechanism in this process. With occasional moderate ethanol consumption, it 
is rapidly metabolized in two successive oxidation reactions. The initial oxidation of 
ethanol is mediated by alcohol dehydrogenase (ALD) which produces acetaldehyde 
which is subsequently oxidized by acetaldehyde dehydrogenase (AHLD) to acetate and 
water. Data suggest that the carcinogenic effects are mediated by acetaldehyde, rather 
than ethanol (Poschl and Seitz, 2004; Seitz, 2006). Acetaldehyde is toxic, and has been 
demonstrated to be mutagenic and carcinogenic. It interacts with cell constituents causing 
lipid peroxidation, forms adducts with protein and DNA (Seitz, 2006; Seitz and Becker, 
2007). Adducts formed with DNA interfere with synthesis and repair pathways. 
Additionally, adducts increase chromosomal instability and become more sensitive to 
sister chromatid exchanges (Seitz, 2006; Seitz and Becker, 2007). Lipid peroxidation 
produces additional toxic aldehydes, malondialdehyde (MDA) and 4-hydroxynonanol  
(HNE) that also promote DNA damage (Bartsch, 2005). Protein interactions and 
aggregates formed with acetaldehyde interfere with normal structure and function. As 
these processes persist there is depletion of intracellular antioxidant defenses, primarily 
glutathione (GSH) (Seitz, 2006). Multiple isoforms of ADH and ALDH enzymes have 
been identified that can influence the rate of acetaldehyde formation and its subsequent 
oxidation, their contribution to HCC development has not been established (Lieber, 
2001). With chronic excessive ethanol consumption, microsomal cytochrome P450 2E1 
(CYP2E1), a mixed function mono-oxidase is induced (Lieber, 1997a). Ethanol 
metabolism mediated by CYP2E1 also produces acetaldehyde as its first metabolite. 
Induction of CYP2E1 with ADH may result in an imbalance of acetaldehyde relative to 
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available ALDH that favors accumulation. This can increase hepatic metabolic stress and 
oxidative injury.  Metabolism mediated by CYP2E1 is associated with increased 
oxidative injury and generation of reactive oxygen species (ROS), O2
.- 
 and H2O2 in 
hepatocytes (Albano, 2002; Lieber, 1997a). This enzyme is poorly coupled and results in 
incomplete ethanol oxidation and formation of hydroxyl-ethyl radical (HER) (Lieber, 
2001). Generation of ROS is partially due to enhanced leakage of electrons from the 
mitochondrial respiratory chain and increased REDOX imbalance (Bailey and 
Cunningham, 2002; Lieber, 2001).   
A secondary source of hepatic oxidative injury occurs due to increased gut 
permeability and translocation of bacterial endotoxin (LPS) from the intestinal tract to the 
liver from the hepatic portal vein (Albano, 2006; Lieber, 2001; Thurman, 1998). Bacterial 
endotoxin entering the liver activates hepatic macrophages, Kupffer cells by interacting 
with the CD14 receptor (Enomoto, 2001; Nagy, 2004; Thurman, 1998). These activated 
Kupffer cells produce pro-inflammatory cytokine TNFα and ROS (Thurman, 1998). This 
response is reported to be increased in females who have demonstrated higher levels of 
gut-derived LPS in their blood following ethanol exposure than males, and as a result 
females are thought to be more susceptible to ethanol induced hepatic injury (Enomoto, 
2001; Ikejima et al., 1998; Kono et al., 2000). Additionally, ROS produced by CYP2E1 
during ethanol metabolism exacerbate Kupffer cell responsiveness to LPS and 
hepatocytes are more vulnerable to the effects of TNFα (Hoek, 2002). Kupffer cells are 
the main effector cell for innate immune response within the liver and many responses 
associated with progressive injury, including lipid accumulation, inflammation, increased 
oxidant generation and necrosis during chronic ethanol exposure are mediated by Kupffer 
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cells (Hines and Wheeler, 2004). However, ethanol can have opposing effects on Kupffer 
cell activation, inducing both tolerance and sensitization (Yamashina et al., 2005). 
Impairment of immune response during hepatic injury is linked to modulation of cytokine 
production by Kupffer cells (Mandrekar et al., 2009). Classically LPS binds to the CD14 
TLR/4 complex followed by activation of interleukin 1 receptor-associated kinase 
(IRAK-1), IKK complex and MAPK followed by the dissociation of IκBα and nuclear 
translocation of NFκB consisting of the p50 and Rel A subunits (Mandrekar et al., 2009). 
This leads to transcriptional activation of proinflammatory cytokines, TNFα, Il-1b, and I-
6.  Alternately, increased IL-1R associated kinase –monocyte (IRAK-M) is a negative 
regulator of LPS induced signaling and leads to impaired NFκB DNA binding and 
decreased TNFα producing an anti-inflammatory response (Enomoto et al., 1998; Liu et 
al., 2008; Mandrekar et al., 2009). Silibinin may directly interfere with these disparate 
processes generating tolerance or sensitization that impedes or promotes HCC 
progression or potentiates the effects of ethanol. 
Persistent oxidative stress and inflammatory responses coupled with hepatic 
accumulation of acetaldehyde, ROS and activation of Kupffer cells stimulate hepatic 
stellate cells to produce type I collagen. This process is initially mediated by 
acetaldehyde directly, but with chronic ethanol exposure TGFβ and TNFα contribute to 
the fibrogenic process (Hoek, 2002; Nieto, 2006). The progressive nature of liver injury 
beginning with steatosis, and hepatitis leading to fibrosis and cirrhosis, occurs through 
chronic oxidative stress and inflammation. Antioxidants have been proposed as a means 
of ameliorating oxidative stress and preventing the chronic inflammatory processes that 
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drive fibrosis and cirrhosis especially during chronic ethanol use and thereby preventing 
progression to HCC.  
Silibinin is a flavinoligand derived from the seeds of Milk thistle (Silybum 
marianum). Historically, it has been used as a hepatoprotectant for several millennia. 
Silibinin is the major and most biologically active component contained in the silymarin 
mixture (Gazak, 2007; Saller, 2007). Clinical trials in Europe demonstrated silibinin 
administered to patients with cirrhosis improved long term prognosis, however these 
studies have not been confirmed (Ferenci et al., 1989; Stickel and Schuppan, 2007). 
Silibinin is a potent antioxidant; however it may also reduce oxidative stress by means of 
inhibitory actions on cytochrome P450 3A4 and 2C9 activity through competitive 
interaction (Sridar et al., 2004). 
Initial in vitro studies examined the effects of ethanol,  in absence of, or with 
silibinin pre-treatment, on CYP2E1 metabolism, oxidative stress and proliferation in a rat 
hepatoma cell line; H4IIE. These studies demonstrated that ethanol increased 
proliferation in cultured H4IIE cells. Additionally, there were dose dependent increases 
(0-75 mM/L) in CYP2E1 expression associated with chronic ethanol exposure (24 hours). 
Peak expression was measured at 25 mM/L ethanol exposure. Based on this, additional 
experiments were conducted at ethanol concentrations of 25 mM/L. Previous studies 
reported therapeutic serum and tissue concentrations at 8.8-10 µM/L (Singh, 2004b).  
H4IIE cells exposed to 25 mM/L ethanol following silibinin pretreatment at 10 µM/L 
demonstrated decreased expression of CYP2E1 protein. We also identified an increase in 
CYP2E1 mRNA with ethanol exposure that was abrogated by silibinin pre-treatment. 
Further examination of ethanol metabolism in these cells demonstrated a ≈10% decrease 
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in metabolism associated with silibinin pre-treatment. To examine proliferation we 
conducted direct counts of H4IIE cells every 24 hours for 96 hours, these data 
demonstrated that ethanol promoted proliferation over silibinin or vehicle (DMSO) 
treated cells alone, and that pre-treatment inhibited this effect to rates comparable to that 
of control.  Because ERK1/2 phosphorylation are associated with proliferation, we 
performed immunoblots for ERK1/2 and active (phosphorylated ERK1/2)(McKillop, 
1999). Previous studies had suggested that silibinin may interfere with ERK activity by 
inhibiting phosphorylation (Momeny et al., 2008). We identified no changes in ERK 
activity between ethanol without or after silibinin pre-treatment. Assessment of oxidative 
stress demonstrated that ethanol resulted in increased thiobarbituric acid reactive species 
(TBARS) as a measure of malondialdehyde (MDA).  This increase in TBARS was 
abrogated by silibinin pre-treatment.  Additionally, we used fluorescent microscopy to 
evaluate celluar oxidative stress.  Metabolism mediated by CYP2E1 is a source of both 
O2
.- and H2O2 formation,  as such we used carboxy-H2 DCFDA a probe to detect 
intracellular ROS. On exposure to cellular peroxides carboxy-H2 DCFDA is cleaved by 
cellular esterases and becomes sequestered in the cytoplasm. In this way we were able to 
demonstrate that ethanol alone produced increased cellular peroxides that were 
ameliorated by silibinin pre-treatment.  Finally, we utilized a human HCC cell line 
HepG2, that was stably transfected to constitutively express CYP2E1(E47-HepG2), and 
cells stably transfected with empty vector (C37-HepG2) to demonstrate that silibinin pre-
treatment inhibited ethanol metabolism and this inhibition was accompanied by a 
decrease in hydroxylation of p-nitrophenol as an measure of CYP2E1 activity.  
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These studies demonstrated that ethanol promotes HCC proliferation, and this 
effect is abrogated by silibinin pre-treatment. Furthermore, silibinin appeared to inhibit 
CYP2E1 protein expression and activity  which reduced cellular oxidative stress and 
inhibited lipid peroxidation and this effect, may be from direct interactions with silibinin 
and CYP2E1 protein. 
The promotional effects of ethanol have been controversial. Numerous studies 
have been conducted in an attempted to determine if ethanol can promote HCC 
progression.  This is particularly important give the long disease latency and absence of 
symptoms, which makes it likely that chronic ethanol abuse could contribute to the clonal 
expansion of transformed cells that drives promotion and progression in HCC. Ethanol 
has the potential to influence tumorigenesis  in multiple ways, facilitation of cellular 
uptake of carcinogens in hepatocytes, modification of metabolic pathways, stimulation of 
DNA synthesis with concurrent reduction in repair capacity, and modulation of immune 
responses (Seitz, 2006; Seitz and Becker, 2007). Additionally, the link between chronic 
inflammatory processes in fibrotic disease states as mediators of promotion in 
progression in cancer have been well documented (Vidali, 2007; Yang et al., 2011).  
Previous studies have utilized a well characterized mouse model of chemical 
carcinogenesis (diethylnitrosamine – (DEN)), whereby DEN is administered in a single ip 
dose to neonatal mice (14-21 days) and tumors develop over a predictable time course 
(Fausto, 2010; Goldfarb et al., 1983; Goldsworthy and Fransson-Steen, 2002; 
Vesselinovitch and Mihailovich, 1983). In most experimental studies administration of 
ethanol was usually accomplished by isocaloric Lieber-DeCarli liquid diet in which 36% 
of calories are derived from ethanol, or dextrose in pair-matched controls (Lieber and 
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Decarli, 1989). Alternately, a gastric infusion model has been employed (Tsukamoto et 
al., 1985). These studies also incorporated partial hepatectomy (removal of 70% of liver 
tissue), or nutritionally restricted diets (low methionine), to induce liver regeneration or 
impair metabolic function and exacerbate the effects of DEN initiation. These studies 
have produced conflicting results demonstration no effect (Mandl, 1989; Schwarz et al., 
1983), co-carcinogenic effects (Seitz et al., 1998), and promotional effects (Takada, 
1986). The variations in these studies complicate interpretation of their results. 
Additionally, these experiments were conducted on limited number of animals, and 
females were not included.  
Given the sexual dimorphism that has been identified in HCC incidence, we 
sought to include males and females.  These studies utilized a DEN mouse model; infant 
B6CH3 mice were given a single ip injection of DEN (1 mg/kg body weight). Animals 
were allowed to recover for 15 or 39 weeks to allow CYP2E1 induction by DEN to abate 
before any further treatment regimes were initiated. Male and female animals were 
randomly assigned to treatment groups for early (24 weeks) when altered hepatic foci are 
expected to form, or late (48 weeks) when HCC is expected to be present (Goldfarb et al., 
1983; Goldsworthy and Fransson-Steen, 2002). These groups were further randomly 
divided to receive DEN, DEN plus silibinin diet (0.05% w/w for 9 weeks), DEN plus 
ethanol drinking water feeding (10/20% v/v alternating daily for 8 weeks), or DEN plus 
silibinin diet (9 weeks) and ethanol drinking water (8 weeks). Ethanol drinking water at 
doses of 5 to 20% is thought to mimic that of moderate human consumption.  This 
method allows for intermittent and lower doses than liquid diets or intragastric infusion 
and results in blood level variations over time. Non-initiated male and female groups 
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were also established to receive no supplementation, ethanol drinking water alone (8 
weeks), or silibinin diet alone (9 weeks). At the end of treatment regimes, mice were 
euthanized with liver and serum harvested.  
These data demonstrated that ethanol promoted HCC progression during early and 
late hepatocarcinogenesis, but this effect was restricted to male mice.  Tumors were 
initiated in both male and female mice, but males demonstrated an incidence 2.6 fold 
higher than female mice. This parallels human HCC whereby females generally have an 
incidence 3 times lower than males (El-Serag, 2007; McKillop, 2005). Progression of 
HCC was accompanied by increased CYP2E1 expression and activity with subsequent 
increases in measures of oxidative injury. Conversely, female DEN initiated mice 
exposed to ethanol presented with smaller tumors than pair-matched DEN initiated mice. 
Female DEN+ethanol mice also demonstrated decreased CYP2E1 expression and activity 
compared to pair-matched males. Additionally, measures of oxidative injury were not as 
severe and females maintained higher glutathione levels. These differences corresponded 
to increased tissue pathology in male compared to female animals. With steatosis as the 
dominate measure of injury. In males this resulted in ballooning degradation of 
hepatocytes with increased necrosis. Of note, females measured higher rates of apoptosis 
and determined by TUNEL positive staining. The differences identified in necrotic cell 
death, which is an inflammatory process versus apoptosis which is non-inflammatory 
likely contribute to differences in tissue pathology. Carcinogenesis is mitigated by 
alterations in growth inhibitory signals, evasion of apoptosis, immortalization, neo-
vascularization and increased invasion potential (Hanahan and Weinberg, 2000). A link 
between inflammation and cancer may be dependent on NFκB, a critical regulator of 
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innate immune responses in the liver (Karin and Greten, 2005; Maeda et al., 2005). 
Chemical carcinogenesis was exacerbated by loss by inhibition of NFκB activation 
through IKKβ in hepatocytes. This corresponded to enhanced ROS production and lead 
to sustained JNK activation.  However, similar inhibition of NFκB in liver macrophages 
(Kupffer cells) significantly reduced hepatocarcinogenesis (Maeda et al., 2005). 
Hepatocyte death in this model occurred by necrosis and led to compensatory liver 
regeneration. This suggests that differences in NFκB regulation in males and females 
may trigger responses that can promote or inhibit HCC progression.  
In examining markers of proliferation we identified that both male and female 
mice had increased PCNA, but in males this increase corresponded to increased cyclin 
D1, indicating that PCNA was due to replication. However, female mice had decreased 
cyclin D1 indicating that PCNA expression may be due to DNA repair mechanisms.  
Proliferating cell nuclear antigen accumulates at sites of double-strand (ds) DNA breaks, 
the decrease in D1 relative to PCNA suggests that females may have induced repair 
pathways while males responded to hepatomitogens to induce proliferation. The effects 
of ethanol and its metabolites can produce oxidative DNA damage, ds DNA breaks and 
adducts. Proliferation in the context of DNA damage can lead to transverion mutations 
and increased chromosomal instability.  
Clinical data indicates the women are more susceptible to ethanol induced liver 
injury and that gut-derived endotoxin and Kupffer cell activation likely plays a pivotal 
role in this difference (Kono et al., 2000). This is dependent on activation of NFκB 
through CD14 receptor. Females demonstrate early activation of Kupffer cells with 
increased CD14 expression and increased TNFα in response to NFκB activation (Kono et 
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al., 2000). This suggests that estrogen may modulate these responses. However, our 
model indicates that females are less susceptible to liver injury and promotional effects 
with chronic ethanol ingestion. Early acute phase response is increased, but long-term 
exposure to ROS, oxidative stress and KC activation does not result in increased tumor 
burden in females.  Female mice in this study had decreased tumor burden, and decreased 
measures of liver injury compared to pair-matched male mice, and this was accompanied 
by increased apoptosis. Transcriptional activation by NFκB is an important mediator of 
inflammatory responses (Kono et al., 2000). Female mice maintained on ethanol in the 
absence of DEN initiation had higher TNFα levels. Most cytokines were decreased in 
ethanol fed DEN-initiated female mice, including TNFα, IL-1b, IFNγ, and IL-10. 
Cytokine levels were based on serum measures and reflective of systemic response. 
These data did not correspond to increased liver mRNA expression of transcription 
factors that initiate T-effector programming T-bet (Th1), and GATA3 (Th2). In female 
mice these transcription factors were increased indicating that females may mount a more 
robust immune response and maintain immunosurveillance in conjunction with DNA 
repair and apoptotic cell death. However, male mice demonstrated increased SMAD3 a 
mediator of TGFβ signaling programs. Male mice also had increased IL-10 an immune 
suppressive cytokine important in T-regulatory cell differentiation. This suggests that 
males may activate an immunosuppressive program in the context of increased necrosis 
and compensatory proliferation as suggested by increased measures of cyclin D1. 
  Alternate modulation of NKκB influences multiple cell types within the liver 
milieu.  Progression of hepatocellular carcinoma is influenced by growth factors, 
cytokines, chemokines and small signaling molecules produced by multiple cell types 
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within the tumor stroma. These effects in the microenviroment are thought to be key 
mediators of progression (Balkwill et al., 2005; Yang et al., 2011). Ethanol induces 
NKκB activation in KC through increased LPS, but this response is not sustained with 
long-term ethanol use. Tolearance or alternate macrophage activation can be triggered by 
changes in the microenvironment that direct different functional programs, similar to T-
cell differentiation into Th1 or Th2 effector cells (Porta et al., 2009). In this case, classic 
or M1 macrophage activation induces IFNγ, IL-12 and IL-23 production with high NO 
and reactive oxygen intermediates.  The M1 macrophage phenotype produces pro-
inflammatory cytokines and is a potent effector for killing intracellular micro-organisms 
and tumor cells. Conversely, differential programming produces an M2 phenotype that is 
characterized by decreased pro-inflammatory cytokines and is more effective at 
scavenging debris, promoting angiogenesis and remodeling of extra-cellular matrix 
(ECM). These are important events during tumor promotion (Porta et al., 2009).  
Cytokines associated with a Th2 effector response (IL-4, IL-13, IL-10), as well as other 
small molecule mediators may enable this shift. This shift is associated with cytoplasmic 
accumulation of the p50 subunit of NKκB may play a role in the polarization of tumor 
associated macrophages (Liu et al., 2008; Mantovani et al., 2002; Porta et al., 2009).
 There are multiple sources for generation of ROS during chronic long term 
ethanol use. Pathological processes mediated by cellular immune response are also a 
major source of oxidative stress.  Previous studies had demonstrated that silibinin may 
directly interact with CYP2E1 inhibiting its activity. This would directly reduce oxidative 
stress that is associated with CYP2E1 metabolism and slow the rate of acetaldehyde 
formation (Brandon-Warner et al., 2010a). Silibinin is a potent anti-oxidant, but in 
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addition it has been demonstrated to inhibit cell cycle progression, decrease angiogenic 
signaling, and inhibit metastasis in cell and animal models of cancer (Chen et al., 2005; 
Cheung et al., 2010; Singh, 2004b). We next sought to determine if the promotional 
affects identified in male animals exposed to ethanol could be abrogated by concomitant 
treatment with silibinin. We also wanted to determine if silibinin could reduce promotion 
and progression in DEN initiated mice in the absence of promoting agent ethanol.  
 In this mouse model of chemically induced hepatocarcinogenesis, silibinin alone 
was effective at reducing tumor size and burden in DEN initiated female mice during 
early formation of altered hepatic foci, however no protective effects were identified in 
male mice in pair-matched group. This benefit was absent during late stage. Tumor 
incidence for males was ≈2:1 compared to females in DEN+silibinin diet groups. 
Silibinin feeding with DEN initiation improved measures of oxidative stress and liver 
injury in both males and females. Markers of proliferation correlated to increased tumor 
burden. Measures of TUNEL positive cells in DEN mice on silibinin diet demonstrated 
reduced levels of apoptosis and increased necrotic cell death. This pathology was similar 
to that identified in ethanol alone, however most measures of injury and oxidative stress 
were improved. Additionally, silibinin diet in non-DEN initiated animals demonstrated 
increased lipid deposition in both males and females. This disparity supports altered 
NKκB activation in males that favors increased necrosis with compensatory hepatic 
regeneration that may lead to sustained JNK activation. While females had reduced 
growth response and increased apoptosis and activation of DNA repair programs. 
Examination of immune response demonstrated that silibinin feeding did not reduce 
cytokine expression compared to DEN initiation only. Increased IL-1b, TNFα, IL-13 and 
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IL-10 were measured in male mice in both DEN and DEN with silibinin diet groups. 
Conversely, females had reduced cytokine expression in DEN group on silibinin diet 
relative to DEN alone, with the exception of IL-13. Measures of mRNA for transcription 
factors T-bet and GATA3 in liver were also elevated in female compared to male groups, 
while SMAD3 was again increased in males. Females may maintain more robust immune 
responses, while males may promote development of T-regulatory cells. The infiltration 
of T-regulatory cells is a predictor of poor prognositic outcome (Chew et al., 2010).  
Tumor incidence in female DEN-initiated mice maintained on both silibinin and 
ethanol was ≈1.4:1 and 2.6:1 in DEN-initiated animals without EtOH-DW compared to 
males. This suggests that ethanol combined with silibinin may increased tumorogeneicity 
in females.  Measures of tissue pathology (steatosis, necrosis, inflammatory cell 
infiltration, collagen deposition) and oxidative stress (ALT, MDA and GSH) were 
improved in both males and females during early (24 week) hepatocarcinogenesis, but 
these affects were largely abrogated during late stage. This is likely due to the extent of 
the pathology and development of an increasingly malignant phenotype in both males and 
females. Increased tumor burden was associated with increased PCNA and decreased 
apoptosis in male mice. Additionally, as with ethanol alone, males had increased 
histological scoring for necrotic cell death.  Silibinin had no effect on CYP2E1 
expression or activity in silibinin diet groups or ethanol drinking water with silibinin. 
Males consistently demonstrated increased CYP2E1 expression and activity compared to 
females. This may enhance ROS and oxidative injury in these groups relative to females 
exceeding the antioxidant capability of silibinin. Immune responses continued to follow 
previously established trends at the systemic level of serum cytokines and in expression 
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of T-bet, GATA3, and SMAD3 mRNA with the exception that males have elevated T-bet 
mRNA in DEN groups on both ethanol and silibinin feeding regime. This did correlate to 
increased Th1 cytokines IL-1b, TNFα, IFNγ identified in this group, and in pair-matched 
females.  However IL-13 was increased 2.4 fold in males and 1.6 fold in females in thse 
same experimental groups compared to control. These data suggest that similar 
mechanisms in ethanol mediated promotion are being affected with silibinin feeding 
alone and with concomitant ethanol exposure.  Increased IL-1b, TNFα and IL-13 in males 
may indicate that macrophage phenotype is polarized from anti-tumor to one that is 
tumor permissive. However, improvements in measures of oxidative stress and the 
potential for accumulation of genetic mutations is decreased, resulting in no net 
improvement.  
Clinical studies have demonstrated that an immune response with a Th1 signature 
in HCC is less likely to promote metastasis, while increased T-regulatory cells are 
associated with increased invasion potential and tumor growth (Chew et al., 2010). Our 
studies demonstrate that ethanol promotes HCC, preferentially in males; while silibinin is 
preferentially protective in female mice during early hepatocarcinogenesis. These 
responses may be influenced through activation of stress-mediated transcription factors. 
Immune function is directed, in part, by NKκB, yet that programming can be inhibited 
through different actions of both ethanol and silibinin. Suppression of NFκB has been 
reported to support sustained activation of c-Jun N terminal kinase (JNK) activity with 
subsequent activation of activating protein-1 (AP-1)(Baker et al., 2010). This is a 
REDOX sensitive transcription factor that can serve to promote or inhibit cancer 
progression (Jeong et al., 2005; Mandrekar et al., 2004; Sakurai et al., 2006).  Increased 
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expression of hepatic growth factors and compensatory proliferation are associated with 
JNK and AP-1 (Sakurai et al., 2006; Schwarz et al., 1983). Transcriptional programming 
by AP-1 generates products that can suppress negative growth regulators (p53, p21cip1/waf, 
and p16) and increases cyclin D1 expression through interactions with two distinct 
promoter regions (Shaulian and Karin, 2001). This shift in metabolically stressed or 
transformed cells could drive progression of HCC. Silibinin and ethanol have both been 
reported to interact with NKκB and can direct both programming pathways. It is possible 
that the silibinin potentiates the effects of ethanol on NKκB activation/suppression; but 
how this is mediated in other cell types and how it is affected by sex-hormone signaling 
remains unknown. The combination of ethanol and silibinin in DEN-initiated mice  
increases hepatocarcinogenesis in males and females, eliminating any protective effects 
achieved through silibinin alone in DEN-initiated female mice.  
In vitro studies reported that ethanol promoted growth of H4IIE cells. 
Promotional effects of ethanol on H4IIE cells were abrogated by silibinin pre-treatment 
with concomitant decreases in CYP2E1 expression and activity. This suggested that 
silibinin could interact directly with CYP2E1 impairing its function and preventing the 
associated ROS/oxidative stress.  However, in a DEN-initiated mouse model of 
hepatocarcinogenesis promotional effects of ethanol were restricted to male mice and 
occurred in early and late hepatocarcinogenesis. Female DEN-initiated mice maintained 
on EtOH-DW had reduced injury and tumor burden when compared to male mice and 
DEN-initiated females. Additionally, these data demonstrate that silibinin feeding 
improved measures of hepatic injury (ALT, MDA, and GSH) during early HCC, but did 
not improve histological characteristics of liver injury. However, silibinin feeding did 
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reduce tumor size by nearly 50% in female DEN-initiated mice, but this effect was 
restricted to early hepatocarcinogenesis. Silibinin feeding in combination with EtOH-DW 
potentiated the promotional effects of ethanol and increased tumorigenesis in both male 
and female DEN-initiated mice. This effect was exacerbated during late 
hepatocarcinogenesis as transformed hepatocytes acquired a more malignant phenotype.  
Millions of Americans are estimated to abuse ethanol, given the cryptic nature of HCC, 
ethanol may contribute to disease progression and formation of primary liver tumors with 
poor prognostic outcomes. The delay between initiation to onset of symptoms and 
confirmation of HCC establishes a protracted period whereby the effects of lifestyle 
choices, including diet and ethanol consumption, and comorbidity can enhance the 
potential for promotion and progression in HCC. In this context ethanol may enhance 
progression in HCC. Further work remains to understand the underlying mechanisms 
behind the sexual-dimorphism in both the response to EtOH-DW and silibinin, and how 
these effects may vary during chronic and acute, or binge ethanol consumption.  
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APPENDIX A: SUPPLEMENTARY DATA 
 
 
 
Appendix A Figure A.1: Representative micrographs (100X) of H&E, Sirius red and 
GSPpi stained liver sections from 24 week male mice in control (C), silibinin diet diet 
(0.5% (w/w) daily for 9 weeks) (Sil), and ethanol drinking water regime (10/20% (v/v) 
alternating daily for 8 weeks) (E) groups. 
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Appendix A Figure A.2: Representative micrographs (100X) of H&E, Sirius red and 
GSPpi stained liver sections from 24 week male DEN-initiated (D), and DEN-intitiated 
mice maintained on silibinin diet diet (0.5% (w/w) daily for 9 weeks) (D+Sil). 
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Appendix A Figure A.3: Representative micrographs (100X) of H&E, Sirius red and 
GSPpi stained liver sections from 24 week male DEN-initiated mice maintained on 
ethanol drinking-water regime (10/20% (v/v) alternating daily for 8 weeks) (D+E), and 
DEN-initiated female mice maintained on Silibinin diet (0.5% (w/w) daily for 9 weeks) 
with ethanol drinking-water (8 weeks) (D+E+Sil). 
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Appendix A Figure A.4: Representative micrographs (100X) of H&E, Sirius red and 
GSPpi stained liver sections from 24 week female mice in control (C), silibinin diet diet 
(0.5% (w/w) daily for 9 weeks) (Sil), and ethanol drinking water regime (10/20% (v/v) 
alternating daily for 8 weeks) (E) groups. 
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Appendix A Figure A.5: Representative micrographs (100X) of H&E, Sirius red and 
GSPpi stained liver sections from 24 week female DEN-initiated (D), and DEN-intitiated 
mice maintained on silibinin diet diet (0.5% (w/w) daily for 9 weeks) (D+Sil). 
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Appendix A Figure A.6: Representative micrographs (100X) of H&E, Sirius red and 
GSPpi stained liver sections from 24 week female DEN-initiated mice maintained on 
ethanol drinking-water regime (10/20% (v/v) alternating daily for 8 weeks) (D+E), and 
DEN-initiated female mice maintained on Silibinin diet (0.5% (w/w) daily for 9 weeks) 
with ethanol drinking-water (8 weeks) (D+E+Sil). 
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Appendix A Figure A.7: Representative micrographs (100X) of H&E, Sirius red and 
GSPpi stained liver sections from 48 week male mice in control (C), silibinin diet diet 
(0.5% (w/w) daily for 9 weeks) (Sil), and ethanol drinking water regime (10/20% (v/v) 
alternating daily for 8 weeks) (E) groups. 
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Appendix A Figure A.8: Representative micrographs (100X) of H&E, Sirius red and 
GSPpi stained liver sections from 48 week male DEN-initiated (D), and DEN-intitiated 
mice maintained on silibinin diet diet (0.5% (w/w) daily for 9 weeks) (D+Sil). 
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Appendix A Figure A.9: Representative micrographs (100X) of H&E, Sirius red and 
GSPpi stained liver sections from 48 week male DEN-initiated mice maintained on 
ethanol drinking-water regime (10/20% (v/v) alternating daily for 8 weeks) (D+E), and 
DEN-initiated female mice maintained on Silibinin diet (0.5% (w/w) daily for 9 weeks) 
with ethanol drinking-water (8 weeks) (D+E+Sil). 
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Appendix A Figure A.10: Representative micrographs (100X) of H&E, Sirius red and 
GSPpi stained liver sections from 48 week female mice in control (C), silibinin diet diet 
(0.5% (w/w) daily for 9 weeks) (Sil), and ethanol drinking water regime (10/20% (v/v) 
alternating daily for 8 weeks) (E) groups. 
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Appendix A Figure A.11: Representative micrographs (100X) of H&E, Sirius red and 
GSPpi stained liver sections from 48 week female DEN-initiated (D), and DEN-intitiated 
mice maintained on silibinin diet diet (0.5% (w/w) daily for 9 weeks) (D+Sil). 
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Appendix A Figure A.12: Representative micrographs (100X) of H&E, Sirius red and 
GSPpi stained liver sections from 48 week female DEN-initiated mice maintained on 
ethanol drinking-water regime (10/20% (v/v) alternating daily for 8 weeks) (D+E), and 
DEN-initiated female mice maintained on Silibinin diet (0.5% (w/w) daily for 9 weeks) 
with ethanol drinking-water (8 weeks) D+E+Sil 
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